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Abstract 
Systemic Lupus Erythematosus is a damaging autoimmune disease afflicting 
millions of people worldwide. Lupus is characterized by an overabundance of 
autoantibodies, proteins directing the immune system to destroy a person's own body, 
what it would normally be protecting. The molecular mechanisms, environmental 
influences, and genetic predispositions of Lupus are not yet fully understood. 
However, nine out of ten Lupus patients are women between the age of puberty and 
menopause, when estrogen levels are highest. The fact that women are significantly 
more prone to suffer from Lupus than men leads experts to believe that the sex 
hormone estrogen which is present at much higher concentrations in females may 
play a role in the initiation and progression of Lupus symptoms. Given the 
complications of working with human subjects in a testing environment, the 
similarities of mammalian immune systems make mammalian models for human 
diseases a useful tool. This study uses a widely- accepted mouse model for Lupus: 
strain NZB/WF 1. 
Two important mechanisms of antigen processing and presentation will be 
examined in the context of the murine Lupus model. First, the activity of cathepsins 
will be measured in several cell types. The cathepsins are a family of mostly cysteine 
lysosomal proteases that play important roles in antigen generation through 
proteolytic cleavage of proteins into small fragments, which are subsequently 
presentated by the major histocompatibility complex (MHC-11) molecule on the 
surface of antigen presenting cells (APCs). We examined the effect of in vitro 
exposure to splenocytes and peritoneal macrophages to physiologically relevant 
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concentrations of estrogen or bisphenol A (BPA). BPA is a high volume production 
chemical used in the polycarbonate plastics industry and humans are exposed to BPA 
through materials such as water bottles, food containers, and epoxy resins. BPA is an 
endocrine disrupting chemical and the molecule has affinity for estrogen receptors 
(ERs), cytosolic proteins which, when bound to estrogen or an estrogenic molecule, 
are able to alter genetic transcription by binding to regions of DNA known as 
estrogen response elements (EREs). It has previously been shown by the Roberts lab 
that genes for cathepsins B, L, and S contain putative EREs through bioinformatics. 
Splenocytes and peritoneal macrophages were cultured in complete PRFCT-RPMI 
medium and activities of cathepsins B, L, and S were measured by fluorescent 
substrate assays. Data suggest that cathepsin B and L activity were altered 
significantly in splenocytes and peritoneal macrophages of NZB/WF1 mice under low 
nanomolar dosage of estrogen and BPA and cathepsin S activity was changed in 
Lupus-prone peritoneal macrophages. The differential activity of cathepsin enzymes 
is particularly relevant in a Lupus model since they play a crucial role in antigenic 
peptide generation and in regulating the process of antigen presentation. Future 
studies may be directed towards related cathepsin activity differences to changes in 
the presented antigenic repertoire in Lupus patients. 
Second, this study examines another aspect of immune function: the presence 
of surface proteins on B cells involved in antigen presentation and costimulation. 
Splenocytes from control and Lupus-prone mice were cultured with varying 
concentrations of estrogen and BPA and surface molecules were analyzed by 
fluorescence activated cell scanning (FACS). Fluorescent-tagged antibodies allowed 
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for the specific analysis of surface molecules B220, MHC-11, CD80, CD86, and 
CD40. Data show that NZB/WF1 lymphocyte populations are composed of fewer B 
cells than C57BL/6 mice. Levels of CD86 were found to be higher in NZB/WF1 mice 
than C57BU6 after 18 hr stimulation with lipopolysaccharide. Also, levels of CD80 
are increased in NZB/WF 1 mice under treatment with 5 nM estrogen. Our results 
indicate that tissues from a Lupus model respond differently to estrogenic regulation 
and further support the hypothesis that estrogen may play a role in Lupus 
pathogenesis and disease progression. Current treatment options for Lupus patients 
are limited in their ability to target specific molecular pathways. Increasing treatment 
specificity and efficacy would be an important step to better treating autoimmunity. 
This study better elucidates the interplay of the endocrine and immune systems in 
immune dysfunction and suggests that further study of antigen processing and 
presentation pathways may better explain the molecular mechanisms of Lupus, 
paving the way to uncover new drug targets and treatment. 
Background 
Goals and Expectations 
This study is concerned primarily with two functions of the immune system . 
The first is antigen processing and the second is antigen presentation. The 
examination of the effect of estrogen and BPA exposure in vitro on the endosomal-
lysosomal proteolysis of engulfed polypeptides by cathepsin proteases will give 
insight to the intracellular proteolytic environment experienced by proteins. 
Alteration of proteolysis of self-peptides could lead to induced autoimmunity. The 
presentation of the processed antigens by MHC-11 molecules and the 
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contemporaneous signaling mediated by costimulatory interactions, and in particular 
the potential for variable expression of these cell surface molecules, will define the 
surface environment of antigen presenting cells and lends insight into importance of 
lymphocyte interactions in establishing acquired immunity. Hormonal regulation, 
especially by BPA, is nearly impossible to predict, so outcomes will be variable. The 
interplay of the endocrine and immune system will be further elucidated through the 
usage of estrogen and the environmental estrogen BPA in studying a model for 
autoimmunity. 
Systemic Lupus Erythematosus 
Systemic Lupus Erythematosus (SLE or Lupus) is an autoimmune disease 
resulting in various immune dysfunctions and often characterized by an 
overabundance of autoantibodies, or antibodies with self targets. Presentation of 
Lupus symptoms is variable. Lupus is often misdiagnosed and many practitioners 
may rush into a diagnosis using solely an anti nuclear antibody (ANA) test or 
overlook Lupus as a diagnosis without considering the broad range of symptoms 
associated with SLE (Manzi 2009). These symptoms include rashes, oral ulcers, 
nephritis contributing to renal failure , fatigue, nausea, chronic pain, accumulation of 
autoantibodies and associated immune complexes, vascular disease, nervous system 
malfunction, increased risk for bone disease and cancer, B cell activation, 
complement cascade activation and the signature 'butterfly rash' (Manzi 2009, 
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Lupus disease progression is not fully understood and many contributing 
molecular mechanisms are as of yet undiscovered. Lupus pathogenesis is related to 
abnormal apoptosis and clearance of cellular debris, leading to immune cell 
disregulation and excess availability of auto-antigenic material (Fig. 1) (Greidinger 
2001). Certain predispositions exist in Lupus disease progression. Women during 
their childbearing years (-15-45 yrs), when estrogen levels are highest, outnumber 
males 12: 1 in disease development, but the ratio drops to 2: 1 among the elderly and 
children (Manzi 2009), and studies in mouse models further suggest role for the sex 
hormone estrogen in Lupus (Voskuhl 2011). Additionally, minorities are 
overrepresented, particularly Hispanics, African Americans , and Asian Americans 
(Manzi 2009). The genetic loci for FcyRIIB and Toll-like receptor 7, differential 
expression of which may lead to protection from the malarial parasite Plasmodium 
falciparum, have been linked with Lupus predisposition, suggesting that genes which 
once protected women of African descent from malaria now contribute to 
autoimmune disregulation (W aisberg et al 2011 ). Important in understanding SLE is 
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that the disease is polygenic and multifactorial. Although some allelic mutations have 
been confirmed to be related to Lupus, for instance the complement protein Clq 
which plays a vital role in cellular debris clearance (Manzi 2009), there are many 
related gene loci that have yet to be discovered. Additionally, environmental factors 
take a significant and multifaceted toll on SLE progression and flaring (Manzi 2009). 
Contemporary treatment options focus on reducing inflammation and 
thrombosis in order to prevent systematic damage which could result in increased 
mortality risk (D'Cruz 2006). Clinical monitoring of Lupus patients includes 
urinalysis and metabolic profiles to insure organ based damage is not accumulating 
and that immunosuppressive drug regimens are not leading to systemic endangerment 
(D'Cruz 2006). Increasingly more attention is being paid to the role of B cell activity 
in SLE. B cells in Lupus patients do not undergo the same maturation processes as 
those of normal patients, leading to increased autoreactivity and specifically increased 
production of autoantibody repertoires (Jacobi and Diamond 2005). B cells are 
integral in propagating antibodies specific to self peptides and DNA (James and 
Harley 1998). Given the relative overactivity of B cells in Lupus patients, new drugs 
including rituximab and belimumab (Manzi 2009, Thanou-Stavraki 2011) are being 
administered which aim to decrease B cell activity while specific inhibitors of 
presented B cell antigens are being considered [see Discussion] (Manzi 2009). 
Traditional treatments for SLE patients include nonsteroidal anti-
inflammatory drugs (NSAIDs), antimalarials, and steroids (Wallace 2001). 
Immunosuppression and subsequent susceptibility to infectious diseases in Lupus 
patients due to drug-induced changes of non-specific immune cells are concerns in 
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treating Lupus (de la Fuente et al 2001). Therefore, more specific and effective drug 
treatment options (Monneaux and Muller 2003) that avoid system-wide 
immunosuppression would be a boon to SLE patients. 
Antigen Processing and Presentation 
Immune Cell Interactions 
Immune system cells perform vital roles in protecting the body from 
pathogens such as bacteria and viruses . The immune system's function may be 
represented by a model of different branches of immunity which are modified by 
interactions between body systems. The cellular component of innate immune 
function is non-specific and is the immediate response in the case of an invasive 
pathogen. This includes the activity of neutrophils, macrophages, and natural killer 
(NK) cells in killing pathogens and initiating inflammatory response. Alternatively, 
the humoral and cellular components of adaptive immune response establishes a 
memory of pathogenic antigens, recognizable components of foreign molecules, and 
prepares the immune system to respond more rapidly in the case of another exposure 
to recognized antigenic materials (Kindt et al 2007). This study focuses on antigen 
processing and presentation: the molecular steps involved in the transition from 
innate to established adaptive immunity. 
Immune recognition involves interactions between various immune cells and 
lymphocytes including T and B cells . It is the job of antigen presenting cells (APCs) 
to act as the sentinels against foreign pathogens. In particular, the professional APCs, 
macrophages (M0), B cells, and dendritic cells (DCs), are the most proactive in the 
presentation of antigenic peptides to other cells. Many APCs circulate through the 
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matrices of the body and engulf antigens through endocytic processes, and once they 
have sampled enough potentially antigenic materials, they change phenotypes and 
present their discoveries to other immune cells. Whole pathogens, cellular matrix 
fluids, and cellular components are taken up into APCs through endocytic processes 
such as phagocytosis, pinocytosis, or receptor-mediated endocytosis (reviewed in 
Roberts 2005). Although B cells are not actively phagocytic under normal 
circumstances (Bryant and Ploegh 2004 ), they are efficient in uptaking antigenic 
materials through the B cell receptor (BCR) and TLR9 pathway (Siemasko and Clark 
2001 ), which has been correlated specifically with the uptake of DNA containing 
antigens and related to autoimmune response (Chaturvedi et al 2008). 
After potential antigens are engulfed by APCs, endocytosed materials are 
shuttled through the endosomal pathway to the lysosome. In the increasingly harsh 
environment of the endocytic pathway, proteins are degraded by proteolytic enzymes, 
generating smaller peptides. Short peptidic fragments of about 10-12 amino acids are 
presented by the major histocompatibility complex (MHC) class Ila molecule on the 
surface of antigen presenting cells (APCs), including B cells, and are recognized by 
hypervariable T cell receptors (TCRs) on the surface of T helper cells. Positive 
recognition by T cell receptors and associated costimulation, discussed later, triggers 
an activating response including lymphocyte proliferation, inflammatory signal 
cascades, and eventual establishment of memory cells and antibody production. This 
• MHC Class I and Class II molecules play different roles in antigen presentation. Whereas MHC-Il are 
specific to APCs, MHC-1 molecules are constitutively expressed and serve as biological signals of 
infectious activity, directing immune response to infected cells. In the case of viral and bacterial 
infections, peptide particles derived from infectious agents may be presented on the infected cell 
surface via MHC-1 molecules. Antigenic particles may then be recognized by the cellular immune 
system, triggering controlled responses to positive foreign antigen recognition (Haffner et al 1995). 
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study focuses primarily on two aspects this process: the cleavage of proteins in the 
lysosome by cathepsin enzymes and the surface expression of MHC-11 and important 
associated costimulatory molecules. 
Cathepsin Proteolysis 
The cathepsins are a family of proteases involved in the processing of antigens 
and regulation of MHC-II presentation pathway. Cathepsins are papain-like proteases 
that are active primarily intracellularly, particularly in the endosomal-lysosomal 
environment, but some are expressed extracellularly (reviewed in Roberts 2005). 
Cathepsins are initially synthesized in the endoplasmic reticulum (ER) as inactive 
zymogens and only attain activation by proteolytic cleavage or autocatalytic 
activation in the low pH of the endosomal-lysosomal environment (Roberts 2005). 
Activity is prevented during their journey through the golgi and endocytic pathways 
by propeptide blockage of the active site to prevent inappropriate proteolysis (Honey 
and Rudensky 2003, Roberts 2005). Once mature, cathepsins are free to degrade 
macromolecules in the endosomal-lysosomal environment. 
The catalytic mechanism of cathepsins is well described. Most cathepsins 
utilize the amino acid cysteine as the nucleophile (Cat B, L, S, H, X, C). The related 
protease asparagine endopeptidase also uses a cysteine nucleophile. Some cathepsins 
are aspartic proteases (E,D) and one is serine based (G) (Liitzner & Kalbacher 2008, 
Honey & Rudensky 2003). For cysteine proteases, the cysteine thiol group is 
stabilized by a neighboring histidine residue, promoting a nucleophilic attack by the 
sulfur on the positive carbonyl carbon of a peptide bond, resulting in peptidic activity 
(Fig. 2) (Roberts 2005, Stryer et al 2007). 
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Figure 2. A generic cysteine-based mechanism for proteolytic cleavage by cathepsin 
enzymes (Roberts 2005). 
Cathepsins Regulate MHC-II Maturation 
Cathepsin activity is of vital importance in the regulation of the MHC-II 
presentation pathway and the generation of antigenic peptides. Cathepsin proteolysis 
is crucial in the degradation of the invariant chain (Ii). Ii is a polypeptide that 
associates with immature MHC-11 as it is formed within the endoplasmic reticulum; 
the Ii serves as a chaperone that guides the MHC-II through the golgi, to the 
endosome, to the plasma membrane (Honey and Rudensky 2003). In B Cells, Ii is 
required to properly transport MHC-II molecules to the cell membrane, although 
some DCs MHC-11 haplotypes have a mechanism through which MHC-11-peptide 
presentation may occur independent of Ii (Rovere et al 1998). MHC-II trafficking is 
in part modulated via the leucine-rich targeting domain of the cytoplasmic tail of Ii 
and is AP2 clathrin mediated (Dugast et al 2005). It has been proposed that certain 
isoforms of Ii are involved in the regulation of cathepsins through inhibitory 
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mechanisms (Lennon-Dumenil et al 2001), but more recent studies have pointed to 
cytokines such as interferon-y (IFN-y) as having more significant regulatory effects 
(Rudensky and Beers 2006). 
The stepwise degradation of Ii as the MHC-ll molecule progresses through the 
endocytic pathways is mediated by various cathepsin enzymes (Honey and Rudensky 
2003). Studies using proteolytic inhibitors show that the initial cleavage of Ii is 
promiscuous, pointing to redundancy for cathepsin enzymes in initiating antigen 
loading mechanisms, but initial cathepsin cleavage is somehow dependent on the 
MHC-11 molecule haplotype (Constantino et al 2008). As the Ii degradation pathway 
continues, cathepsin cleavage sites become increasingly specific and may be variable 
among different cell types. Indeed, in some human nonprofessional APC lines, the 
final cleavage of Ii is inextricably dependent on cathepsin S, with Ii intermediate 
molecule buildup in cells that are deprived of IFN-y, verifying the importance of IFN-
'Y signaling required for Cat S transcription (Bania et al 2003). In DCs and B cells, 
Cathepsin S makes the final cut of Ii to leave a small peptide, the class II-associated 
invariant-chain peptide (CLIP), within the binding groove (Honey & Rudensky 
2003). Alternatively, in cortical thymic epithelial cells (cTEC' s) , which are involved 
to some degree in antigen presentation in the thymus, Cat L makes the final cleavage 
while Cat Fin macrophages may perform the job of Cat S in the last cleavage step of 
the Ii to produce a small bound peptide in the absence of active Cat S (Shi et al 2000, 
Honey and Rudensky 2003). These networks of cathepsin mechanisms allow the 
immature MHC-11 molecule to progress through the endosomal maturation pathways 
without premature loading of an improper peptide in the binding groove. 
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During the maturation of MHC-II in the late endocytic pathway, CLIP is 
exchanged for an antigenic peptide via the H2-DM regulatory molecule in mice 
(Unanue et al 2005), which is highly conserved as HLA-DM in humans (Sanderson et 
al l 995, Dugast et al 2005). Ii is therefore a crucial subsidiary molecule in the MHC-
11 antigen presentation pathway and its cleavage is influenced in a stepwise fashion 
by different cathepsins in a cell-specific manner (Santambrogio et al l 999, Unanue et 
al 2005). 
Cathepsins Mediate Antigen Generation 
In addition to cathepsins' roles in MHC-II trafficking, they are actively 
involved in generating antigenic peptide repertoires in APCs through the proteolytic 
degradation of endocytosed macromolecules (Honey and Rudensky 2003). Each 
cathepsin is capable of cleaving a variety of peptides by recognizing a cathepsin-
specific sequence of residues in the target substrate (Liitzner and Kalbacher 2008, 
Roberts 2005). Although many cathepsins have promiscuous proteolytic activity, they 
have certain predispositions to substrate qualities; for example, Cat B prefers 
arginine-glycine and hydrophobic residues at certain substrate positions, Cat L prefers 
hydrophobic residues, while Cat S prefers leucine or valine at specified residues 
(Roberts 2005). The preference of cathepsins for certain substrates is an important 
quality that allows for quantitation of activity using fluorescent substrates targeted for 
individual cathepsins (Fig. 10). 
Cathepsins may have both productive and destructive effects in defining 
antigenic repertoires (Bryant and Ploegh 2004); that is to say that epitopes may be 
either generated or destroyed by variations of proteolytic activity experienced in the 
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endosomal-lysosome pathway. Cathepsin activities are intricately related to each 
others' enzymatic activity in the lysosome and the processing of antigenic materials 
thereof (Driessen et al 2001). Analysis of peptides eluted from MHC-II complexes 
via mass spectroscopy has revealed that both Cat L and Cat S are critical in 
determining the peptides presented to the surface of the cell either by directly 
affecting the degradation of antigenic peptides themselves or degrading Ii 
intermediates differentially, changing MHC-II presentation profiles (Hsieh et al 
2002). It follows that altered cathepsin activity may alter the balance of proteolysis in 
the endosomal-lysosomal pathway and induce immunologic changes, especially in 
A PCs. 
Cathepsins are expressed to a range of degrees dependent on tissue, cell type, 
genetic makeup, cellular signaling, and environmental stress (Rudensky and Beers 
2006), lending to the diversity of their molecular actions. The cathepsins analyzed 
herein are cathepsins B, L, and S, whose roles are pivotal in antigen processing and 
presentation in addition to other functions. 
Cathepsin B is expressed ubiquitously and is an important protease integrally 
involved in reworking cellular structure, digesting pathogenic proteins, and digesting 
extracellular matrix (Honey and Rudensky 2003). Also, Cat B is important in the 
maturation of the central nervous system (CNS) and maintenance of nerve tissue 
homeostasis (Felbor et al 2002). Cathepsin Lis also ubiquitously expressed. Its 
proteolytic activity is vital to the continual restructuring of the morphology of the 
myocardium (Stypmann et al 2002), activation of zymogens such as proheparanase in 
the degradation of extracellular matJices (Abboud-Jimous et a. 2008), and 
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maintenance of the CNS (Felbor et al 2002). Unlike other cathepsins, cathepsin Sis 
expressed specifically in APCs. As described earlier, it is central to Ii chain 
processing as well as antigenic processing. The broad array of cathepsin targets has 
yet to be fully uncovered. 
Despite the utility of their normal cellular function, cathepsins may be 
hijacked by rogue cells to perform novel , injurious functions. Cathepsins have been 
implicated in various pathologies, especially in cancer metastasis and tumorigenesis. 
The overactivity of Cat B in tumor cells has been associated with greater metastatic 
potential, with as much as 11 times the amount of Cat B being released in malignant 
breast tumor cells compared to normal tissue (Sloane et al. 1981). Given that some 
cathepsins maintain collagenolytic and elastinolytic activities (Lah et al 1996), 
extracellular activity of cathepsins, particularly cathepsins Land B, is a mechanism 
for malignant cancer cells to digest surrounding matrices, assisting in the tumorigenic 
progression of malignant cells (Sloane et al 1981 ,Brujan et al 2009, Turk et al 2004). 
Other cathepsins have been implicated in extracellular roles; for instance, cathepsin K 
expression in osteoclasts is requisite in performing vital bone matrix resorption, and 
impedance of expression leads to debilitating bone disorders (Gelb et al 1996). The 
control of activity through intracellular signaling is paramount to proper cathepsin 
regulation as deviations from the controlled state could result in pathology. Estrogen 
in particular has been related to cathepsin regulation (Capony et al 1990). If abnormal 
estrogenic regulatory mechanisms are activated then cathepsin function could go 
awry. 
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It is plausible that changes in cathepsin activity could lead to the generation of 
a different set of antigenic peptides available for MHC-11 presentation. These antigens 
could be derived from self-epitopes and some may bind to MHC-11 with high affinity 
and/or elicit positive response from T cell receptors. The binding groove of MHC-11 
is selective of families of antigenic peptides of around 12-26 mers which share a 
common sequence at the core with variable residues flanking either terminus of that 
core (Suri et al 2006). The allelic haplotype of MHC-11 molecules is therefore crucial 
when considering autoimmunity since promiscuous binding sites could potentially 
present a wider range of epitopes, including autoantigens, and bypass negative 
selection in the thymus due to low affinity for the bound antigen (Unanue et al 2005, 
Suri et al 2006). This model for autoimmune pathogenesis calls into question the 
available peptides for presentation; could a larger pool of self-derived antigens, 
perhaps due to differential cathepsins activities , lead to increased risk for 
autoimmunity? Variation in the activity of cathepsins could alter the antigenic 
repertoire available for MHC-11-restricted presentation by APCs and change the 
efficacy of MHC-11 antigen binding, trafficking to the membrane, and presentation to 
T cells. 
Cathepsin L 
Cathepsin B __ [~-­
Cathepsin S ~~-·--" 
Figure 3. Bioinformatic studies located several putative EREs in the genes for Cathepsins 
L, B, and S. In total , Cathepsin L contains 5, Cathepsin B contains 14, and Cathepsin S 
contains 10 putative EREs. Yellow represents lOkb nucleotide sequences upstream and 
downstream of the green primary transcript region. Red lines indicate ERE in forward 
direction, blue lines indicate ERE in reverse direction. Identified using Dragon ERE 
Finder in the Mus musculus genome (Roberts and Heayn, unpublished) . 
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APC-T cell Costimulation 
Although cathepsins are crucial to the generation and subsequent presentation 
of antigenic peptides, complementary recognition of a peptide-class II complex by a 
TCR is not adequate for a full-fledged immune response. The interaction of an MHC-
II molecule, presenting an antigen loaded in the binding groove, with a specific, high 
affinity, complementary TCR on an adjacent T cell surface is necessary but not 
sufficient in stimulating a lymphocyte response (Kindt et al 2007). Additional events 
must occur to fortify the signal and encourage immune cell activation (Fig. 4). 
Several costimulatory molecules are expressed on the surface of antigen-presenting B 
cells, including cluster(s) of differentiation (CD) CD40, CD80 and CD86. When a 
TCR is positively complimentary to an antigen presented by an MHC-11 molecule, 
other proteins become involved to initiate activation of the interacting cells. These 
events include the binding of CD40 (CD154) on the APC to CD40 ligand (CD40L) 
and APC CD80/CD86 interaction with CD28 and/or CD152 (CTLA-4) on T cells. 
Negative 
Control Proliferation T cell 
crf" 
Differentiation lgG Production B cell 
Proliferation 
Cell Cycle Regulation 




Interaction of CD40 on APCs, in particular B cells, with CD40L promulgates 
influential cellular signals. CD40 is a transmembrane protein and part of the tumor 
necrosis factor (TNF) receptor superfamily (NCBI CD40). CD40 signals serve as 
proliferative B cell activators (Clark and Ledbetter 1986). The molecular mechanisms 
of CD40 interactions involve binding of CD40 to CD40L, which initiates recruitment 
of several TNF receptor-associated factors (TRAFs) to the protein complex; these 
signals are reinforced synergistically by interleukin (IL)-4 (Kuhne et al 1997). CD40 
signals are variable depending on the phenotype of the B cell. For instance, in 
immature B cells, CD40:CD40L binding prevents the upregulation of Fas protein, an 
important TNF receptor mediating apoptosis, thus prolonging cell propagation and 
preventing cell death. Alternatively, germinal center (GC) B cell CD40 binding does 
the exact opposite, promoting apoptosis, therefore implicating that CD40 pathways 
can change in different phenotypic environments (Kuhne et al 1997). Proper 
immunoglobulin class switching and antibody (Ab) production are dependent on 
established signaling through CD40:CD40L and defects may present pathology such 
as X-linked hyper IgM syndrome (Nonoyama et al 1993). Other established CD40 
related pathways include B cell memory establishment and formation of germinal 
centers in lymphatic tissues (NCBI CD40). The expression of CD40 influences 
several aspects of B cell function and its signals are vital to maintaining normal B cell 
action. Ligation of CD40:CD40L has profound effects on immune function outside 
the scope of lymphocytes, such as in vascularization and endothelial adhesion and 
migration of leukocytes to sites of inflammation (Urban et al 2011). 
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The costimulatory molecules CD80 and CD86 (also called B7-1 and B7-2 
respectively) are surface proteins expressed primarily in APCs, including B cells. The 
two molecules bond to each other and form a membrane oligomer (Greene et al 
1996). Both CD80 and CD86 act as receptors for T cell molecules CD28 and CTLA-4 
(Borriello et al 1997). The immunoglobulin (lg) extracellular domain of CD80 
contains structural domains that mediate binding to T cell surface proteins CD28 and 
CTLA-4; protein moieties allow both of these molecules to bind either receptor but 
with different kinetics, as later discussed (Peach et al 1995). The binding of the B7 
molecules to the ligand CD28, a protein expressed on the surface of T cells, is a key 
step in lymphocyte costimulation, resulting in activation and proliferation signaling 
among T cells interacting with APCs (Linsley et al 1991 ). When MHC-11-restricted 
binding occurs at a TCR on a T cell , subsequent signals upregulate the expression of 
CD28 on the cell surface and the CD28 molecule directs further signaling reinforcing 
T cell activation (Sansom et al 2003). Alternatively, B7 molecules may bind to the 
CTLA-4 protein which, unlike CD28, is shuttled to the membrane only in the case of 
T cell stimulation and experiences rapid recycling (Sansom et al 2003). Knockout 
mice that are CTLA-4+ display a fatal phenotype due to highly proliferative T 
lymphocytes, showing that CTLA-4 acts as an import negative regulator of T cell 
activation and proliferation (Waterhouse et al 1995), either by disrupting TCR initial 
signaling or by generating negative signals further down the road to reduce the 
efficacy of activation events (Sansom et al 2003). Data clearly suggest that B7 
binding to CTLA-4 versus CD28 have opposing effects in terms of APC controlled T 
cell activation (Krummel and Allison 1995), but it is still uncertain whether the 
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contradictory roles of these molecules is due to ligand competition, in which higher 
affinity CTLA-4 competes for lower affinity CD28 binding, thus thwarting 
proliferative CD28 signals, or by each molecule controlling unique positive or 
negative signaling pathways, or by unknown mechanisms (Sansom et al 2003). 
COBO (1 -50kB) 
COBO (50-60kB) 
COB6(1-50) 
COB6(50-B3) II II 
Figure 5. The genes for clusters of differentiation CD80 and CD86 contain putative EREs in 
the encoding regions and in the 10 kilobase-pair regions flanking the upstream and 
downstream coding regions. Red lines represent motifs in the forward directions and blue 
lines in the reverse direction. Sequences located using Dragon ERE Finder Ver. 2.0. Roberts 
and Heayn, unpublished data. 
CD80 has higher avidity and affinity for CTLA-4, suggesting that CD80 may 
be a more effective ligand for CTLA-4 and that CD80 is the preferred over CD86 in 
generating negative signaling for T cells (Sansom et al 2003). The kinetics of 
CD28/CTLA-4 surface presentation and binding produces unclear effects on the 
signaling produced by surface B cell - T cell interactions (Greene et al 1996). 
Additionally, since CTLA-4 does not bind to CD86 monomers with high avidity, it 
is hypothesized that CD80/CD86 oligomerization or surface clustering of bound 
oligomers may be a pivotal step in achieving ligand binding efficacy (Greene et al 
1996). A model has been suggested to describe the function of CD80-CTLA-4 
interactions in the absence of inflammatory signals (Sansom et al 2003). In this 
model, APCs expressing CD80 interact with CTLA-4 of Treg cells in the absence of 
inflammation, thus acting as a control for immune cell homeostasis and suppressing 
the potential signal generated by autoantigens. This would promote tolerance of 
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autoantigens. In the event of inflammatory signaling, APCs upregulate the expression 
of CD86 and T cell activation is favored , thus overcoming the suppressive signals of 
CD80. Given the upregulation of CD86 on DCs in the presence of antigenic stimuli, 
this model could be a viable explanation of the CD80-CD86-CD28-CTLA-4 complex 
interactions. However, further studies are required to better define the exact role for 
CD80-CTLA-4 signals in maintaining tolerance to autoantigens. 
Although much is known about T cell activation through B7 family 
molecules, relatively little is known about B cell changes resulting from these 
molecular interactions. However, research suggests that CD80 binding inhibits B cell 
differentiation and proliferation whereas CD86 binding spurs B cell growth, 
implicating CD80 involvement in a negative signaling pathway while CD86 may 
serve as a growth promotion pathway for B cells (Suvas et al 2002). Both CD80 and 
CD86 are crucial to B cell phenotypic development as influenced by T cells. Mice 
that are CDS0-1- and CD86_,_ do not undergo antibody class switching and show 
deficient germinal center formation , but B cells produce IgM, showing that B7 
molecule interaction with T cells is crucial to switching production to IgG (Borriello 
et al 1997). Moreover, in the absence of CD80, CD86 is able to partially compensate 
for CD80 signals in GC formation whereas CD80 is incapable of making up for a 
deficiency in CD86, implying that CD86 is more necessary to T cell induction of B 
cell phenotypes (Borriello et al 1997). Activated B Cell CD86 interactions with CD28 
on T cells stimulated human B cells to produce increased levels of IgE and IgG4, 
showing that the B7 molecules do indeed influence B cell activation in addition to 
their important jobs in T cell coactivation (Jeannin et al 1997). Some cellular actions 
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of CD86 binding affect B cells independent of T cell stimulation (Rau et al 2009). A 
chimeric in vitro study in which only B cell populations were B7-i-'- proved that B7-2 
activation was paramount to stimulate lgG production by B cells which had already 
been class-switched without regard to cytokine signals from activated T cells, 
verifying importance of B7 stimulation in Ab production independent of soluble T 
cell molecular signals (Rau et al 2009). The sum of these data suggests that both 
CD80 and CD86 are integral players in lymphocyte costimulation and B cell 
differentiation and activation. 
Other costimulatory pathways have been identified that have a dramatic effect 
in T cell coactivation through B cells. The human protein ICOS, which has a murine 
homologue, is structurally similar to CD28 and is expressed on activated T cells. 
ICOS can bind to a membrane ligand on B cells with similar structure to the B7 
molecules called B7-related protein-1 (B7RP-1) (Yoshinaga et al 1999). Together this 
costimulatory pair of molecules influences activation of lymphocytes during immune 
response and blocking the interaction of these molecules partially ameliorates 
lymphocyte overactivity in NZB/WF1 mice (Hu et al 2009). Immunoglobulin 
mediated costimulatory blockage of both CTLA-4 and CD40L significantly delayed 
the onset of murine Lupus in NZB/WF1 mice, further defining a role for lymphocyte 
interactions through costimulatory molecules in autoimmune pathogensis for a Lupus 
model (Wang et al 2002). Previously, members of the Roberts lab have identified 
estrogen response elements [see Estrogen and Bisphenol A] in the regulatory regions 
of the CD80 and CD86, opening up new doors to investigate estrogen or related 
molecules influence on costimulatory profiles (Fig. 5) (Roberts and Heayn, 
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unpublished data). This study examines the surface molecular profile of splenic B 
cells NZB/WF 1 mice versus that of control C57BL/6 mice and attempts to elucidate 
the influence of the physiological hormone estrogen and the environmental endocrine 
disrupting chemical bisphenol A on normal immune function. 
Estrogen and Bisphenol A 
Estradiol 
The primary female steroid sex hormone estrogen (l 7~-estradiol;E2) is 
responsible for many of the endocrine differences between males and females. The 
hydrophobicity of E2 allows the molecule to freely diffuse across cell membranes 
while its vascular transport is crucial in distributing the hormone throughout the body 
(Fig. 7) (Stirone et al 2003). Estrogen is capable of binding soluble proteins in the 
nuclear receptor family called estrogen receptors (ERs) whose corresponding 
expression is controlled directly by estrogen concentration (Fig. 6). This feedback 
mechanism is hypothesized to be a naturally-selected mechanism to counter the 
constant degradation of ERs by the 26S proteosome, making E2-regulation effective 
by providing enough ER to breach regulatory thresholds (Wijayaratne and McDonnell 
2001,Stirone et al 2003, Horigome et al 1988). It should be noted that the stability of 
ligand-bound ERs is dependent in part on the identity of the ligand, the conformation 
of the receptor, and cytosolic protease activity (Wijayaratne and McDonnell 2001 , 
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Figure 6. The genes for ERa and ER~ contain putative estrogen response elements; ERa 
contains 51 EREs and ER~ contains 6. Yellow represents IOkb nucleotide sequences 
upstream and downstream of the green primary transcript region. Red lines indicate ERE in 
forward direction, blue lines indicate ERE in reverse direction. Identified using Dragon 
ERE Finder in the Mus musculus genome (Roberts and Heayn, unpublished). 
Of particular relevance to estrogenic regulation are nuclear receptors ERa and 
ERp. Multiple splice variants of these protein hormone receptors exist (Stirone et al 
2003).The mechanisms of these nuclear receptors are well understood (Stryer et al). 
E2 binds ERa or ERP in the cytosol and the protein undergoes conformational 
changes that allow the ER:E2 conjugate molecule to enter the nucleus through the 
nuclear pores. Within the nuclear environment, ligand-bound, activated ERs bind to 
regions of DNA called estrogen response elements (EREs). An ERE is a span of 
nucleotides where an ER receptor-ligand complex is capable of binding. When bound 
ERs are able to regulate transcriptional activity via recruitment of coactivators or 
corepressors. 
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The aforementioned transcription factor complex is the classical estrogen 
response pathway, although others exist (Razandi et al 1999, Pierdominici et al 
2010). It has been shown that membrane bound ERs, which exist as transmembrane 
proteins anchored in the cell membrane, are derived from the same mRNA transcripts 
as ERu and ERP nuclear receptors (Razandi et al 1999) and are highly homologous to 
the nuclear receptors (Stirone et al 2003). They act in G protein, ERK, and various 
other intracellular signaling cascades and perform other cytosolic functions that are 
not involved in gene regulation directly (Razandi et al 1999, Pierdominici et al 2010). 
Both ERu and ERP nuclear receptors are expressed in circulating blood lymphocytes 
(T, B, and NK cells) and at least one membrane ER (mER) closely resembles the 
structure of the ERa.46 isoform, consistent with its binding site and mode of action 
(Pierdominici et al 2010). Therefore, transcriptional activity may be influenced by 
estrogenic molecules in lymphocytes through nonclassical estrogen pathways in 
addition to nuclear receptor mechanisms of action. 
Estrogen levels are regulated differentially over the course of menstruation 
and ontogeny. E2:ER binding leads to myriad molecular modifications. Estrogenic 
effects are particularly relevant in understanding induced changes of immune system 
mechanisms. Increased estrogen concentrations have been shown to depress 
hematopoietic development of lymphocytes in bone marrow and inhibit APC function 
(Lang 2004). Retrospective studies correlate increased estrogen levels with Lupus 
flares during pregnancy when estrogen levels are high, but this mode of action is 
opposite in other autoimmune diseases such as rheumatoid arthritis (RA) and multiple 
sclerosis (MS) in which pregnancy normally triggers a disease remittance (Lang 
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2004). These counterintuitive estrogenic effects are in part explained by a model 
suggesting that a significantly increased estrogen concentration triggers an elevated 
T H2 response while suppressing TH 1 response, which is a reversal of the normal 
female condition, therefore favoring humoral over cellular immune system function 
and potentially exacerbating the antibody-related symptoms of SLE (Lang 2004). The 
induced humoral response may therefore compel antibody class switching, T cell-B 
cell interactions, increased plasma cell activity, and lead to the production of ;m 
excess of antibodies, including autoantibodies such as antinuclear antibodies (Lang 
2004). Estrogen evidently modulates the immune system in a variety of ways. 
Bisphenol A 
Humans are constantly exposed to exogenous chemicals from the 
environment, some of which can have detrimental effects and may play a role in 
disease progression. While endogenous estrogen concentrations are normally 
managed by the endocrine system, particularly by ovarian tissues in females, 
environmental chemicals with similar molecular properties as estrogen may disrupt 
normal hormonal pathways. The chemical bisphenol A (4,4'-dihydroxy-2,2-
diphenylpropane;BPA) has been classified as an endocrine disruptor (Schonfelder et 
al 2002) and is thus of concern in examining the effects of environmental hormonal 
activity in immune dysfunction. 
BPA is a high production chemical with >8 billion pounds being produced 
annually on the global scale (Vandenberg et al 2010), including 2.4 billion pounds 
produced in the United States alone in 2007(EPA BPA). Its usage varies, but BPA is 
utilized primarily as a monomer in the manufacture of polycarbonate plastics and 
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epoxy resins. Humans are constantly exposed to BPA through products such as hard 
plastic water bottles, compact disks, dental sealants, medical equipment, baby bottles, 
lacquers, linings for food containers, and non-carbon papers used in printing and 
receipts. Heat and wear can accelerate BPA leaching from products and thus increase 
ingestion (NTP BPA factsheet) . In 2009, a non-randomized study at Harvard College 
found that drinking out of polycarbonate bottles over the period of 1 week increased 
urinary concentrations of BPA by two-thirds (Carwile et al 2009). People are exposed 
to BPA through a variety of products and activities, potentially making them 
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Figure 7. Chemical structures of 17P-estradiol (left) and bisphenol A (right). Drawn using 
ChemDraw Ultra vl 1.0. 
By binding to ERs, estrogenic chemicals can alter the transcriptome in target 
cells. A transgenic murine model derived from the C57Bl/6 strain with a luciferase 
reporter downstream of estrogen response elements (EREs) has shown that BPA 
binding to both ERa and ERP is capable of inducing transcription at a fraction of E2 
induction, based on concentration (Lemmen et al 2004). The reported EC50 (median 
effective concentration) of ERa and ERP for BPA were 1.6 x 10-7 M and 1.6 x 10-7 
M respectively, suggesting that BPA binds to both endogenous estrogen nuclear 
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receptors with similar affinity albeit with far (-10,000 x) less efficacy than strong 
estrogenic molecules such as 17~-estradiol (Lemmen et al. 2004). BPA and BPA 
homologues, such as hexafluoro-bisphenol A, another chemical utilized in polymer 
industries, have been shown to bind to other nuclear receptors such as estrogen-
related receptor gamma (ERR-y), indicating that BPA and related molecules may act 
through additional hormonal pathways not yet considered in the context of Lupus 
(Okada et al 2008, Matsushima et al 2010). Despite BPA's dissimilar binding kinetics 
for estrogen receptor molecules, it still maintains the ability to activate transcription 
at ERE localities. Importantly, EREs have been located both upstream and 
downstream of initiation sites for genes of cathepsins B, L, and S, the costimulatory 
molecules CD80 and CD86, and the pattern recognition receptors TLR4 and TLR9 
(Fig. 9) [see Antigen Processing and Presentation and Cathepsin Enzymes] (Roberts 
Lab, unpublished). 
Recent metabolic studies have proven that people are constantly exposed to 
BPA and that the body circulates the chemical. Parent (unmetabolized) BPA 
molecules are hydrophobic and BPA has been connected with altered metabolic 
activity due to accumulation within hydrophobic adipose tissue (Fig. 7) (Ben-
Jonathan et al 2009). BPA accumulates through exposure and circulates within the 
human body. A recent analysis of a sample population found that 92.6% of 
Americans > 6 years of age have detectable metabolites of BPA in their urine, 
suggesting constant, low-level exposure to the chemical in vivo. Exposure is variable, 
with women, youth , and those with low income maintaining the highest 
concentrations (Calafat et al 2008). Calaf at et al found that BPA concentrations are 
variable throughout the day and relate this variability to lifestyle and a flux in 
exposure to BPA-containing products (Calafat et al 2008, Calafat et al 2005). 
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The nonlinearity of BPA dosage and BPA or BPA-conjugate bioavailability 
may imply that there are limits to BPA metabolism in which high dose exposure may 
result in inordinately high absorbed concentrations (Domoradzki et al 2003), 
increasing the risks of high levels of exposure. Some evidence suggests that the low 
bioavailability of parent BPA molecules, those with estrogenic capacity, in vivo is due 
to an extensive first pass metabolism, the first time a molecule enters the hepatic 
portal system, and the removal of BPA from the blood plasma (Domoradzki et al 
2003), but unconjugated estrogenic BPA still circulates in the blood at measurable 
concentrations, and BPA metabolites have the capacity to be reactivated by 
degradation or through catalytic mechanisms (Vandenberg et al 2010), putting people 
at risk to the estrogenic effects of BPA. High concentrations of BPA may cause 
detrimental effects due to improper metabolic control (Domoradzki et al 2003). 
However, low levels of exposure are the normal situation for most people (Calafat et 
al 2008) and those low doses displayed a myriad of biological effects, including 
immunomodulatory effects (Sawai et al 2003, Lang 2004, National Toxicology 
Program 2008). 
Those people suffering from autoimmune disease are at increased risk of 
suffering the consequences of environmental endocrine disruptors. This study 
examines the role of BPA and E2 in antigen processing and presentation (Fig. 8). 
Studies in mouse models have ascertained immunomodulatory roles for BPA (Yan et 
al 2008, Sawai et al 2003 ). As of 2006, 92% of the l 09 government funded in vivo 
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studies involving low dosages have uncovered harmful biological effects of BPA 
using mammalian models (vom Saal and Welshons 2006). Given the endocrine bias 
in Lupus patients (Lang 2004), physiological functions may be particularly vulnerable 
to BPA-induced changes (Lemmen et al 2004, Schonfelder et al 2002). Also, women 
maintain higher circulating concentrations of BPA (Calafat et al 2008), which may be 
relevant especially in the context of Lupus. This study may further contribute to 
understanding the molecular targets of environmental estrogens by examining the 
influence of low nanomolar dosages of E2 and BPA in vitro on cathepsin activity and 
B cell surface molecules involved in lymphocyte costimulation. 
Changes in cathepsin activity could change the antigens being presented by 
APCs and thus redirect immune system activity. Changes in cathepsin activity could 
be due to regulation by estrogen or BPA through EREs (Fig. 8). In addition, 
estrogenic molecules might change the surface expression of MHC-II and associated 
costimulatory molecules and thereby change the degree of immune response (Fig. 8). 
The interplay of antigen processing, presentation, and immune response may be 
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The ease of care, sustainability, and well-studied genome of the mouse makes 
it an invaluable model of human physiological systems and disease (Bedell et al 
1997). Two strains of mice will be considered in this study. C57BL/6 (BL6; Black 6; 
B6) mice will act as a control strain. These are laboratory-raised mice commonly used 
as controls or transgenic models and have a history of successful implementation in 
immunological experiments (Caturegli et al 2000). Additionally, BL6 mice were used 
as the source of DNA in developing the primary draft of the mouse genome (Jackson 
Zuber33 
Labs), crystallizing its utility in genetically different cross comparison to other mouse 
strains. The BL6 mice used in the study were either bred at Jackson Laboratories 
(Jackson Labs) or were bred at Ursinus College under the protocol later described in 
the Materials and Methods section: Mice. 
The experimental strain will be the hybrid first generation offspring (F 1) of 
female NZB/BlNJ crossed with male NZW/LacJ (NZB x NZW[Fl]) . Females of the 
NZB/WF1 strain are genetically predisposed to Lupus-like autoimmunity early in 
their lifetime due to hormonal disregulation (Jackson Labs, Pollard et al. 1999). They 
are generally accepted as an excellent murine model for SLE (Rudofsky and 
Lawrence 1999) and will be used as such. SLE is a polygenic and multifactorial 
disease, and the genetic loci causing autoimmune symptoms in these mice is as 
misunderstood as human genetic predispositions, but the similarity of symptoms 
support the rationale of these mice as a model for human Lupus. Female mice will be 
used in order to mimic the overrepresentation of women affected by Lupus (Manzi 
2009) and the nature of the estrogen sex hormone in females. The homology of the 
mammalian immune system will allow concepts of immune system disruption in mice 
to be applied to humans (Bedell et al 1997). 
Techniques 
Cathepsin Activity 
Peritoneal macrophages, splenocytes, liver, and kidney cells can be obtained 
from C57BL/6 and NZB/WF1 mice and cultured in a complete PRFCT-RPMI 
medium (see Materials and Methods). Splenocytes for enzyme activity assays can be 
exposed to the mitogenic stimulator concanavalin A (ConA), which perpetuates the 
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cells to allow for a better assessment of stimulated immune function (Dutton 1972). 
Gram negative bacteria-derived lipopolysaccharide (LPS) may be used to stimulate 
splenic B cells prior to FACS analysis (Skidmore et al 1975). Lysing the 




Figure 9. The genes for Toll-like receptor 4 and 9 contain putative estrogen response 
elements (EREs). Yellow represents lOkb nucleotide sequences upstream and downstream 
of the green primary transcript region. Red lines indicate ERE in forward direction, blue 
lines indicate ERE in reverse direction. Identified using Dragon ERE Finder in the Mus 
musculus genome (Roberts and Heayn, unpublished). For a description of ERE function , see 
Estrogen and Bisphenol A: Estradiol. 
The protein concentrations of samples must first be obtained to normalize the 
protein content of samples when performing enzyme activity fluorescence assays . 
The Bradford protein concentration assay is advantageous in that it is highly 
sensitive, so it doesn't compromise the use of limited amounts of protein sample, and 
quick. The chemistry of the Bradford assay relies on the colorimetric change resulting 
from the deprotonation of a blue dye (coomassie blue G dye) in the presence of 
certain residues of amino acids. The more protein present in solution, the darker the 
solution and the higher the absorbance recorded at a wavelength of 595 nm (Bradford 
1976). 
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Cathepsin activity can be determined using fluorescent substrates as measured 
by a fluorometer. Aminofluorocoumarin (AFC) molecules are quenched by a peptide 
bond between a conjugated ring system and specified amino acids residues that can 
be exchanged to match the specificity of a cathepsin enzyme. In this way, a certain 
cathepsin can recognize the molecule, cleave the peptide bond, and release the ring 
system which fluoresces with an excitation wavelength of 400 nm and an emission 
spectrum of 505 nm. We will use AFC substrates specific to Cathepsins B, L, and S 
(Fig. 10). 
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Fluorescence Activated Cell Scanning 
Fluorescence activated cell scanning (FACS) may be employed to analyze 
cellular features using fluorescent properties of molecules. Antibodies conjugated to 
specific fluorochromes are used to tag a cell for molecular traits. The mean 
fluorescence intensity of colors can be compared if cross-referenced carefully and 
accounting for the differences between FACS machines and the variability of FACS 
lasers and sensors from day to day (Wells & Loken 2008). In essence, FACS is a tool 
for imaging cellular components in both a qualitative and quantitative fashion. 
The goal of sample preparation prior to FACS analysis is the creation of a 
suspended solution of individual particles. In order to accomplish a valid analysis of 
cell surfaces, cells should be intact for FACS. Apoptotic or necrotic cells and 
associated debris can be eliminated from the cells of interest (Fig. 12). In analyzing B 
cell surface molecules, it is important to keep B cells alive for the period of culture. 
Splenocytes were cultured for 18 hours in PRFCT-RPMI with various concentrations 
of E2 or BPA. In order to maintain B lymphocyte viability, 20 µg/mL 
Lipopolysaccharide (LPS) from Escherichia coli was added. LPS is an endotoxic 
lipoglycan molecule found on the surface of Gram-negative bacteria (Kindt et al 
2007) and is a powerful B cell mitogen (Skidmore et al 1975) which acts through the 
Toll-like receptor (TLR) 4 activation pathway (Triantafilou and Triantafilou 2002). 
LPS signals should be sufficient to perpetuate the B cell cycle in the culture 
environment. Interestingly, the TLR4 gene contains putative EREs, implicating a 
potential for estrogenic regulation of TLR expression and consequently for LPS-
mediated B cell mitogenic potential (Fig. 9). Proper FACS analysis of membrane 
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proteins per cell requires whole cells, so this step was taken to ensure B cell survival 
over the course of in vitro exposure to E2 or BPA (see Materials and Methods). 
Each cell may be tagged with specific fluorescent-conjugated antibodies 
targeting molecules of interest. Internal targets can be labeled if the cells are 
permeabilized prior to addition of antibody. Alternatively, when intact cells are 
labeled, primarily cell surface targets become conjugated to the antibodies. Here, 
non-permeabilized cells were labeled so all results correspond to the cell surface 
expression of the proteins under investigation. 
O_nce antibodies have bound to their target molecule, cells are resuspended in 
sheath (FACS Flow), a liquid designed specifically to run samples through a flow 
cytometer. The suspension of single particles will allow for laminar flow through a 
tiny tube near the laser detector, discussed later. In a process known as hydrodynamic 
focusing, single cells are directed to the center of a flowing liquid through the sensor 
tube, generating a laminar fluidic flow. Over the course of a distance known as the 
inlet length, the velocity of the fluid front can be described as a parabola, with the 
highest velocity liquid at the center of a cylinder dropping to a velocity of zero at the 
tube walls, allowing for analysis of cells one at a time. As the cells flow past a 
specific point of the tube they are optically analyzed by specific laser wavelengths 






Figure 11. A FACS flow chamber consists of a narrow space through which 
single particles pass and are bombarded with beams of high intensity light from 
lasers. Emitted light first passes through various filters designed to focus certain 
colors and electromagnetic signals are converted to digital signals by the machine 
prior to representation as data. 
Flow cytometers analyze cells by using specific wavelengths of intense light 
to excite fluorescent molecules which in turn emit light at a less energetic wavelength 
that can be detected, amplified, and evaluated as digital data (Ormerod 1990). The 
two initial parameters that are used to discern differences between cell populations 
are based on the principle of light scattering. Forward scatter (FSC) is detected in 
parallel to the light beam and describes the relative size, or volume, of a cell or 
particle. For example, a population of large leukocytes would appear higher on a 
scale of FSC than smaller erythrocytes. Side scatter (SSC) detectors are normally 
positioned perpendicular to the angle of incidence of a light beam and distinguish the 
relative complexity or granularity of the cell. Accordingly, if observing complex cells 
such as mast cells or eosinophils one might expect to detect high SSC for these cell 
populations. As a result, a plot of SSC versus FSC can be used to focus in on a cell 
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population (such as lymphocytes) that displays an expected SSC/FSC profile (Fig. 
12). 
Other parameters are measured based on the concept of fluorescent excitation. 
All cells autofluoresce at a low degree of intensity (Schwartz and Fernandez-Repollet, 
1994), so this characteristic must be considered and accounted for in the analysis of 
fluorescence intensities. Additionally, it gives the user the ability to discern between 
the background fluorescence of a color in the absence of fluorochrome-labeled 
antibodies. A threshold can then be set, where fluorescence detected beyond the 
threshold can be considered as representing the specific binding of the antibody to the 
molecule of interest (Figs. 13,14). 
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Figure 12. A representative scatter plot of forward scatter (FSC) versus side 
scatter (SSC) allows for population gating based on principals of light diffraction. 
20,000 events were gated. Increasing value on the x axis equates to larger cell 
volume while increasing value on they axis equates to increased intracellular 
complexity. The comet-shaped population of lymphocytes was gated separately of 
all other splenocytes and debris. This step allows for allows for a more specific 






Figure 13. Representative histogram of FITC fluorescence intensity in an 
unstained sample of 20,000 splenocytes. This graph is limited to lymphocytes 
only. The entirety of lymphocytes is gated by the interval gate in order to establish 
background autofluorescence of the cells for all relevant colors (Fig). Splenocytes 
are derived from a BL6 mouse. After establishing the background gates with a 
parent population of <l % ( <5% for PerCP-Cy5.5), the gate for B220-FITc+ cells 
was readjusted to encompass <I % of lymphocytes to ensure that positive gating is 






Figure 14. Representative histogram of FITC fluorescence intensity in a stained 
sample of 20,000 splenocytes. This figure is limited to lymphocytes only. Only 
B220+ B cells (background fluorescence in the positive intensity region accounts 
for <l % of parent population) are found in the interval gate and may then be used 
to examine costimulatory molecules on B cells only (Fig). Splenocytes are 
de1ived from a BL6 mouse. 
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Figure 15. Population hierarchies are established to examine qualities of specific 
subpopulations of cells . Dashed lines represent derivation of a subpopulation from 
parent populations. % parent describes the ratio of cells gated as positive in a 
subpopulation to the total number of cells in the parent population. % total 
describes the ratio of cells in a subpopulation to the total 20,000 events observed. 
MHC-11 and all costimulatory molecule positive subpopulations were examined in 
B220+ B cells only. B cells were examined in lymphocyte gates only. 
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Figure 16. Representative scatter plot of FSC versus SSC used to examine the 
relative sizes of B220+ B cells in splenocytes. Distinct populations of B cells can 
be observed on this graph, with the smaller B cells representing resting B cells, 
while the B cells of the larger population are blasting or growing in volume. 
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Experiment Name: NZB Spleen 7-13-10 
Specimen Name: Control 
Tube Name: All Colors 
Record Date: Jul 13, 20101:11 :42 PM 
$OP: Administrator 
F8C-A BBC-A 
Population 'Events %Parent Mean Mean 
• Lymphocytes 17,521 87.6 88,434 46,280 
• B Cells 8,446 48.2 1 04,216 59,011 
OMH C-11 8,089 95.8 10'5,'593 '59,765 
D COBO 1,678 19.9 130,629 B2,300 
• CD86 8,281 98.0 104,688 59,327 
D C040 7,703 91 .2 107,621 60,465 
• Resting B Cells 1,604 19.0 5B,-438 35,316 
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Mean Mean Mean Me:an 
3,493 6,026 467 7,146 
7,083 11,850 600 12,179 
7,284 12,346 BOB 12,562 
7,339 14,125 2,277 21,104 
7,162 12,046 594 12,421 
7,509 12,741 611 12, 755 
4,133 6,528 337 7,999 
7,612 12,626 445 10,571 
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A useful way to characterize the molecules embedded in the cellular 
membrane is the development of antibodies against a molecular target of interest and 
the subsequent conjugation with fluorescent dyes, or fluorophores. The antibodies are 
covalently linked to particular fluorescent molecules in a specific ratio, allowing for 
multi-parametric analyses that can correlate relative fluorescence intensities at 
different wavelenghts to the amount of target molecule on the surface of the cell. This 
study utilizes the florescent conjugates fluorescein isothiocyanate (FITC), phycoerythrin 
(PE), cyanine (Cy) , peridinin chlorophyll protein (PerCP) and allophycocyanin (APC) (Fig. 
I 9). Many of these molecules are derived from naturally occurring fluorescent 
proteins produced by organisms and their use is well-established in flow cytometry 
(Haugland 1994 ). In the process of radiative fluorescence, an electron is excited by 
incoming high-energy electromagnetic radiation , and the return to ground state may 
result in the quantized emission of a photon of lower energy than the exciting light 
(Ormerod 1990); these emitted photons can be picked up by sensors and translated 
into quantitative emission spectra (Fig. 18). The below molecules share in common 
conjugated ring systems allowing for excitation and emission at known wavelengths 
(Fig. 19). The relative intensities of emitted light will be correlated with the relative 














Figure 19. Fluorescent dyes utilize photoelectrically excitable molecules to grant 
detectability. FITC= fluorescein isothiocyanate; PE= phycoerythrin (molecule: 
phycoerythrobilin) ; Cy= cyanine (increase n carbons for Cy(n)) ; PerCP= peridinin 
chlorophyll protein (molecule= peridinin) ; APC= allophycocyanin 
(molecule=phycocyanobilin). Structures comtesy Wikipedia.org. 
Analysis of FACS Data 
The data gained from flow cytometry provides ample quantitative 
information. Typically 10-20,000 individual cells are analyzed. Parameters for each 
cell including SSC, FSC, and fluorescent emissions yield a huge dataset. 
Accordingly, the careful analysis of the data through the generation of appropriate 
plots is essential to translate the data into qualitative characteristics for a chosen cell 
population. First, lymphocytes have a characteristic comet-shape on a graph of FSC 
vs. SSC, so this cell population can be discerned by light-scattering properties of the 
lymphocytes (Fig. 12). Within the lymphocyte population, B cells that display a 
positive expression (i.e. above the autofluorescence threshold) of B220 (B220+ cells) 
can be gated off with an interval gate (Figs. 13,14). All further analysis, such as 
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determining the % parent population of molecules of interest, can be determined 
using gating hierarchies (Fig. 15). 
Two ways in which this study will describe the data will be through the 
percentage of a parent population and the mean fluorescence intensity (MFI) of a 
fluorochrome. The MFI for any population of cells can be determined by taking the 
average fluorescence intensity of any color of interest within the whole population of 
interest (Fig. 17). For example, the MFI of the PE color in B cells can be found in the 
second row and seventh column (Fig. 17). Note that the color is specific to the B cell 
subpopulation (Fig. 15). 
In order to compare samples analyzed on different dates, some mathematical 
adjustments must be made in the analysis of MFI. There are variations from day to 
day in the power of the instrument lasers, depending on warm-up time and 
mechanical wear, and the FSC and SSC voltages may be different as adjusted by the 
investigator (see below) (Schwartz and Fernandez-Repollet 1994 ). Due to these 
variables, MFI will be represented as a ratio of the fluorescence intensity of a certain 
color within the population of B cells divided by the background MFI of that same 
color among all lymphocytes of an unstained control (Figs. 13,17). For example, the 
MFI of MHC-11 PE was calculated on a particular date by dividing the MFI of PE in 
B cells of a treated sample by the MFI of PE of all lymphocytes in the untreated 
(control) sample. In this way, the inconsistency of instrumental analysis will in part 
be better represented (Gallucci, personal communication). 
Although flow cytometry generates numerical data, it should be noted that 
several steps along the way to collecting that data, including gating of populations of 
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cells (Figs. 12-14,16,18), are at the experienced discretion of the investigator. To 
maximize validity and minimize systematic errors in analysis, several steps are taken 
to maintain consistency in instrument function and performance. Cytometer setup and 
tracking (CST) is an important step in maintaining reproducibility of fluorescence 
intensity analysis for the FACS instrument. CST beads, microbeads tagged with 
fluorescent dyes of specific fluorescent values, are consistently (-once per 1-2 
analysis performed) run in order to digitally calibrate the fluorescent wavelengths 
which the machine is capable of analyzing (Schwartz and Fernandez-Repollet 1994, 
see Calibration of Fluorescence Intensity). Cytometer performance is preserved over 
time to ensure that error is minimized by checking changes in coefficient of variation 
(CV) and other technical parameters relevant to laser maintenance (BD 2007). 
In order to best visualize what is happening at the cellular level in digital, 
graphical form, the optical parameters of the cytometer may be adjusted to best 
capture the cellular events in a relevant perspective. Changing the photomultiplier 
tube (PMT) voltage of the laser does not change the intrinsic properties of a sample. 
Instead, it changes the perspective of the instrument in terms of how the events 
appear dispersed across a range of parameters. For instance, increasing the FSC 
voltage in the Parameter tab in FACS Diva software appears to shift the population of 
cells to the right on a graph of SSC vs. FSC, but this does not mean that emission 
intensity is increasing for these cells, it just moves the range of intensity visualized 
(see Figure 12 for a point of reference). Similar effects occur when increasing SSC 
voltage. These changes allow the population of lymphocytes in which we are 
interested to appear clustered a stereotyped comet shape, to maximize the range of 
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cell types in the 'field of vision ' of the cytometer, and to best distinguish between 
whole cellular material and debris (Fig. 12). (Schwartz and Fernandez-Repollet 1994, 
see Window of Analysis). 
Materials and Methods 
Mice 
The first filial progeny of New Zealand Black and New Zealand White 
(NZB/WF1) mice were obtained from Jackson Laboratories (Bar Harbor, ME). 
Female mice of strains NZB/WF1 were received at the age of 5 weeks and were 
sacrificed at ages 6-7 weeks. C57 /BL6 (Black 6) mice were bred at Ursinus College 
by members of the Roberts Lab (P.I. Dr. Rebecca Roberts). Mice were first bred from 
an original Black 6 breeding pair acquired from Jackson Laboratories. The inbred 
strain was perpetuated via filial crosses. Facility temperature was maintained at 
approximately 23°C, light cycle was controlled, and mice were provided unlimited 
access to tap water and Lab Diet mouse food . 
Treatment of Liver and Kidney Samples and Preparation of Lysate 
Mice of either strain BL6 or NZB/WF 1 were placed in a C02 chamber until 
breathing had ceased for at least 30 seconds and cervical dislocation was performed 
to ensure fatality. The exteriors of the mice were sterilized with ethanol. Incisions 
were made to the midlateral torso of the mouse in order to gain access to the 
peritoneal cavity. Kidneys are located dorsal to the other viscera and are anterolateral 
to the thoracic vertebrae. Liver is ventral to the small intestines and consists of 
several lobes. The organs were removed using stainless steel tools sterilized with 
ethanol. Organs were homogenized in a Petri dish filled with cold 1 X phosphate 
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buffered saline (PBS: 137 mM NaCl, 2 mM KCI, 4.3 mM Na2HP04 , 1.5 mM KH2P04 
in ddH20, pH 7 .2) using single frosted glass slides (Corning). Homogenate was 
strained through 40 µm nylon filters (BD Falcon) into labeled plastic conicals. 
Samples were spun at 1600 RPM for 5 minutes at room temperature in a table-top 
centrifuge. Supernatant was removed via vacuum pump. Erythrocytes were lysed 
using 2 mL 4°C red blood cell lysing buffer (Sigma, St. Louis, MO) and samples 
were quickly neutralized with 40 mL cold IX PBS following I minute exposure to 
lysing buffer. Samples were spun at 3000 RPM for 5 minutes at room temperature. 
The cells were washed again using 40 mL cold 1 X PBS and the same centrifuge 
settings. After the supernatant was removed via vacuum pump, pellets were 
resuspended in 20 mL cold IX PBS. Cells were counted via Trypan blue exclusion 
(Trypan Blue Solution, 0.4% Sigma) using a hemocytometer (Reichert Bright Line®) 
on a light microscope. Corrections were made for a 1: 10 dilution in IX PBS and a I: I 
dilution in Trypan blue solution and for the grid of the hemocytometer. Samples were 
spun at 3000 RPM for 5 minutes at room temperature. The cell count data were used 
to calculate the amount of phenol red free charcoal treated PRFCT-RPMI (PRFCT-
PRFCT-RPMI) (500 mL incomplete phenol-red free PRFCT-RPMI (Sigma), 5 mL L-
glutamine (brought up 10 mL ddH20) (Sigma), 5 mL aliquot 5mg/mL 
penicillin/streptomycin (Sigma), 500 µL 50 mM ~-mercaptoethanol, 50 mL dextran 
coated charcoal-treated (saline, sterile charcoal solution) newborn calf serum (PCS) 
(Sigma), mixed under sterile conditions) necessary to dilute the cells to a final 
concentration of 4x 106 cells per 1 mL culture medium. PCS was charcoal treated by 
adding 1.6 g Dextran coated charcoal (Sigma) and 0.175 g NaCl to 20 mL ddH20 and 
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autoclaving. Five mL of the solution was added to 100 mL FCS and incubated for 45 
minutes at 55°C. Mixture was centrifuged at 800 RPM for 20 minutes and supernatant 
was saved, discarding the charcoal pellet. Centrifugation was repeated until 
supernatant was clear of charcoal. Cells were resuspended in complete PRFCT-RPMI 
under sterile conditions to achieve the concentration of 4x 106 cells/mL and were split 
into three equal partitions of flasks , one for control, one for a 5 nM treatment, and one 
for a 50 nM treatment. ln order to retain enough cells for each treatment, treatments 
were alternated between E2 and BPA for each consecutive sacrifice. The treatments 
received the appropriate amounts of ~-estradiol or bisphenol A (Sigma). Samples 
were incubated for 18 hours at 37°C and 5% C02. Culture flasks were removed after 
18 hours of incubation and were transferred to labeled plastic conicals. Samples were 
spun at 3000 RPM for 5 minutes at room temperature. Supernatant was removed with 
a vacuum pump. Pellets were resuspended in 1 mL cold lX PBS. If treatment 
volumes were greater than the 50-mL conical maximum, sample pellets were 
combined at this point for ease of handling. Cells were counted via Trypan blue 
exclusion as described above to determine cell viability post-culture. After cell counts 
were complete, tubes were filled to 40 mL with cold IX PBS and spun at 3000 RPM 
for 5 minutes at room temperature. The pellet wash with PBS was repeated as 
described and the supernatant was removed. Pellets were resuspended in 1 mL cold 
1 X PBS and transferred to snap-cap tubes. Samples were spun at 8000 RCF for 5 
minutes and the pellet was resuspended in lysis buffer pH 5.5 (50 mM NaAcetate, 10 
mM MgCh, 0.5% IGEPAL CA-630 (Sigma) in ddH20 pH 5.5) of approximately 
equal volume to the pellet. Samples were incubated on ice for 20 minutes. Following 
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lysis, tubes were srun at 8000 RCF for 5 minutes. The supernatants containing the 
cell lysates were then stored in labeled snap-caps at -80°C. 
Macrophage Isolation 
Approximately twelve five-week old C57BL/6 and NZB/WF1 mice were 
obtained from Jackson Laboratories for each macrophage harvest. At 6 weeks of age, 
-1.5 mL Brewer's Thioglycollate Medium solution (3% Brewer Thioglycollate 
Medium (Sigma) in autoclaved ddH20) was injected into the lower peritoneal cavity 
of the mice using a 25 G 1112 needle with a 5 mL syringe (BD Biosciences). Sacrifice 
took place three days post-injection to allow for an immune response. Mice were 
placed in a C02 chamber until breathing had ceased for at least 15 seconds and 
cervical dislocation was performed to ensure fatality. The exterior of the mice was 
sterilized with ethanol. A midsagittal incision was made with sterile steel scissors 
starting at the lower abdomen of the mouse (approximately 10 mm superior to 
genitals) to the upper sternum. From the endpoints of this incision, axillary incisions 
were made in towards the extremities and the skin was pulled back and pinned to 
expose the peritoneum. A 16 G 1 needle and 5 mL syringe (BO Biosciences) were 
used to inject 3 mL of cold IX PBS into the cavity space with care not to puncture 
any organs. The filled peritoneal cavity was agitated manually in order to dislodge 
macrophages on the surface of the organs. This cavity wash was repeated twice to 
achieve a greater quantity of cells. Solution was collected into 50-mL conical tubes. 
Raw macrophages were spun at 1600 RPM for 5 minutes at 4°C in a Beckman 
Coulter Centrifuge. If any trace of blood was detected, an erythrocyte lysis was 
performed by resuspending pellet in 3 mL of red cell lysis buffer (Sigma). After one 
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minute, the solution was neutralized with 30 mL cold IX PBS. Sample was washed 
by repeating the resuspension in IX PBS and centrifugation. A 10 µL aliquot of the 
sample resuspended in 30 mL 1 X PBS was taken to count cells and determine 
viability. A dilution of the raw macrophage sample was achieved by adding I 0 µL 
sample to 10 µL Trypan Blue Solution (Sigma). The number of dead versus alive 
cells was determined using a Reichert Bright Line® Hemocytomer (1E4 cells/mL 
correction factor) and Trypan Blue exclusion. Cell counts were recorded and the 
sample was placed in a centrifuge, run at 3000 RPM for 5 minutes at 4°C, and the 
supernatant was decanted. Using the determined total number of cells, the volume of 
complete PRFCT-RPMI necessary to dilute the cells to a final concentration of 4x 106 
cells was calculated. Cells were resuspended in complete PRFCT-RPMI under sterile 
conditions. The number of treatments was determined by dividing the total volume of 
PRFCT-RPMI by 10 mL, with each treatment requiring at least 10 mL of cells in 
PRFCT-RPMI. The volume of E2 or BPA dissolved in methanol [ <<1 %] was 
determined to bring the final concentration in PRFCT-RPMI to either 5 nM or 50 nM. 
Cell-PRFCT-RPMI solution was divided equally on sterile culture plates. Plates were 
incubated for 18 hours at 37°C 5% C02 in a gas incubator. On the following day, 
plates were removed from incubator and gently scraped using a culture plate scraper 
under sterile conditions. Aliquots of the treated cells were taken to count dead versus 
alive cells as described above. Samples were kept separated by treatment and were 
transferred into vessels to be centrifuged at 1500 RPM for 5 minutes at 4°C. The 
pellet was resuspended in 1 mL cold lX PBS and transferred to snap-cap tubes. 
Samples were spun at 8000 RCF for 5 minutes and the pellet was resuspended in 
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Lysis Buffer pH 5.5 of approximately equal volume to the pellet. Samples were 
allowed to incubate on ice for 20 minutes and were then stored in labeled snap-caps at 
-80°C. 
Bradford Assay 
A Bradford assay was performed to determine the protein concentration of all 
liver and kidney samples in order to normalize the protein enzyme analyzed in 
fluorometry assays. Wells of a 96-well microtiter plate were filled with 250 µI 
Bradford solution (Sigma). Samples were diluted 1 :5, 1: 10, 1: 15, and 1 :20 using lysis 
buffer pH 5.5. Then, 2 µL bovine serum salbumin (BSA) standards of concentrations 
0, 0.1, 0.25 , 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, and 2.0 mg/mL were added to the wells in 
triplicate while unknown samples were run in duplicate with 2 µL of sample added to 
the respective wells. The filled plate was allowed to incubate at room temperature for 
5 minutes before running readings. Absorbance was read at 595 nm on a Beckman-
Coulter AD340 plate reading machine and analyzed using AD LD Control Software. 
A standard curve was developed using BSA (Albumin from Bovine Serum (Sigma) in 
ddH20) with concentration ranging from 0.1-2.0 mg/mL. Linear regressions were 
developed using Microsoft Excel and concentrations of unknown samples were 
extrapolated using the standard curve. Curves were used only if R2 ~ 0.950, signifying 
statistical linear relationship between protein concentration and absorbance as would 
be expected. The sample dilution with an average absorbance closest to 0.500 was 
used to calculate the sample concentration since this absorbance is near the center of 
the accurate range of the Bradford Assay according to Sigma. 
Fluorescence Assay 
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Eppendorf tubes were filled with 172.5 µL of lysis buffer pH 5.5. The 
appropriate amount of sample (based on Bradford Assays) was added to bring the 
final concentration of the sample to 34.5 µg/ 345 µL.b The samples were incubated on 
ice for 10 minutes. The remaining volume of 1 ysis buffer (172.5 - amount of sample 
µL) was added to bring the total volume to 345 µL. This tube was gently vortexed 
and split into three equal tubes containing 115 µL of dilute sample. Then, 2 µL of 
substrate specific to cathepsins B (Ac-R-R-AFC), L (Ac-F-R-AFC), or S (Ac-V-V-R-
AFC) (Bio Vision) was added to each tube (Fig. 10). Tubes were incubated for 2 hours 
in a 37°C water bath. Samples were transferred to a Sub Micro Quartz Cuvette 
(Starna Cells) and measured using a Fluoromax-3 Fluorometer with an excitation 
wavelength of 400 nm and emission wavelength of 505 nm. Each sample was run in 
triplicate. Using the data parameter S, data was analyzed with Microsoft Excel. Data 
was normalized by correcting to the control (untreated) fluorescence to 1. Average 
fluorescence was plotted for each treatment including error bars displaying the 
standard error. A one-way ANOVA and a Tukey-Kramer Multiple Comparison Test 
were performed using GraphPad© InStat® v3.0 biostatistical analysis software in 
order to deem collected data as significant. Significance was determined at the 95% 
confidence interval. 
Preparation of Splenocytes for Treatment and Surface Protein Analysis 
A single mouse of either strain was placed in a C02 chamber until breathing 
had ceased for at least 30 seconds and cervical dislocation was performed to ensure 
fatality. The exterior of the mouse was sterilized with ethanol. The spleen, located on 
the dorsal left torso, was removed using sterile tools and was homogenized in a Petri 
b It was previously determined by the Roberts Lab that using a protein concentration of O.lg/ml 
would result in the smallest standard deviation of fluorescence readings (Mercadante 2010). 
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dish filled with cold 1 X PBS using single frosted glass slides (Coming). Homogenate 
was strained through 40 µm nylon filters (BD Falcon) into labeled plastic conicals. 
The conical was spun in a centrifuge at 1600 RPM for 5 minutes at room temperature 
in a Thermo Scientific ST16 tabletop centrifuge. The resulting supernatant was 
removed through a vacuum pump. The pellet was resuspended in 2 mL 4°C red blood 
cell lysing buffer (Sigma) and a minute later the solution was neutralized with 40 mL 
cold IX PBS. The sample was spun in the centrifuge at 3000 RPM for 5 minutes at 
4 °C. The pellet was washed twice by decanting supernatant via vacuum pump, 
resuspension in 40 mL cold IX PBS, and centrifugation at 3000 RPM for 5 minutes 
at room temperature. The pellet was resuspended in I mL cold IX PBS and cells were 
counted via trypan blue exclusion (Trypan Blue Solution, 0.4% Sigma) using a 
hemocytometer (Reichert Bright Line®) on a light microscope. Corrections were 
made for a 1: 10 dilution in 1 X PBS and a 1: 1 dilution in trypan blue solution and for 
the grid of the hemocytometer. After the total number of cells had been calculated, 
the volume of complete PRFCT-RPMI necessary to dilute the cells to a final 
concentration of 4x 106 cells was calculated. Cells were resuspended in complete 
PRFCT-RPMI under sterile conditions into flasks for the following treatments: 
control, compensation control, 5 nM E2, 50 nM E2, 5 nM BPA, and 50 nM BPA. 
Lipopolysaccharide (LPS) from E. coli (Sigma) was added to achieve a concentration 
of 20 µg LPS per 1 mL culture medium. The treatments received the appropriate 
amounts of P-estradiol or bisphenol A (Sigma, dissolved in methanol). Samples were 
incubated for 18 hours at 37°C and 5% C02. Culture flasks were removed after 18 
hours of incubation and were transfeITed to labeled conicals . Samples were spun at 
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3000 RPM for 5 minutes at room temperature. Supernatant was removed and pellets 
were resuspended in 1 mL cold FACS buffer (lX PBS pH 7.5, I % BSA, 0.1 % g 
Sodium Azide). Cells were counted via trypan blue exclusion as described above. 
After the total number of cells had been calculated, the volume of FACS buffer to add 
was calculated to achieve a final concentration of Ix I 06 cells/mL. Aliquots of 1 mL 
or 1 million cells were taken into Eppendorf tubes (snap-caps). Eight total tubes were 
taken between the control and compensation control (untreated) samples while 3 
tubes were made for each of the four treatments. Fe Block (Rat anti-Mouse 
CD I 6/CD32, BD Pharmingen) was added at a concentration of 0.06 µg/ million cells 
and the samples were incubated on ice in the dark for 20 minutes. Following Fe Block 
incubation period, fluorophore-conjugated antibodies were added to the tubes as 
follows. Compensation controls consisting of tubes of unstained control , control with 
IgG isotype (0.15 µg/l x 106 cells FITC rat IgG2a, BO Pharmingen), control with all 
fluorophore-conjugated antibodies (0.2 µg/lxl06 cells FITC anti-mouse C045/B220, 
BO Pharmingen, 0.15 µg/1E6 cells PE rat anti-mouse 1-NI-E [MHC-11) M5/114.15.2, 
BO Pharmingen, 0.5µg/lx106 cells PerCP-Cy™5.5 Hamster Anti-mouse C080, BD 
Biosciences, 0.25 µg/lxl06 cells APC Rat anti-Mouse C040, BO Biosciences, 0.5 
µg/lxl06 cells PE-Cy™7 Rat anti-Mouse C086, BD Biosciences) and 5 tubes, each 
containing an individual fluorophore color, were generated. Samples were kept on ice 
and in the dark for 30 minutes to allow for conjugation of the antibodies. Tubes were 
spun at 1600 RPM for 5 minutes at room temperature in an Eppendorf Centrifuge 
5415 0 . The resulting supernatant was decanted and pellets were resuspended in 100 
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µL FACS buffer in preparation for analysis. Samples were analyzed via FACS within 
two hours of resuspension in FACS buffer. 
Fluorescence Activated Cell Scanning (FACS) Analysis of B Cell Surface Molecules 
Splenocytes conjugated with fluorescent antibodies were analyzed with a BO 
FACSCanto™ II flow cytometer. Cells suspended in FACS buffer were transferred to 
to 5 mL Polystyrene Round-Bottom Tubes (BD) containing 350 µl FACSFlow 
(Sheath). Tubes were loaded onto the sit and data were retrieved and analyzed using 
BO FACSDivaTM software. Compensation controls were generated and spectral 
overlap was calculated for the following wavelengths: FITC, PE, PerCP-Cy™5.5, 
PE-CyTM7, and APC. Color laser voltages were established weekly utilizing the 
Cytometer Setup and Tracking (CST) feature while forward scatter (FSC) and side 
scatter (SSC) were adjusted manually in order to encompass the greatest number of 
events. Lymphocyte populations were gated within a total population of 20,000 
events based on distinctive comet shape on a graph of FSC vs. SSC. Within 
lymphocytes, B Cells were designated as those cells with a positive intensity of FITC-
B220. All other populations were gated as hierarchy within B cells. Therefore, the 
cells positive for MHC-11, CD86, CD80, and CD40 must first be positive as a B cell 
to be included in their respective histograms. An event was determined to be 
'positive' for a color if it appeared at a greater intensity than that of the background 
intensity of unstained controls. Data were further analyzed using Microsoft Excel. 
Statistics and Data Analysis 
Outliers within the enzyme activity data were defined using Dixon's Q test, in 
which Q= (possible outlier - next closest number)/(range of values), using the 95% 
confidence interval (a.=0.05) of r'° (single outlier) values (Rorabacher 1991). The 
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assumption was made that data would resemble a Gaussian population. All samples 
with a Q value greater than the Critical Values at a 95% confidence interval (Table l 
in Rorabacher 1991) were rejected as outliers and not included in calculations. Data 
were analyzed with GraphPad InStat® version 3.0. A one-way analysis of variance 
(ANOV A) was performed followed by a Tukey test. Statistical significance was 
determined at the 95 % confidence interval assuming a normal distribution. Three p 
values were determined ( <0.05, <0.01 , and <0.001) and were applied in a cross 
comparison of different strains, concentrations, and chemical treatments. 
FACS data was acquired using BD FACSDiva™ software and data were 
transferred to Microsoft Excel for further analysis . Standard deviations and errors of 
the mean cell population percentages and mean fluorescence intensity were calculated 
by cr1=(L(X-Xmean)2l(n-1)) and SE=cr/n°·5. 
Results 
Cathepsin Activity 
Cathepsin activity was measured for both splenocytes and peritoneal 
marcrophages. Before comparing fluorescence data between for different treatments 
and strains, the amount of protein in the cell lysates must first be established in order 
to create a controlled environment in which, all else being equal, the amount of 
cathepsin enzyme would be the same ratio to the total amount of protein. Cell lysates 
were tested for protein concentrations using Bradford assays in the case of 
splenocytes or BCA for M0s. A standard curve was established by plotting known 
concentrations of BSA versus absorbance. Linear regressions (R 22:0.95) were 
developed and protein concentrations were extrapolated using the equation of the best 
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fit line and the absorbance of the dilute unknown sample, correcting for all dilutions 
(Fig. 20). The protein concentrations of lysates could then be used to standardize 
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Figure 20. Representative Bradford protein concentration assay standard curve. 
Splenocyte sample was isolated 3/18/09. BSA standard concentrations ranged from 0 
µg/µL (lysis buffer pH 5.5) to 2.0 µg/µL. Points on graph signify averages of tripUcate 
measured values. Equations derived from linear regressions (R2.:?,0.95) were utilized to 
determine concentrations of unknown samples by; absorbance of the unknown must faJI 
within the range of absorbance for the standard curve. Assay performed together with 
Allison Young. 
It was previously determined by members of the Roberts lab that the ideal 
concentration of protein to use for fluorescent cathepsin activity assays would be 10 
µg/1 OOµL solution (Mercadante 2010), as this concentration resulted in the least 
standard deviation among all tested concentrations, equating to the smallest variation 
in fluorescence between assays. Additional controls were established to best assess 
cathepsin activity. The lysis buffer in which cells were lysed was at a low pH of 5.5, 
as cathepsin activity normally peaks in the acidic environment of the lysosome 
(Roberts 2005), so cathepsin activity would be measured in a similar environment. 
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Cathepsin activity assays were run using specifically designed AFC fluorescent 
substrates (see Techniques). The amount of fluorescent product released in a given 
amount of time could be compared in order to assess the efficacy of proteolytic 
cleaveage of the cathepsins of interest. In order to acquire valid numerical values for 
cathepsin activity, further steps were taken to ensure reputability of the assay. 
Samples were run in three separate vessels, and three readings were made of each 
vessel. Therefore, cathepsin activity was found as an average of three triplicate 
readings and compared to a control in which no fluorescent substrate was present. 
Evaluating the activities against a standardized control allows for ease of comparison 
between differential activities. Fluorescence activities were averaged for each strain, 






















































Cathepsin activities were significantly altered differentially dependent on cell 
type, genetic strain, estrogenic chemical, and concentration of the chemical (Fig. 21 ). 
Cathepsin L activity in splenocytes was greatly increased in NZB/WF1 mice under 
exposure to 50 nM and 100 nM concentrations of E2 as compared to untreated 
splenocytes of the same strain and to treated splenocytes of C57BL/6 mice (p<0.001). 
In contrast, 50 nM E2 reduced Cat L activity in peritoneal macrophages as compared 
to BL6 mice (p<0.01). Cat L activity was changed differently under exposure to BPA; 
in splenocytes 50 nM BPA significantly increased CatL activity as compared to 
untreated sample in Lupus prone mice but not in control (p<0.05), whereas in 
macrophages Cat L activity in either strain did not experience a reduction with 50 nM 
BPA as it did with 50 nM E2 (p<0.05). 
Cathepsin B activity increased significantly in NZB/WF1 splenocytes under 
treatment with 50 nM and 100 nM E2 and BPA (p<0.001 , p<0.01 for 100 nM E2), 
with 50 nM E2 and BPA causing significant increases in Cat B activity in NZBWF 1 
not seen in control mice. Other changes of note are differences in BPA concentrations 
affecting splenocyte Cat B activity differentially in both strains. In macrophages, Cat 
B activity is significantly upregulated by 50 nM E2 in Lupus prone mice but not in 
control mice while BPA appears to elicit no response (p<0.001). 
In splenocytes, no significant variation in cathepsin S activity was observed 
regardless of treatment, concentration, or strain. Cathepsin S activity remained 
unchanged in control macrophages, but 5 nM treatments of E2 and BPA significantly 


















B Cell Surface Molecule Profile 
Recovery of Splenocytes from Culture 
Cell counts were performed using Trypan Blue dye exclusion in order to 
determine cell density of samples in preparation for culture and antibody staining. Far 
fewer cells were counted post culture than were counted directly after spleen harvest. 
The number of splenocytes recovered after culture varied between experiments and 
showed no evident relationship to the treatment applied or the strain of mouse. In 
(Fig. 22), the samples labeled 'control' and 'comp control' were in the same culture 
environment, showing that variation in recovery between experiments is unrelated to 
the treatment applied. The poor recovery of cells after culture suggests that there are 
errors in the technique beyond the scope of the culture environment (Fig. 23). Some 
systematic experimental error is occurring such that fewer cells are acquired on Day 2 
than are placed in culture on the first day. The source of the variation is unknown, but 
application of more careful technique in future experiments may reveal the problem. 
•Control Comp Control • S nM E2 •SO nM E2 • S nM BPA SO nM BPA 
0.36 
BL6 NZB/WFl 
Figure 22. The average fraction of splenocytes recovered after an 18 hr incubation in 
PRFCT-PRFCT-RPMI suggests that a large pottion of cells are being lost <luting 
culture. Control and comp control treatments were placed in PRFCT-PRFCT-RPMI 
+ LPS without E2 or BPA. Treatment with low nanomolar in vitro dosage of E2 or 
BPA does not affect cell recovery. n=4 
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Figure 23. The recovery of splenocytes post cu lture in PRFCT-PRFCT-RPMI is not 
dependent on strain. Data show the ratio of the sum of cells for all treatments counted 
after culture to the total number of splenocytes originally placed in culture, n=4. 
Percentage of B Cells Present in Lymphocyte Subpopulations 
Lymphocytes were gated in splenocytes using a scatter plot of FSC vs. SSC 
(Fig. 12) and B cells within the lymphocyte population were defined as B220 positive 
if they fluoresced in the positive gate of B220-FITC (Fig. 24). These defined 
subpopulations al lowed for analysis breakdown of cell types . The cellular makeup of 
lymphocyte subpopulations appears to be different in NZB/WF1 mice than in BL6 
mice (Fig. 24). In a control environment, the percentage of B220+ cells in lymphocyte 
subpopulations is 18% higher in BL6 mice than Lupus-prone mice. Additionall y, it 
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Figure 24. NZB/WF1 mice have fewer B cells in lymphocyte populations than do BL6 
mice. B cell constituency in a lymphocyte subpopulation, as determined by B220 surface 
availability, is unchanged by treatment with either E2 or BPA after 18 hr in PRFCT-
PRFCT-RPMI culture. Data represent averages for B220+ B cells, n=4. Error bars 
represent standard error. 
Effect of Treatment on B cell Differentiation 
Over the period of B cell development, the cells may change phenotype based 
on environmental and chemical cues. The stage of B cell differentiation can be 
correlated to their size, and therefore physical properties of the cells may tell 
something about their current stage of growth, with smaller cells considered resting 
and larger cells blasting (Gallucci, personal communication). Blasting B cells are 
increasing in size due to an immunologic stimulus whereas resting cells are less 
active. These characteristics may be gated off in a scatter plot of FSC vs. SSC (Fig. 
16). There is a 24% lower percentage of total B220+ B cells of NZB/WF1 mice 
blasting under exposure to 5 nM BP A in 18 hr culture as compared to control (Figs. 
25,26). These preliminary data suggest that Lupus-prone B cells may be reacting to 
BPA in a different way than normal phenotype B cells. These results are from a single 
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experiment only and therefore statistical analysis was not carried out. Further analysis 
of the data is required to fully understand the relationship between estrogenic 
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Figure 25. The percent of blasting B cells ranges between 57-66% in BL6 
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Figure 26. The percent of blasting B cells ranges between 43-66% in 
NZB/WF1 mice under 18 hr exposure to 20 µg/mL LPS in PRFCT-PRFCT-
RPMI culture. n= 1 
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NZBIWF1 Mice Express Lower MHC-II than BL6 
The major histocompatability complex class II (MHC-II) molecule was tagged 
with a PE conjugated anti-MHC-II antibody and analyzed by FACS. Both strains of 
mice appear to have splenic B cells on which MHC-11 is constitutively expressed 
(Fig. 27). That is to say, almost all B cells express MHC-II in both strains, which is 
the expected phenotype of antigen presenting cells. However, the level of expression 
on these cells ranges from 67-100% more in BL6 mice than in NZB/WF1 mice (Fig. 
28, Appendix B). Consequently, while all B cells are expressing MHC-11, Lupus-





















Figure 27. The average percentage of MHC-Ii+ cells within B220+ B cells is slightly 
less in NZB/WF1 mice. The MHC-11 molecule appears to be constitutively expressed 
on B cells and is not regulated by estrogenic treatments. Data represent average 
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Figure 28. Of those B220+ B cells expressing MHC-11, NZB/WF1 mice have less MHC-
11 molecule on the surface than do control B cells as determined by MHC-11-PE intensity. 
The fluorescence intensity of PE was averaged across 4 samples per strain. Data were 
normalized by dividing the fluorescence intensity of PE within B220+ B cells by the 
background (due to autofluorescence) level of PE intensity for all cells analyzed (see 
Materials and Methods). Therefore, the MFI is expressed as a ratio to normalize for the 
background of the instrument in order to more accurately compare data collected using a 
number of voltages. Error bars represent standard error. 
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CD40 Expression is Not Regulated by E2 or BPA 
Splenocytes from both strains were tagged with anti-CD40 Abs conjugated to 
APC fluorochrome and analyzed by FACS. The percentage of B220+ B cells 
expressing CD40 at the surface did not change under treatment with either E2 or BPA 
and is approximately the same for both strains (Fig. 29). Of those cells that are 
CD40+, the fluorescence intensity of bound anti-CD40-APC is between 22-43% 
higher for Lupus-prone B cells, suggesting higher levels of membrane CD40 (Fig. 
30), but the narrow range of differences suggests little effect by treatment. However, 
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Figure 29. The average percentage of CD40+ cells within B220+ B cells is slightly 
less in NZB/WF1 mice. There appears to be no differences in CD40 expression due 
to treatment or genetic differences independent of the en-or in the experiment. Data 
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Figure 30. Of those B220+ B cells expressing CD40, NZB/WF1 mice have slightly more 
CD40- molecule on the surface than do control B cells as determined by anti-CD40-APC 
normalized MFI. The fluorescence intensity of APC was averaged across 4 samples per 
strain. Data were normalized by dividing the fluorescence intensity of APC within B220+ 
B cells by the background (due to autofluorescence) level of APC intensity for all cells 
analyzed (see Materials and Methods). Therefore, the MFI is expressed as a ratio to 
normalize for the background of the instrument in order to more accurately compare data 
collected usin!! a number of voltages. Error bars reoresent standard error. 
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CD80 and CD86 Surface Expression 
CD80 May be Upregulated by 5 nM E2 in NZBIWF1 Mice 
Splenic B cells positive for B220 were tagged with anti-CD80-PerCP-Cy5.5 
and analyzed by FACS in order to examine the surface expression of CD80 
molecules. The percentage of B cells expressing CD80, as determined by positive 
fluorescence in a PerCP-Cy5.5 gate controlled to background, was slightly lower in 
NZB/WF1 mice, but this trend may be insignificant due to overlapping standard error 
(Fig. 31 ). Of those B cells positive for CD80, Lupus-prone cells express higher 
amounts of CD80 based on increased MFI ranging from 4-39% higher depending on 
treatment (Fig. 32), while MFI was only 2% lower under treatment with 5 nM BPA, 
but with large amounts of error. The low levels of CD80 were confirmed using 
another clonal antibody: anti-CD80-APC; results were of similarly low levels. Of 
note is the increase in CD80 MFI in NZB/WFI B cells and the concomitant decrease 
in CD80 in control mice under treatment with 5 nM estrogen, as this shift has very 
little associated standard error, potentially describing a difference in estrogenic 

















Figure 31. The average percentage of CD80+ cells within B220+ B cells is slightly 
less in NZB/WF1 mice. The percentage of B cells expressing CD80 in NZB/WF1 
mice mirrors BL6 levels under treatment with 5 nM E2 but is appears to decrease in 
the presence of 50 nM E2. Data represent average percentages, n=4. Error bars 
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Figure 32. Of those B220+ B cells expressing CD80, NZB/WF1 mice have slightly more 
CD80 molecule on the surface than do control B cells as determined by anti-CD80-
PerCP-Cy5.5 normalized MFI. The fluorescence intensity of PerCP-Cy5.5 was averaged 
across 4 samples per strain. Data were normalized by dividing the fluorescence intensity 
of APC within B220+ B cells by the background (due to autofluorescence) level of 
PerCP-Cy5.5 intensity for all cells analyzed (see Materials and Methods) . Therefore, the 
MFI is expressed as a ratio to normalize for the background of the instrument in order to 
more accurately compare data collected using a number of voltages. Error bars represent 
c::t::in rl::irrl P.tTnr 
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CD86 Levels are Higher in CD86+ B cells in NZB/WF1 Mice 
The levels of CD86 were assessed with anti-CD86-PE-Cy7. Nearly all splenic 
B cells in both mouse strains express CD86 (Fig. 33). Levels of CD86 on 
CD86+/B220+ B cells are between 39-50% higher in NZB/WFl mice than in BL6 as 
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Figure 33. The average percentage of CD86+ cells within B220+ B cells is 
consistent for both strains of mice. The CD86+ B cells appear to be the dominant 
phenotype after 18 hr culture in the presence of LPS but appear independent of 
estrogenic regulation of CD86 surface expression during that period. Data represent 
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Figure 34. Of those B220+ B cells expressing CD86, NZB/WF1 mice have more CD80 
molecule on the surface than do control B ceIJs as determined by anti-CD86-PE-Cy7 
normalized MFI. The fluorescence intensity of PE-Cy7 was averaged across 4 samples 
per strain. Data were normalized by dividing the fluorescence intensity of PE-Cy7 within 
B220+ B cells by the background (due to autofluorescence) level of PE-Cy7 intensity for 
all cells analyzed (see Materials and Methods). Therefore, the MFI is expressed as a ratio 
to normalize for the background of the instrument in order to more accurately compare 
data collected using a number of voltages. Error bars represent standard error. 
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CD80/CD86 Ratio: The Importance of Oligomerization 
CD80 and CD86 interact on the cell surface to elicit costimulatory response 
when binding T cell ligands. The ratio of CD80 to CD86 ranged from 11-27% higher 
in BL6 mice except for treatment with 5 nM E2, where the CD80/CD86 ratio is the 
same for both strains (Fig. 35). The difference in the ratio is derived from 
upregulation from CD80, not downregulation of CD86 (Fig.32). 
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Figure 35. Ratio of CD80+ to CD86+ splenic B cells appears to vary slightly under 
treatment with estrogen. The ratio of CD80 to CD86 is consistently lower (-12%) in 
NZB/WF1 mice versus C57BL/6. 
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Discussion 
Estrogenic Regulation of Cathepsins May Alter Antigen Presentation 
The splenocytes of NZB/WF1 appear to be more prone to estrogenic alteration 
of cathepsin L activity than do peritoneal macrophages. Both E2 and BPA at 50 nM 
concentrations significantly increase CatL activity in NZB/WF1 mice while 50 nM 
BPA also increased activity. On the contrary, 50 nM E2 reduced CatL activity in 
macrophages for the same strain. It is clear that the effects of estrogen on cathepsin L 
activity are cell type specific and a stereotyped approach in analyzing estrogenic 
effects on lysosomal proteolysis must take into consideration the cell type in question. 
Additionally, effects of BPA in Lupus-prone splenocytes parallel the action of 
estrogen, but not in control mice, and are opposite in macrophages at the 50 nM 
concentration, suggesting that BPA-induced immunomodulations may be either 
typified as estrogenic or counter-estrogenic depending on the phenotype and, 
assumedly, the genetic environment of the cellular target. 
Cathepsin B activity is upregulated in Lupus prone mice under in vitro 
exposure to 50 nM treatments of both E2 and BPA. In this situation, BPA is 
mimicking estrogenic effects in the Lupus prone mice while neither chemical induce 
significant changes in normal mice. These differences may indicate some sort of 
autoimmune phenotypic predisposition to estrogenic influence on lysosomal 
proteolysis. Unlike cathepsin L, cathepsin B activity is increased in peritoneal 
macrophages under exposure to estrogen, albeit at different concentrations. These 
data implicate that even among the same populations of cells estrogenic regulation of 
cathepsins may be variable depending on the enzyme in question. 
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Although both cathepsin B and cathepsin L activities experienced changes 
under exposure to both BPA and E2, cathepsin S activity remained unchanged in 
splenocytes of both Lupus-prone and control mice. Interestingly, Cat S makes the 
final cleavage of the invariant chain in many APCs (Honey and Rudensky 2003). On 
the other hand, Cat F is able to cleave Ii to generate CLIP in macrophages in the 
absence of Cat S activity (Shi et al 2000). The data described herein shows that Cat S 
activity was altered by estrogenic molecules in macrophages but not in splenocytes, 
perhaps providing evidence that Cat S independence from hormonal regulation may 
be conserved in some APCs where an alternative route to MHC-II maturation is 
unavailable but that Cat S regulation has plasticity in macrophages where Cat F can is 
able to generate CLIP in the absence of cathepsin S. 
This study reviews the compiled results of the Roberts Lab showing that 
cathepsin activity is differentially regulated by estrogen and BPA in NZB/WF1 mice, 
a murine model for SLE. The degree of regulation is dependent on cell type, chemical 
identity, and concentration and appears to be specific to Lupus-prone mice in almost 
all occasions. In some cases, BPA regulates cathepsin activity in similar ways as 
estrogen by in others it appears to act in opposite ways, perpetuating the idea that 
hormonal regulation and especially endocrine disruption by chemicals such as BPA 
unpredictable. The fact that changes were observed in the experimental strain but 
were absent in the control strain suggests that genetic predispositions to Lupus 
pathogenesis are compounded with environmental influences, in this case exogenous 
E2 and BPA, in generating potentially detrimental cellular conditions: increased 
cathepsin proteolysis. 
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Future analysis of the samples analyzed here [see Appendices in Mercadante 
2010] should confirm in what ways cathepsin activity was estrogenically modified as 
it is not yet known whether cathepsin protein levels were increased over the period of 
incubation. Examination of the affected proteome via Western blotting or the 
transcriptome via RT-PCR could extrapolate whether the changes that this study 
observed in cathepsin activity were due to changes at the level of translation or 
transcription respectively, or by some other cellular mechanism. Some Western blots 
had been attempted in the past but were not discernable due some source of 
experimental error (Mercadante 2010), so these assays should be conducted more 
thoroughly in the future. In addition, estrogen receptors antagonist drugs such as 
Tamoxifen could be utilized to see whether the E2 and BPA treatments were working 
through the classical ER pathway or alternative pathways and whether the protein 
targets are the same for both chemicals. 
The changes observed in cathepsin activity beg the question of what other 
effects on antigen processing and presentation may be altered by estrogenic 
molecules in an autoimmune environment. Changes in cathepsin activity, in particular 
cathepsins S and L, have been implicated in altered MHC-II-loaded peptide 
generation in antigen presenting cells (Rudensky and Beers 2006). The differential 
activity, however, is not necessarily predictable and changes with the environmental 
conditions. Surprisingly, basal levels of cathepsin Band D activities are low in 
human SLE PMNs and monocytes as compared to non-Lupus patients (de la Fuente 
et al 2001). Here, increased cathepsin activity is observed via estrogenic regulation. 
The differences in cathepsin activity are clearly, as previous studies have shown and 
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this study also suggests, dependent on cell type, stages of cell differentiation, 
environment, function, and genetic differences. Therefore, the results shown here 
should not be taken at their face value as describing the whole picture. 
Estrogen dependent regulation of cathepsin activity has been described in 
previous studies. Interestingly, EK breast cancer cell lines did not undergo 
differential cathepsin expression (Lah et al 1996), whereas malignancy was correlated 
with increased cathepsin secretion in ER+ breast cancer lines treated with estrogen 
(Capony et al 1990), confirming estrogen's involvement in regulating cathepsin 
activity in cancerous cells. Here, estrogen and the estrogenic molecule BPA regulate 
cathepsin activity in both splenocytes and macrophages in a model for autoimmunity. 
Cathepsin activity has a powerful effect in generating and maintaining MHC-
II-restricted antigenic peptide repertoires. This makes cathepsins potential targets for 
drug therapy, especially in autoimmune diseases in which immune cells become 
activated by autoantigens (Roberts 2005). Administration of small molecular 
inhibitors of cathepsin S in vivo to a mouse model of Sjogren syndrome, an 
autoimmune disorder, was found to deplete peptide-class II complex surface 
expression, uncovering cathepsin S inhibition as a possible target for specific drugs in 
controlling autoantigen presentation (Saegusa et al 2002). Cathepsin S serves as a 
gatekeeper in the Ii degradation pathway and activity in APCs is prerequisite for 
peptide loading in the MHC-II binding groove, so complete inhibition of cathepsin S 
activity could be detrimental; cathepsin inhibitors would have to be administered with 
caution and specificity to avoid disruption of normal immune functions, a concern in 
modern available autoimmune treatments. Other cathepsins, if targeted specifically, 
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could be regulated in an attempt to control MHC-II-restricted autoantigen 
l 
presentation. Studies are currently underway to analyze the effects of estrogenic 
exposure on the antigenic repertoire bound to MHC-11 molecules on Lupus-prone 
cells (Roberts, personal communication). 
Altered Costimulatory Profiles in SLE 
There appear to be basal level differences in the cellular makeup of 
lymphocyte populations in Lupus-prone versus control mice. The percentage of B 
cells constituting the lymphocyte populations of both BL6 and NZB/WF1 mice 
appears to be unaffected by treatment with either E2 or BPA (Fig. 24). Since B cells 
were gated using an anti-B220 antibody, these data suggest the regulation of the 
surface marker B220 on splenic B cells is unaffected by estrogenic chemicals when 
treated in vitro. However, there are basal differences in the lymphocyte populations of 
Lupus prone versus control mice. Without treatment, NZBW/F1 mice have 18% fewer 
B cells among lymphocytes than do control mice (Fig. 24). The percentage of B cells 
in lymphocytes was between 63-68% in BL6 while the percentage varied between 46-
49% in NZB/WF1 mice. There is precedence for finding these levels of splenic B 
cells in NZB/WF 1 mice (Theofilopoulos et al 1979). Theofilopoulos et al analyzed 
the cellular content of splenic lymphocytes of one month old NZB/WF1 mice and 
found that 51 % of lymphocytes could be· defined as B cells. Similar findings are 
reported here for mice 6-8 weeks old (Fig. 24). In contrast, they found that the 
composition of lymphocytes in 1 month old BL6 mice was 52% B cell. Here, higher 
percentages of B cells were determined: BL6 B cells as defined by B220+ expression 
composed 63-68% of lymphocytes. These differences might be explained in the 
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difference in B cell subpopulation definition. In this study, the B220 protein was used 
to define B cells whereas the above mentioned study used surface expression of lg 
and the C3d receptor, a complement receptor expressed on B cells (Lambris et al 
1985), to define B cell populations. They also used a small sample size of 3 and the 
sample sizes in this study were 4, increasing the likelihood of experimental error. In 
addition, Theofilopoulos et al found that B cell distribution changed over time in 
Lupus-prone mice. B cell composition decreased in the spleen but increased in the 
thymus in mouse splenocytes when comparing mice at one month of age and others at 
eight months of age, when mice developed severe disease symptoms. The mice used 
in this study were between 6-8 weeks old. These findings may point to the importance 
of change in B cell population in Lupus, where B cell overactivity is implicated in 
etiology. 
Both NZB/WF1 and BL6 mice appear to constitutively express MHC-II on B 
cells, which is the expected phenotype for antigen presenting cells (Fig. 27). 
However, NZB/WF1 mice appear to have lower levels of MHC-II on B220+ B cells, 
but the significance of this differential must first be established through statistical 
analysis before any molecular changes may be safely assumed. The surface 
expression of MHC-II appears to be unregulated by either estrogen or bisphenol A in 
both strains of mice (Fig. 28). However, the amount of MHC-II is not the controlling 
factor of establishing autoimmunity; instead, the bound antigen and TCR positivity 
are the determinant factors of autoepitope recognition. Lupus susceptibility has been 
correlated with certain allelic haplotypes of MHC-II in mouse models and the 
suppressive effects of certain haplotypes has been related to decreased activity of B 
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cells, perhaps due to decreased likelihood to present self peptides (lbnou-Zekri et al 
1997). It has been determined that NZB/WF 1 spleens contain autoreactive T cell 
clones with TCRs specific to the mixed haplotype APz/ Aa.d class II molecules, and it 
is theorized that this derived trait may contribute to these Lupus-prone mice acquiring 
a higher affinity for presented autoantigens (Gotoh et al 1993). In other words, the 
different class II haplotype may contribute to changed antigen presentation profiles 
and induce autoreactivity. Bioinformatic techniques using a consensus approach may 
be used to assess the potential for MHC-11-restricted antigen presentation for specific 
peptide epitopes and to predict resultant CD4+ T cell response, particularly in 
C57BU6 mice (Wang et al 2008). The predictive power of these models could be 
useful in seeking out epitopes that could vary in presentation among model 
organisms. The efficacy of MHC-II-restricted antigen presentation, therefore, is an 
influential factor in the extent of SLE damaging symptoms. In order to better 
understand the decreased levels of MHC-11 on NZB/WF1 mice versus a control strain, 
further studies must be conducted to indentify the affinity of these molecules for 
certain peptides and the identity of favored antigens must be established. 
Expression of CD40 on splenic B cells is approximately the same in BL6 and 
NZB/WF1 mice (Fig. 29). Also, levels of CD40 appear independent of estrogen of 
BPA concentration (Fig. 30). Previous data report a similar situation in young, 
healthy mice in which NZB/WF1 B cells express only slightly higher CD40 than BL6 
mice (Colonna et al 2005); however, other professional APCs, namely DCs, express 
an increased level of CD40 in Lupus-prone mice at a young age, perhaps indicating a 
role for CD40 in pathogenesis (Colonna et al 2005). It is unknown whether the levels 
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of CD40 on DCsare affected by estrogen or bisphenol A, but here it is reported that 
splenic B cell CD40 levels are independent of estrogenic regulation. Therefore, B cell 
expression of CD40 appears to parallel normal conditions in a murine model for 
Lupus while CD40 upregulation is specific to DCs (Colonna et al 2005). Deficiencies 
in CD40L have been established in the disease X-linked immunodeficiency with 
hyper-IgM (HIGMl), so the CD40 pathway is irreplaceable in proper class switching 
from IgM to IgG, lgA, and IgE antibodies, which may be a way through which CD40 
acts in Lupus pathogenesis (Nonoyama et al 1993, Hill and Chapel 2003). 
Additionally, blocking the CD40-CD40L interaction has been associated with an 
increase in Treg cells (Bour-Jordan et al 2004). An increase in these cell types would 
assist in suppressing autoimmune response. The levels of CD40 on splenic B cells 
appear unchanged by E2 and BPA and are similar to normal levels in healthy, 6-8 
week old NZB/WF1 mice, but other cell subpopulations are potential targets for future 
study in understanding the role of CD40 in autoimmunity. 
Both strains of mice express CD86 on nearly all splenic B cells under 
stimulation with LPS (Fig. 33). However, the levels of CD86 are between 39-50% 
higher on Lupus-prone cells (Fig. 34 ). Regardless of treatment with E2 or BPA, levels 
of B cell surface CD86 are higher in young NZB/WF1 mice versus BL6 controls. So, 
although CD86 levels appear to be independent of treatment with E2 or BPA, levels 
are higher under stimulation by LPS while mice are still healthy. Previous 
examination of DC costimulatory phenotypes shows that CD86 levels are similar to 
control mice on Lupus-prone DCs (Colonna et al 2005). Since the levels of B220+ B 
cell surface CD86 are higher in young Lupus-mice as compared to control, there may 
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be a role for CD86 in Lupus pathogenesis in NZB/WF1 mice, and this finding should 
be examined in old, diseased mice to look for differences in observed costimulatory 
phenotype over the course of Lupus pathology. 
Levels of CD80+B220+ cells are relatively similar among Lupus-prone and 
control splenocytes (Fig. 31). Interestingly, preliminary results suggest that low 
nanomolar concentrations of estrogen may increase levels of CD80 on Lupus-prone 
splenic B cells (Fig. 32). These results have yet to have significance established so 
statistical analysis should be performed. The increase in CD80 appears to be specific 
to the NZB/WF1 strain and BPA does not seem to elicit similar response. Given the 
relevance of estrogen in the autoimmune disease Lupus, this finding may suggest 
susceptibility to estrogenic stimulation of an important immune regulator, CD80, in a 
model for Lupus. 
Also interesting is the apparent shift in the ratio of CD80 to CD86 under 
treatment with 5 nM estrogen (Fig. 35). Since the T cell costimulatory ligand CTLA-
4 does not bind with high avidity to monomeric CD80, but CTLA-4 does bind to 
APCs with high avidity, the model for CD80/CD86 cell surface clustering and 
oligomerization has been proposed to account for costimulatory efficacy (Greene et al 
1996). This suggests the importance of maintaining a proper balance of CD80 and 
CD86 expression (Colonna et al 2005). The ratio of CD80 to CD86 is consistently 
different in NZB/WF1 mice except with 5 nM treatment, in which the Lupus-prone 
ratio mirrors the BL6 ratio. It has been hypothesized that improper balance of CD80 
and CD86 expression could lead to changes in cellular regulation and stimulation 
signals, leading to improper immune response (Colonna et al 2005). 
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Burgeoning Evidence BPA Endocrine Disruption 
The synthetic chemical bisphenol A has been shown to act via estrogenic 
pathways on the cellular level. Both estrogen and bisphenol A, at physiologically 
relevant concentrations, have been shown to increase expression of estrogen receptors 
in mouse prostate cells, uncovering a potential positive feedback mechanism through 
which BPA may bind to estrogen receptors and simultaneous increase concentrations 
of ERs (Richter et al 2007). This study reports putative estrogen response elements 
for the genes of ERa and ERP (Fig. 6), suggesting pathways through which BPA 
could act estrogenically in these experiments. A study on human seminoma cells 
confirmed that BPA acts through an E2-binding G-protein coupled membrane 
receptor to increase cell proliferation, confirming that the classical nuclear receptor 
pathways are not the only mechanisms through which BPA alters cellular activity 
(Bouskine et al 2009). Genetic targets of activated estrogen receptors can modify 
normal cellular conditions and potentially may lead to pathogenecity. 
Bisphenol A has been shown to have profound negative effects in diseased 
cellular environments. For instance, low nanomolar exposure to BPA increases 
resistance of breast cancer cells to chemotherapeutic agents (LaPensee et al 2009). In 
ERa+ and ERa- breast cancer cell lines, environmentally relevant doses of BPA 
increase levels of antiapoptotic proteins and confer resistance to the drugs 
doxorubicin, cisplatin, and vinblastine, showing that BPA can act independently of 
the classical estrogen nuclear receptor pathways and have a detrimental effect in 
diseased cells via other pathways, including surface G-proteins and estrogen-related 
receptors (LaPensee et al 2009). The influence of BPA in malignant tumors may 
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overlap with the proposed effects of BPA on increased cathepsin activity described by 
this study. Targeted inhibition of cathepsins may effectively change the environment 
of metastatic tumor cells and thereby combat malignancy (Joyce 2005). Additionally, 
cathepsins have become important diagnostic markers of cancer tissues (Turk et al 
2004). The influence of BPA on cathepsin activity described here may have 
undiscovered implications in the molecular environment of cancerous tissues. 
One of the most disconcerting facts of BPA xenoestrogenecity is that 
detrimental effects are observed at incredibly low concentrations, to which humans 
are constantly exposed, and that pre-natal and young individuals may be particularly 
vulnerable to BPA toxicity. Even at exposure levels five times lower than the 
recommended daily intake by the EPA (50 µglkg bw/day), mice develop 
hyperinsulinemia and subsequent insulin resistance under in vivo exposure to BPA, 
which was clearly shown to act in classical and non-classical estrogenic pathways 
(Alonso-Magdalena et al 2006). Using relevant reference dosages, as defined by the 
Environmental Protection Agency in the United States and the European Food Safety 
Authority in the European Union, a study in rats found that BPA oral dosage to 
mothers lactationally transferred BPA to breast-feeding pups, leading to delayed 
ontogenetic effects. These effects included a two-fold increase in the ratio of 
proliferation to apoptosis in mammary gland cells and upregulation of enzymes 
involved in apoptotic pathways, increasing the susceptibility to mammary 
carcinogenesis (Jenkins et al 2009). 
People are particularly vulnerable to BPA exposure at young ages and during 
early development due to metabolic susceptibilities. In mice, nanomolar 
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concentrations of BPA upregulate ERa and PR in the luminal epithelium of uterine 
tissue, leading to significant cellular changes that ultimately alter the morphological 
characteristics of the uterus as an adult (Markey et al 2005). That is to say, prenatal 
exposure occurring across the placental barrier due to exposure of the mother to 
environmental BPA has a lasting effect on the reproductive systems of offspring. This 
is particularly frightening when considering that BPA has been shown to cross the 
placental barrier in humans and accumulate in fetuses, which are more vulnerable to 
BPA since embryonic and fetal metabolic enzymes neccessary to inactivate BPA are 
underdeveloped (Schonfelder et al 2002). The Sprague-Dawley rat model 
demonstrated that fetal tissues maintain a different BPA metabolic and 
pharmacokinetic environment than fully developed tissues (Domoradzki et al. 2003) 
and it has been observed that BPA and major BPA metabolites, such as BP A-
glucoronide, are capable of crossing the placental barrier (Schonfelder et al 2002) and 
thus become bioavailable to the cells of developing fetuses . The National Toxicology 
Program Monograph on the Potential Human Reproductive and Developmental 
Effects of Bisphenol A concluded that there is "some concern for effects on the 
brain, behavior, and prostate gland in fetuses, infants, and children at current human 
exposures to bisphenol A," and, "[the NTP] has minimal concern for effects on the 
mammary gland and an earlier age for puberty for females in fetuses, infants, and 
children at current human exposures to bisphenol A,", but there is no concern for 
fetal exposure to BPA affecting pregnancy outcomes (emphasis added) (NTP 2008). 
Part of the hesitation of the NTP to condemn BPA exposure as a potentially 
dangerous chemical is the broad use of non-human models and consideration of high, 
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and therefore physiologically irrelevant, concentrations of BPA. So, it could be more 
relevant for future studies to consider human tissues as models and to use established 
circulating concentrations of BPA to conduct studies. However, some studies do 
uncover detrimental biochemical disruption due to low BPA concentrations. For 
instance, low levels of BP A concentrations in humans, as indicated by urine content, 
have been correlated with increased risk of abnormal liver enzyme profiles, 
cardiovascular disease, and diabetes (Lang et al 2008). Further studies are needed to 
crystallize the range of findings associated with BPA exposure. 
Further confounding the study of BPA endocrine disruption are findings 
suggesting non-pathogenic and in some cases beneficalt effects of BPA exposure. 
Low nanomolar dosage of BPA administered in vivo to NZB/WF1 mke significantly 
reduced IFN-y production, increased secretion of IL-10, and decreased secretion of 
IgG2a antibodies, independent of B cell population shifting, after the onset of 
proteinuria and under exposure to LPS (Sawai et al 2003). These findings suggest that 
BPA is capable of influencing cytokine and antibody profiles with the opposite effect 
of estrogen, begging the question of whether BPA activity may consistently be related 
to an estrogen mimic, as in this case it was antagonistic. Although some studies using 
the NZB/WF1 found that low BPA concentrations actually improved disease 
conditions, by reducing IFN-y production, preventing Ab class switching to IgG2a, 
and delaying the onset of proteinuria (Sawai et al 2003), the differences between in 
vivo and in vitro experiments, the importance of having positive controls (vom Saal 
and Welshons 2006), the genetic identity of the model animals, and the 
concentrations of estrogenic hormones must all be carefully weighed in assessing the 
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effects of BPA in disease models. Although higher levels of BPA in urine have been 
correlated with increased health risks and disease, causality has not yet been 
established (Lang et al 2008); it could be that other factors such as socioeconomic 
status, which has been correlated with increased health risk (Olafsdottir 2007), make 
increased exposure to BPA through plastic products more likely. There are interacting 
biological and social factors that must be considered when applying BPA research 
findings to the model of human exposure. 
Crucial to the public debate surrounding BPA regulations are two major 
concerns of whether BPA causes detrimental and medically relevant effects at the 
molecular level and the maximum safe limit of exposure to BPA at the level of 
ingestion. An assumption of the political community is that exposure or dosage 
directly corresponds with effect, which endocrinologists understand is not the case 
due to the inverted 'U' shape of some hormone binding curves in which low 
concentrations doesn't necessarily correspond with low activity (vom Saal and Myers 
2008). Some researchers, including those funded by the non-profit NSF International 
whose independence is somewhat compromised by industrial private-sector funding, 
suggest that BPA efficacy curves resemble a monotonic dosage dependency in which 
BPA concentration is directly proportional to receptor binding and genetic response, 
which others argue is false information (Willhite et al 2008, vom Saal and Myers 
2008). Given the perpetual widespread usage of BPA for industrial purposes, the most 
effective public health initiative to reduce exposure to this high volume production 
chemical would arguably be government limitation of BPA manufacture and 
subsidized design of benign alternatives (vom Saal and Myers 2008). The current 
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trajectory of the BPA debate, the continued exposure of humans to BPA, and the 
dearth of legislative action in protecting the public from sources of BPA exposure 
(EPA BPA Action Plan, 2010) make BPA as an endocrine disruptor particularly 
relevant to research during the upcoming years. 
Expanding the Horizon for Autoimmune Treatment 
B cell function has been implicated in several aspect of SLE pathogenesis, 
including production of antibodies and pathways independent of Abs, including 
antigen presentation and costimulation, leading to increased cytokine profiles and 
activated T cells (Calero and Sanz 2010). B cell inactivation and suppression have 
therefore been key modalities in treating SLE. Several drugs have been developed 
that target B cells in treating autoimmunity, including rituximab (anti-CD20) and 
belimumab (anti-BLyS, see below). Given the heterogenei.ty of SLE predisposing 
genetic factors , it is not surprising that B cell depletion treatment has shown variable 
outcomes. Successful treatment is dependent on factors that vary on an individual 
basis and which are not yet fully uncovered (Calero and Sanz 2010). B cell activity 
depletion may therefore not be enough as some plasma cells, those cells producing 
autoantibodies in Lupus patients, are unaffected by treatments such as rituximab. 
Other options in targeting Ab activity exist, such as blocking the binding site of anti-
dsDNA antibodies using small molecules specific to Abs (Diamond et al 2010). 
Blocking anti-dsDNA antibodies could be a viable and specific approach to alleviated 
SLE symptoms (Diamond et al 2010), but targeted treatment could go one step 
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further in preventing the generation of those antibodies in the first place through 
costimulatory blockade. 
Molecular inhibition of costimulatory pathways is a powerful tool in treating 
autoimmune disease. Several modern drugs effectively target the pathways analyzed 
in this study. Rituximab, an antibody directed against CD20 on B cells, has been 
shown to improve clinical symptoms and downregulate molecular markers of B cell 
activity, such as CD40 and CD80, in patients with neuropsychiatric systemic lupus 
erythematosus (Tokunaga et al 2007). By blocking CD20 signaling, the administered 
antibody reduced inflammatory interactions between lymphocytes, thus moderating 
autoimmune symptoms. A promising prospect for treatment of SLE is belimumab: an 
immunoglobulin directed against the homeostatic factor B-lymphocyte stimulator 
(BLyS) (Thanou-Stavraki and Sawalha 2011). Belimumab blocks B cell activation 
signals and its efficacy in combating Lupus symptoms has been confirmed by various 
clinical trials. Costimulatory blockade has been implemented in treating other 
autoimmune diseases. Clinical trials have shown that abatacept safely and efficiently 
reduces the associated symptoms in rheumatoid arthritis (RA) patients via T cell 
costimulatory modulation (Westhovens et al 2009). Abatacept is a fusion protein 
composed of an lg domain bound to the extracellular domain of CTLA-4; the soluble 
ligand may bind to CD80 or CD86 and thus effectively block this costimulatory 
interaction between lymphocytes. Treatment with CTLA4Ig with background 
cyclophosphamide significantly reduced Lupus nephritis, decreased proteinuria, and 
prolonged survival in NZB/WFI mice, showing that blockade of the CD80/86 
pathway in combination with background immunosuppression is an effective method 
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in modulating autoimmune disease in a murine model for Lupus (Daikh and Wofsy 
2001). In addition to CD80 activity on B cells, T cells may also express CD80. In 
particular, a subset of IL-17-secreting T cells upregulate CD80 in SLE and have been 
implicated in increased inflammation in the kidneys of SLE patients (Dolff et al 
2010). This pathway may be relevant in the NZB/WF1 model and peripheral blood 
samples could be analyzed through FACS. T cell studies may be increasing relevant 
in uncovering the mysteries of autoimmune dysfunction. 
Exploratory studies have analyzed the efficacy of blocking the CD40 pathway 
in a mouse model for autoimmunity (Zheng et al 2010). Using RNA interference, 
CD40 was targeted in a mouse strain with collagen-induced arthritis, a model for the 
autoimmune disease RA. Blocking CD40 using siRNA improved autoimmune disease 
as defined by reduced Abs production, depletion of Th 1 cytokines, and increased 
levels of Treg cells. Although other studies have shown that Ab-mediated direct 
blockade of CD40 is an effective treatment model for mice with RA, humans have 
high levels of expression of CD154 on platelets and translation of this method to 
human treatment may induce thromboembolic events (Zheng et al 2010). Therefore, 
the CD40 costimulation pathway may be an important target in treating autoimmune 
RA patients and further studies should be conducted to elucidate the role of CD40 in 
Lupus. The CD40 pathway acts in conjunction with the CD80/86 pathway in Lupus 
pathogenesis in NZB/WF1 mice. Treatment of this strain with tandem CTLA41g and 
anti-CD40L decreased disease symptoms in NZB/WF1 mice (Wang et al 2002). 
In addition to blanket immunosupression and targeted costimulatory blockade, 
some other novel treatments for SLE are being considered. For instance, introduction 
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of short peptides in Lupus models has been shown to improve T cell tolerance of 
autoepitopes (Monneaux and Muller 2004, Kaliyaperumal et al 2002). Well-
developed supplemental treatment options for SLE include administration of 
Prasterone, a synthetic version of the endogenous hormone dehydroepiandrosterone 
(DHEA), which is a partially androgenic hormone (Wallace 2001). Administration of 
Prasterone in combination with other treatments changes hormonal profile in female 
SLE patients and has been reported to improve symptoms (Wallace 2001). 
Endrocrine homeostatis plays a vital role in maintaining proper immune 
function, so the influence of environmental endocrine disruptors is important in 
understanding proximal causes of autoimmunity. Preliminary data described here 
suggest that increased estrogen levels may have an effect in Lupus prone mice in 
increasing CD80 expression on splenic B cells (Fig. 32). Given the implications of 
estrogen in SLE pathogenesis and the estrogenic capacity of BPA, these data should 
be further analyzed to better determine the molecular targets of estrogen which appear 
to be different from normal in the physiological context of autoimmunity. A distinct 
trait of SLE is the overrepresentation of women. Understanding the molecular 
actions, genetic predispositions, and environmental influences will prove to be 
keystone information in developing novel treatment options for SLE and in 
understanding the root causes of autoimmune disease. 
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Appendix A 
Enclosure. The next 62 pages contain the compiled relevant acquired 
FACS data for all mouse sacrifices described. 
BL6 Spleen 6-22-10 
Control-Unstained Control-Unstained 
· ·. · ;'.::·:·: · · . L~~hocytes 
: • •• ~ .: • .:::... : • l ~ • • • B Cells 
. , 
100 150 200 250 10~ 10'" 
FSC-A (x 1,DDD) B220 FITC-A 
Tube: Unstained 
Control-Unstained 
Population #Events %Parent %Total 
•All Events 20,000 ttn 100.0 
• Lymphocy1es 18,121 90.6 90.6 
·• B Cells 
16,826 92.9 84.1 
t ... 0 MHC-11 123 0.7 0.6 
• co00 721 4.3 3.6 
' • co06 124 0.7 0.6 
' 0CD40 171 1.0 0.9 
f • Resting B 8,014 47.6 40.1 
! • Blasting B 7,677 45.6 38.4 











I I 1111111 I 1111111 I 
102 10'" IDS 
COBO 




Experiment Name: BL6 Spleen 6-22-1 o 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Jun 22, 201 O 4:42:35 PM 
$OP: Administrator 
FSC-A SSC-AB220 Fl... PE-A PerCP-... PE-Cy? ... APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocy1es 18,1 21 90.6 B0,291 39,350 174 90 136 11 BO 11,104 
• B Cells 16,826 92.9 81 ,212 39,852 187 94 142 12 82 11 ,100 
D MHC-11 123 0.7 93,501 81 ,869 2,073 1,899 3,978 368 996 11 ,522 
• coao 721 4.3 73,752 52,581 815 745 1,637 154 529 11,243 
• co06 124 0.7 85,182 67,714 1,375 1,354 3,177 602 940 11,555 
0CD40 171 1.0 86,896 66,408 1,253 1,176 2,829 317 1,140 11,151 
• Resting B Cells B,014 47.6 56,520 32,008 150 89 146 14 85 11, 157 
• Blasting B Cells 7,677 45.6 103,309 43,262 194 76 95 7 67 11,087 
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BL6 Spleen 6-22-10 
Control-I G 
B Cells 
50 100 150 200 250 
FSC-A (x 1,000) 
Tube: lgG 
Population #Events %Parent %Total Control-I G 
•All Events 20,000 ###- 100.0 
· · • Lymphocytes 17,426 87.1 87.1 
• B Cells 15,921 91 .4 79.6 
L.0 MHC-11 83 0.5 0.4 
: • co00 483 3.0 2.4 
• co86 81 0.5 0.4 
f .. 0CD40 95 0.6 0.5 
'.· · Resting B 4,828 30.3 24.1 












Control- I G 
CDB6 ..... CD40 c: 
::s o-
() 





t:xpenmem Name: ljLtl ~p1een tl-LL- 'I u 
Specimen Name: Control 
Tube Name: lgG 
Record Date: Jun 22, 201 O 4:46:23 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7 ... Af'C-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,426 87 .1 90,284 43,593 194 85 110 8 65 7,680 
• B Cells 15,921 91 .4 91,904 44,536 213 89 114 9 66 7,635 
DMHC-11 83 0.5 104,361 88,392 1,823 1,721 3,501 313 939 8,070 
• c o00 483 3.0 82,843 59,009 831 696 1,461 136 465 7,984 
• c o06 81 0.5 83,480 70,195 1,21 8 1,214 2,748 559 877 8,395 
0 CD40 95 0.6 98,228 78,711 1,392 1,346 3,117 339 1,11 7 8,300 
• Resting B Cells 4,828 30 .3 55,871 32,955 171 89 144 13 79 7,912 
• Blasting B Cells 9,978 62 .7 105,415 46,016 208 74 75 5 52 7,520 
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Control-All Colors 
50 
Tube: All Colors 
Population 
•All Events 
· ·· • Lymphocytes 
• B Cells 
i D MHC-11 
, • co00 









BL6 Spleen 6-22-10 
200 250 







Restlng~BCells . ' . ' . ,,,.. . _,I 
• ·-r , '' . t; · ~;, ·t " 
irq B Cells 
~ • Resting B 
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ID:i 
PE-A 
10:1 10• 105 
PE-Cy7-A 
txpenmem Name: t:1Lt> ::;p1een o-u-1 u 
Specimen Name: Control 
Tube Name: All Colors 




• B Cells 
OMHC-11 
• c o00 
• cD06 
0 CD40 
• Resting B Cells 






11 ,005 99.0 
10,596 80.2 
3,242 27 .0 
7,949 66 .2 
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10:1 10 .. 
PerCP-Cy5-5-A 










40,528 9,21 4 
33,463 4,931 
47,490 9,547 
Page 1 of 1 
PE-A PerCP-... PE-Cy7 ... 
Mean Mean Mean 
25,331 045 9,609 
33,600 609 11 ,375 
33,916 690 11 ,434 
39,219 1,957 14,640 
33,930 655 11 ,491 
36,554 642 11,622 
10,002 216 9,124 
37,953 554 10,970 
(x I .ODD) 
COBO 
CD40 






















BL6 Spleen 6-22-10 
5 nM BPA-All Colors 
.. ': .. . :".· . 
50 100 150 200 260 
FSC-A (x 1,000) 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 #If:#. 100.0 
· .. • Lymphocytes 16,660 83.3 83.3 
• B Cells 11,913 71 .5 59.6 
f ·OMHC-11 11 , 762 98.7 58.B 
f • COBO 5,121 43.0 25.6 
t • CDB6 11,7 48 98.6 58.7 
'. .. D CD40 10,854 91.1 54.3 
f .... Resting B 2,474 20.B 12.4 
l _ . • Blasting B 7,991 67.1 40.0 
5 nM BPA-All Colors 
10J 10 .. 10s 
PE-Cy7-A 
t:xperiment Name: t:1L t:> ::;p1een t:> -.l F I u 
Specimen Name: 5 nM BPA 
Tube Name: All Colors 
Record Date: Jun 22, 201 o 5:08:41 PM 
$OP: Administrator 
FS C-A SSC-A FITC-A 
Population #Events %Parent Mean Mean Mean 
• Lymphocytes 16,660 83.3 92,665 50,899 8,583 
• B Cells 11,913 71 .5 99,900 56,771 11,977 
OMHC-11 11,762 98.7 100,381 56,943 12,104 
• co00 5,121 43.0 109,257 64,789 13,307 
• co06 11,7 48 98 .6 100,323 57,058 12,083 
0 CD40 10,854 91 .1 103,749 58,978 12,81 1 
• Resting B Cells 2,474 20.8 56,905 32,081 5,158 
• Blasting B Cells 7,991 67.1 104,619 54,766 12,583 
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10J 
FITC-A 
5 nM BPA-All Colors 
50 100 150 
FSC-A 
5 nM BPA-All Colors 
10J 10 .. 
PerCP-Cy5-5-A 
5 nM BPA-All Colors 
10J 
APC-A 
PE-A PerCP-... PE-Cy7 ... 
Mean Mean Mean 
35,371 933 9,860 
46,546 780 11,51 8 
47,137 782 11,567 
52,186 1,909 12,614 
46,933 720 11,683 
49,708 645 11,315 
18,613 372 12,983 
















BL6 Spleen 6-22-10 
5 nM E2-All Colors 
. :- .· .. ·:. : 
100 150 200 250 
FSC-A (X 1,DDD) 
Tube: All Colors 
Population #Events %Parent %Total 
•All Events 20,000 f:tt:ll. 100.0 
• Lymphocytes 17,106 85.5 85.5 
• BCells 9,997 58.4 50.0 
:··OMHC-11 9,816 98.2 49.1 
'. .. . COBO 3,428 34.3 17.1 
l • co06 9,826 98.3 49.1 
' CD40 8,658 86.6 43.3 i '"' 
~ ..... Resting 8 3,118 31 .2 15.6 
I 
t ... • Blasting 8 5,719 57.2 28.6 
PE-A 
10~ 10" 105 
PE-Cy7-A 
t:xperimem Name: l::ILt> ::;p1een t>-LL- ·1 u 
Specimen Name: 5 nM E2 
Tube Name: All Colors 
Record Date: Jun 22, 201 o 4:58:32 PM 
$OP: Administrator 
Population 





• Resting 8 Cells 
• Blasting B Cells 
# Events %Parent 



































10, 1 41 
4,653 
10,460 
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5 nM E2-All Colors 
.· 
50 100 150 200 250 
FSC-A (x 1,DDD) 
CD80 




PE-A PerCP-... PE-Cy7 ... 
Mean Mean Mean 
23,344 709 7,530 
36,896 626 9,919 
37,568 629 10,011 
42,170 1,903 11 ,344 
37,372 61 3 10,092 
40,637 509 9,951 
17,892 256 9,129 
43,105 448 8,149 
CD'Hl 






















BL6 Spleen 6-22-10 
50 nM BPA-All Colors 
. . . . . ·. :.: . 
B Cells 
50 100 150 200 250 10~ 10" 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 50 nM BPA-All Colors 
•All Events 20,000 ti###- 100.0 
.. • Lymphocytes 17,058 85.3 85.3 
' • B Cells 9,893 58.0 49.5 
f .. 0 MHC-11 9,724 98.3 48.6 
~- · COBO 3,496 35.3 17.5 
t • CD86 9,686 97.9 48.4 
l ·fll CD40 8,426 85.2 42.1 
I • . 3,000 30.3 15.0 i"" Resting B 










10° 10· 105 100 10" IOS 
PE-Cy7-A 
APC-A 
t:xperimem Name: t::1Ltl ::;p1een ti- LL-'I u 
Specimen Name: 50 nM BPA 
Tube Name: All Colors 
Record Date: Jun 22, 201 o 5:1 4:37 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7 ... APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,058 85.3 85,670 45,022 5,181 23,241 766 7,150 1,985 2,761 
• B Cells 9,893 58.0 93, 179 52,086 8,883 36,513 607 9,276 3,020 2,752 
D MHC- 11 9,724 98.3 93,639 52,292 8,993 37,139 609 9,344 3,064 2,754 
• coeo 3,496 35.3 1 04,045 61 ,363 9,949 41,849 1,796 10,395 3,679 2.728 
• coe6 9,686 97.9 93,648 52,310 8,991 37,102 580 9,473 3,068 2,753 
0CD40 8,426 85.2 98,903 55,404 9,855 40,620 506 9,282 3,473 2,759 
• Resting B Cells 3,000 30.3 56,350 31,430 4,360 17,178 326 8,882 1,237 2,740 
• Blasting B Cells 5,879 59.4 104,129 53,491 10,232 43,347 460 7,976 3,390 2,767 
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Printed on: Sun Mar 20 , 2011 12:07:01 PDT 
BL6 Spleen 6-22-10 
50 nM E2-All Colors 50 nM E2-All Colors 
B Cells 
60 100 160 200 260 
FSC-A (x 1.000) 
Tube: All Colors 
Population #Events %Parent %Total 
•All Events 20,000 #1# 100.0 
• Lymphocytes 17,392 87.0 87.0 
• B Cells 11,27 4 64.8 56.4 
D MHC-11 11 ,087 98.3 55.4 
t • co00 4,427 39.3 22.1 ! 
~ • co06 11,053 98.0 55.3 
t GJ CD-40 9,896 87.8 49.5 
' 
' • Resting B 2,998 26.6 15.0 
. .. • Blasting B 6,884 61 .1 34.4 
50 nM E2-All Colors 
PE-A 
10:) 10 10s 
PE-Cy7-A 
t:xpenmem Name: ljLtl ::;p1een t>-.l.l-·1 u 
Specimen Name: 50 nM E2 
Tube Name: All Colors 
Record Date: Jun 22, 201 o 5:02:20 PM 
$OP: Administrator 
FSC-A SSC-A 
Population IEvents %Parent Mean Mean 
Lymphocytes 17,392 87.0 88,572 48,4 75 
• B Cells 11 ,27 4 64.8 96,351 55,767 
OMHC-11 11 ,087 98.3 96,854 56,005 
• co00 4,427 39.3 106,320 64,923 
. CD86 11,053 98.0 96,911 56,116 
0 CD40 9,896 87.8 1 01,348 58,890 
• Resting B Cells 2,998 26.6 57,323 32,120 









~1 .. ,,,, 
102 10:) 10' 
APC-A 
FITC-A PE-A PerCP-... PE-Cy7 ... 
Mean Mean Mean Mean 
6,260 27,543 728 7,680 
9,611 39,733 576 9,515 
9,736 40,395 577 9,599 
10,700 44,321 1,529 10,585 
9,736 40,364 557 9,706 
10,509 43,659 536 9,678 
4,661 18,250 257 8,360 
10,489 44,731 492 8,345 
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' D MHC-11 
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Experiment Name: 8L6 Spleen 6-24-1 o 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Jun 24, 201 O 2:37:02 PM 
$OP: Administrator 
FSC-A SSC-A 8220 Fl... 
Populatlon #Events %Parent Mean Mean Mean 
• Lymphocytes 17,447 87.2 77,637 42,955 137 
• 8Cells 14,729 84.4 78,526 44,217 163 
D MHC-11 145 1.0 77,997 68,252 1,854 
• co00 522 3.5 73,303 59,706 956 
• c o06 143 1.0 68,305 62,484 1,411 
0CD40 127 0.9 73,140 63,087 1,361 
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I I liiiij I 
10s 
PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
69 110 11 73 
75 122 12 75 
1,688 3,807 336 738 
797 1,826 157 419 
1,272 3,039 514 621 











Tube: All Colors 
Population 
•All Events 
' • Lymphocytes 
:._ .• 8 Cells 
f··· OMHC-11 
t • COBO 
f··-· CD86 









BL6 Spleen 6-24-10 
200 250 
(x 1.000) 
#Events %Parent %Total 
20,000 #### 100.0 
17,370 86.9 86.9 
11, 1 95 64 .5 56.0 
11,045 98.7 55.2 
3,653 32.6 18.3 
11,051 98 .7 55.3 











Experiment Name: 8L6 Spleen 6-24-1 O 
Specimen Name: Control 
Tube Name: All Colors 
Record Date: Jun 24, 2010 2:45:52 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,370 86.9 78,844 44,477 3,888 16,136 434 8,255 
• 8 Cells 11 '195 64 .5 87,064 50,015 5,960 23,832 407 10,844 
D MHC-11 11 ,045 98.7 87,504 50,268 6,015 24,148 409 10,923 
• c oeo 3,653 32.6 97,464 59,409 6,639 27,752 1,272 13,366 
• c oe6 11,051 98.7 87,427 50,203 6,005 24,021 377 10,985 
0 CD40 10,177 90 .9 90,582 51,892 6,333 25,557 391 10,964 
Printed by: Administrator Page 1 of 1 










5 nM SPA-All Colors 
50 
Tube: All Colors 
Population 
•All Events 
·· • Lymphocytes L_. S Cells 
[·-0 MHC-11 
f .... . COBO 






5 nM SPA-All Colors 
PE-A 
10:1 10 .. 
PE-Cy7-A 
BL6 Spleen 6-24-10 
5 nM SPA-All Colors 
200 260 
(x 1.000) 
#Events %Parent %Total 
20,000 'f#l:l:I. 100.0 
17,255 86.3 86.3 
9,961 57.7 49.B 
9,837 98.B 49.2 
3,560 35.7 17.B 
9,827 98.7 49.1 
8,937 89.7 44.7 
COBO 
10:1 10 .. 
PerCP-Cy5-5-A 
10:1 10 .. 
APC-A 
Experiment Name: SL6 Spleen 6-24-1 O 
Specimen Name: 5 nM SPA 
Tube Name: All Colors 
Record Date: Jun 24, 201 o 2:57:01 PM 
SOP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP- .. . PE-Cy7-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,255 86.3 77,520 41 , 731 3,525 17,792 498 7,071 
• s Cells 9,961 57.7 85,354 46,785 5,983 29,249 544 10,361 
DMHC-11 9,837 98.B 85,670 46,934 6,035 29,611 547 10,425 
• co00 3,560 35.7 94,033 54,049 6,628 33,109 1,559 12,315 
• co86 9,827 98.7 85,677 46,933 6,029 29,492 489 10,503 
0CD40 8,937 89.7 88,996 48,385 6,418 31,692 437 10,450 
Printed by: Administrator Page 1 of 1 






3,097 1 ,054 
3,706 1,062 
3,096 1 ,055 
3,375 1,053 
5 nM E2·All Colors 
50 
Tube: All Colors 
Population 
• All Events 
• Lymphocytes •s Cells 
. D MHC·ll 
· • coao 
- · COBB 
. D CD40 
·: · . . 
100 150 
FSC·A 
5 nM E2-All Colors 
I I I I 
PE·A 
BL6 Spleen 6-24-10 




























~ ~' """' 
102 
5 nM E2·All Colors 
ID:l 
FITC·A 
5 nM E2·All Colors 
COBO 
10:1 10' 105 
PerCP-CyS..5-A 
CD40 
1 1 I I 11111 I 
10' 1Ds 
Experiment Name: 8L6 Spleen 6·24· 1 O 
Specimen Name: 5 nM E2 
Tube Name: All Colors 
Record Date: Jun 24, 201 O 2:49:29 PM 
$OP: Administrator 
FSC-A SSC-A FITC·A PE·A PerCP· ... PE-Cy7-A APC·A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,984 84.9 B0,257 43,535 4,390 22,308 570 B,970 2,327 
• 8 Cells 11,323 66.7 BB,016 48,558 6,513 31 ,81 9 516 11,549 3,244 
D MHC·ll 11,168 98.6 BB,422 48,784 6,575 32,254 519 11 ,642 3,281 
• coao 4,243 37.5 97,156 56,202 7,251 36,41 6 1,440 13,662 3,832 
. COBB 11, 1 87 98.B BB,300 48,691 6,555 32,020 453 11 ,692 3,274 
0 CD40 10,279 90.B 91 ,543 50,320 6,943 34,193 450 11,659 3,539 
Printed by: Administrator Page 1 of 1 









50 nM BPA-All Colors 
50 100 150 




i • B Cells 
r OMHc- 11 














































50 nM BPA·All Colors 
10:1 
FITC·A 









I I II 11111 I 
10s 
Experiment Name: BL6 Spleen 6-24-1 O 
Specimen Name: 50 nM BPA 
Tube Name: All Colors 
Record Date: Jun 24, 201 O 3:00:49 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,705 83.5 78,056 43,502 3,993 19,715 544 7,982 2,059 
• B Cells 10,406 62.3 86,739 49,555 6,336 30,069 535 10,873 3,060 
D MHC-11 10,251 98.5 87,245 49,825 6,405 30,515 538 10,957 3,100 
• coeo 3,648 35.1 97,224 59,056 7,076 34,765 1,569 13,590 3,910 
• coe6 10,277 98.8 87,059 49,696 6,382 30,244 451 11 ,01 3 3,091 
0CD40 9,190 88.3 91,303 51,928 6,878 33,089 475 11,058 3,41 B 
Printed by: Administrator Page 1of1 










BL6 Spleen 6-24-10 
50 nM E2-All Colors 
. • ':• .... . . 
. · .';·:· , . 
.... ".':\~· " " " :_.· ------~-----" . "; 
100 150 200 260 
FSC-A (x 1,000) 
Tube: All Colors 










L • 8 Cells 
!-OMHC- 11 
t • co00 








Experiment Name: 8L6 Spleen 6-24-1 O 
Specimen Name: 50 nM E2 
Tube Name: All Colors 
Record Date: Jun 24, 201 O 2:53:32 PM 
$OP: Administrator 
FSC-A SSC-A 
Population #Events %Parent Mean Mean 
• Lymphocytes 16,686 83.4 78,187 42,589 
• 8 Cells 10,817 64.8 85,720 47,634 
D MHC-11 10,643 98.4 86,214 47,869 
• co00 4,836 44.7 93,478 54,703 
• cD86 10,671 98.7 86,074 47,812 




















IO:i 10• IDS 
PerCP-Cy5-5-A 
CD40 
I I liiilj I 
10s 
FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean Mean 
3,912 19,788 797 8,324 4,058 
5,972 28,829 693 10,791 5,582 
6,040 29,292 697 10,884 5,667 
6,582 31,919 1,573 12,509 9,228 
6,016 29,123 653 10,939 5,599 
6,452 31,614 682 10,849 6,242 
Printed by: Administrator Page 1 of 1 



















! - · 8 Cells 
: OMHC-11 
... • coao 
····· · COBS 
. D CD40 
100 160 
FSC-A 















I I iiiiij 
10s 
CD86 
%Parent % Total 
"###- 1 00.0 
61 .3 61 .3 





Experiment Name: 8L6 Spleen 6-29-10 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Jun 29, 201 O 1 :21 :06 PM 
SOP: Administrator 
FSC-A SSC-A 8220 Fl ... 
Population #Events %Parent Mean Mean Mean 
• Lymphocytes 12,254 61.3 78,137 37,820 133 
• 8 Cells 1 0,242 83.6 78,160 38,829 160 
D MHC-11 100 1.0 87,457 87,996 2,120 
• co00 202 2.0 86,320 76,373 1,312 
• co0s 103 1.0 86,196 75,883 1,495 
0 CD40 106 1.0 83,075 71,754 1,539 
Prin1ed by: Administrator Page 1 of1 










111 I I I 1111111 
10~ 10' 
I 11 illlj I 
10s 
APC-A 
PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
68 97 12 69 
74 107 13 72 
1,766 3,357 410 715 
1,049 2,088 262 478 
1,255 2,61 B 548 542 










. ·. · 
Tube: All Colors 
Population 
•All Events 
" ·• Lymphocytes l-· 8 Cells 
f O MHC- 11 
f .. · . CDBO 
f-- · CDB6 









#Events %Parent %Total 
20,000 ### 100.0 
12,987 64.9 64.9 
B,754 67.4 43.B 
B,5B5 9B.1 42.9 
2,304 26.3 11 .5 
B,50B 97.2 42.5 
7,363 B4.1 36.B 







I 1111111 I 
10s 
i ~"'" ., 
102 
CD'IO 
Experiment Name: BL6 Spleen 6-29-1 o 
Specimen Name: Control 
Tube Name: All Colors 
Record Date: Jun 29, 201 O 1 :25:11 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 12,987 64.9 75,310 36,262 3,981 13,222 421 7,430 1,760 
• 8 Cells B,754 67.4 77,865 3B,B31 5,805 1 B,4B4 397 9,277 2,380 
D MHC-11 B,5B5 98.1 78,225 39,040 5,BB4 1 B,841 401 9,359 2,420 
• c o00 2,304 26.3 90,214 49,127 7,121 23,857 1,482 11 ,728 3,298 
• co06 8,508 97.2 78,337 39,194 5,BB1 1 B,B4B 376 9,548 2,427 
0CD40 7,363 B4.1 B1 ,B29 40,994 6,421 21,054 403 9,695 2,778 
Printed by: Adminis1rator Page 1 of 1 









BL6 Spleen 6-29-1 0 
5 nM BPA-All Colors 5 nM BPA-All Colors 
.. . : . : ··. 
50 100 150 200 250 
FSC-A (x 1,000) 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 ### 100.0 
• Lymphocytes 13,490 67.4 67.4 t_. B Cells 8,831 65.5 44.2 
! O MHC-11 8,672 98.2 43.4 
L ..• CD80 2,166 24.5 10.8 
1···· • CD86 8,534 96.6 42.7 
L. D CD40 7,685 87.0 38.4 





10~ 10' 105 
PerCP-Cy5-5-A 
~~""" ' : 
CD40 
I 
I I 1111111 I 
105 102 1 0~ 105 10~ 10' 
PE-Cy7-A APC-A 
Experiment Name: BL6 Spleen 6-29-10 
Specimen Name: 5 nM BPA 
Tube Name: All Colors 
Record Date: Jun 29, 201 O 1 :33:44 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A nme 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 13,490 67.4 78,519 38,217 4,306 13,480 386 6,903 1,944 900 
• BCells 8,831 65.5 82,334 41 ,455 6,401 19,464 372 8,956 2,756 903 
D MHC-11 8,672 98.2 82,701 41,670 6,482 19,815 375 9,049 2,800 903 
• co00 2,166 24.5 97,084 53,152 7,690 24,310 1,489 11 ,800 3,800 895 
• co06 8,534 96.6 83,003 41,955 6,506 19,888 322 9,271 2,826 904 
0 CD40 7,685 87.0 86,015 43,474 6,967 21,542 339 9,423 3,122 901 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20. 2011 12 :23:59 PDT 
BL6 Spleen 6-29-10 
5 nM E2-All Colors 5 nM E2-All Colors 
. . :::·.: . 
60 100 160 200 260 10:1 105 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 "" 100.0 • Lymphocytes 13,866 69.3 69.3 
L• s Cells 9,242 66.7 46.2 
[ .. - O MHC-11 9,086 98.3 45.4 
: • co00 2,585 28.0 12.9 
• co06 8,974 97.1 44.9 
0 CD40 8,112 87.8 40.6 
5 nM E2-All Colors 5 nM E2-All Colors 
COBO 
10:1 10:1 10' 105 
PE-A PerCP-Cy5-5-A 







I I ' 111 1111 I 
10:1 10' 105 102 10:1 105 
PE-Cy7-A APC-A 
Experiment Name: 8L6 Spleen 6-29-1 O 
Specimen Name: 5 nM E2 
Tube Name: All Colors 
Record Date: Jun 29, 201 O 1 :28:08 PM 
SOP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A nme 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 13,866 69.3 78,652 37,873 3,643 14,658 396 7,269 2,185 1,294 
• B Cells 9,242 66.7 81,593 40,732 5,399 20,755 349 9,311 3,000 1,295 
D MHC- 11 9,086 98.3 81,945 40,926 5,462 21, 1 05 351 9,404 3,044 1,295 
• co00 2,585 28.0 94,385 51 ,598 6,453 25, 111 1,194 12,577 4,327 1,298 
• co06 8,974 97.1 82,156 41 ,153 5,474 21 ,229 354 9,590 3,066 1,298 
0CD40 8,112 87.8 84,918 42,481 5,841 22,903 363 9,773 3,376 1,299 
Printed by: Administra1or Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:22:05 PDT 
BL6 Spleen 6-29-10 
50 nM BPA-All Colors 50 nM BPA-All Colors 
Tube: All Colors 
Population 
• All Events 








I 11 11 I 
10l 10• 
PE-A 













Experiment Name: 8L6 Spleen 6-29-1 o 
Specimen Name: 50 nM BPA 
Tube Name: All Colors 





"" 100.0 67.1 67.1 
66.2 44.4 
90.6 43.0 
25.4 11 .3 
97.7 43.4 
92.3 41 .0 
COBO 
10l 10· 105 
PerCP-Cy5-5-A 
10l 10· 105 
APC-A 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Populallon #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 13,424 67.1 01 ,411 39,000 5,856 17,583 444 8,299 2,807 
• BCells 8,885 66.2 86,105 43,690 B,701 25,220 416 10,777 3,056 
D MHC-11 0,764 90.6 06,449 43,089 B,871 25,572 420 10,061 3,903 
• co00 2,261 25.4 100,075 55,504 10,404 31 ,499 1,656 13,655 5,240 
. CD06 0,601 97.7 86,644 44,000 0,005 25,647 377 11,033 3,925 
0CD40 0,201 92.3 00,459 44,934 9,259 26,872 387 11,034 4,154 
Printed by: Administrator Page 1 or 1 









BL6 Spleen 6-29-10 
50 nM E2-All Colors 50 nM E2-Afl Colors .. .. 
B Cells 
50 100 150 200 250 10:1 10s 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 ftt#. 100.0 
• Lymphocytes 12,805 64.0 64.0 
:. • B Cells 8,456 66.0 42.3 
i OMHC-11 8,308 98.2 41 .5 
;····• CD80 2,227 26.3 11 .1 L. CD86 8,185 96.8 40.9 
'·· D CD40 7,278 86.1 36.4 





10:1 104 10:1 104 
PE-A PerCP-Cy5-5-A 
50 nM E2-All Colors 
CD10 
10:1 104 10:1 104 
I I I 11111 I 
10s 
PE-Cy7-A APC-A 
Experiment Name: BL6 Spleen 6-29-1 O 
Specimen Name: 50 nM E2 
Tube Name: All Colors 
Record Date: Jun 29, 201 O 1:30:47 PM 
SOP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A nme 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 12,805 64.0 77,992 37,484 3,878 14,066 337 7,033 1,932 742 
• B Cells 8,456 66.0 81 ,344 40,391 5,799 20,229 312 9,122 2,688 746 
D MHC-11 8,308 98.2 81,730 40,564 5,871 20,584 315 9,208 2,730 747 
• co00 2,227 26.3 95,544 52,045 7 ,163 25,263 1,174 12,551 3,945 763 
• co0s 8,185 96.8 81,973 40,848 5,887 20,731 316 9,426 2,751 746 
0 CD40 7,278 86.1 85,356 42,603 6,345 22,623 338 9,628 3,077 751 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:22:43 PDT 




50 100 150 200 250 10:1 10· 105 
FSC-A (X I ,ODO) 8220 FITC-A 
Tube: Unstained 
Population #Events %Parent %Total 
• All Events 20,000 ## 100.0 
• Lymphocytes 17,441 87.2 87.2 
• 8 Cells 15,472 88.7 77.4 
- D MHC-11 152 1.0 0.8 
• • co00 731 4.7 3.7 
•·- · CD86 
150 1.0 0.8 












I I 1111111 I lllll ij I 
10• 105 
PE-Cy7-A APC-A 
Experiment Name: 8L6 Spleen 7-1-1 O 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Jul 1, 2010 12:53:50 PM 
$OP: Administrator 
FSC-A SSC-A 8220 Fl... PE-A PerCP-... PE-Cy7-A APC-A nme 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,441 87.2 76,649 41 ,756 164 83 148 17 75 2,520 
• 8 Cells 15,472 88.7 77,164 42,771 185 88 160 19 77 2,518 
D MHC-11 152 1.0 99,377 90,527 1,912 2,000 5,364 566 950 2,362 
• co00 731 4.7 72,645 57,297 830 812 2,274 249 454 2,478 
• co06 150 1.0 85,867 75,593 1,431 1,551 4,459 784 848 2,474 
0CD40 153 1.0 99,092 83,381 1,422 1,572 4,680 543 1,100 2,514 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:25:22 PDT 
Control-All Colors 
50 




• B Cells 
. D MHC-11 
, ... . COBO 
• coe6 
0 CD40 









Experiment Name: BL6 Spleen 7-1 -10 
Specimen Name: Control 
Tube Name: All Colors 
BL6 Spleen 7-1-10 
Control-All Colors 
200 250 10~ 10s 
(x 1,000) FITC-A 
#Events %Parent %Total 
20,000 ## 100.0 
18,1 49 90.7 90.7 
12,725 70.1 63.6 
12,636 99.3 63.2 
3,331 26.2 16.7 
417 3.3 2.1 
12,1 05 95.1 60.5 
C> Control-All Colors 
COBO 




~ ~' ""' 
CD'IO 
I 
I I I II 1 I ii I Ill) I 
IDS ID2 10~ IDS 
APC-A 
Record Date: Jul 1, 2010 12:56:25 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 18,149 90.7 78,160 42,298 4,564 16,955 534 7 2,562 
• 8 Cells 12,725 70.1 82,647 45,957 6,313 22,970 390 18 3,433 
D MHC-11 12,636 99.3 82,808 46,043 6,340 23,128 391 18 3,453 
• coeo 3,331 26.2 91 ,049 54,070 6,719 25,239 1,520 -105 3,899 
• coe6 417 3.3 98,111 60,772 7,025 27,316 830 617 3,918 
0 CD40 12,105 95.1 83,960 46,486 6,486 23,581 294 27 3,593 
Printed by: Administrator Page 1 of 1 









BL6 Spleen 7-1-10 
5 nM SPA-All Colors 
50 100 150 200 250 1Dl 105 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
'All Events 20,000 "" 100.0 '- • Lymphocytes 14,947 74.7 74.7 L_. s Cells B,539 57.1 42.7 
r·-0 MHC-11 B,355 97.B 41 .B L. COBO 2,071 24.3 10.4 
t···· • CDB6 B,335 97.6 41 .7 
L. fJ CD40 6,711 78.6 33.6 
c 
J ~" ""'' 
COBO 
I I I 




10l 10· IDS 1Dl 10s 
PE-Cy7-A APC-A 
Experiment Name: SL6 Spleen 7-1-1 O 
Specimen Name: 5 nM SPA 
Tube Name: All Colors 
Record Date: Jul 1, 201 0 1 :07:43 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 14,947 74.7 68,482 36,923 3,132 9,922 423 7,195 1,589 1,856 
• S Cells 8,539 57.1 74,147 40,461 5,339 16,189 368 9,385 2,550 1,850 
D MHC-11 8,355 97.8 74,530 40,656 5,409 16,533 367 9,499 2,596 1,853 
• co00 2,071 24.3 83,259 51 ,379 6,1 09 19,388 1,495 11,313 3,448 1,881 
• co06 B,335 97.6 74,478 40,456 5,411 16,473 311 9,611 2,592 1,849 
0CD40 6,711 78.6 78,845 43,638 6,079 1 B,982 379 10,044 3,141 1,850 
Printed by: Administrator Page 1of1 
Printed on: Sun Mar 20 , 2011 12:27:41 PDT 
BL6 Spleen 7-1 -10 
5 nM E2-All Colors 
·.·· .. ' ' 
. · ~ .. ::· .· . .. 
100 150 
Tube: All Colors 
Population 
• All Events 
L • Lymphocytes 
t ... • 9 Cells 
[·····OMHC-11 
;··- · COBO 
:_ .. . CD86 
L D CD40 
FSC-A 
















10:1 10• 10s 
PE-Cy7-A 
Experiment Name: BL6 Spleen 7-1-10 
Specimen Name: 5 nM E2 
Tube Name: All Colors 
Record Date: Jul 1, 201a12:59:55 PM 
$OP: Administrator 















FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean 
• Lymphocytes 18,1 07 90.5 79,484 42,909 3,905 15,033 437 7,268 
• B Cells 12,178 67.3 85,644 47,653 5,728 21,383 315 9,677 
D MHC-11 12,086 99.2 85,838 47,743 5,756 21 ,541 314 9,733 
• coeo 3,084 25.3 95,522 57,528 6,300 23,31 a 1,31 a 12,586 
• coe6 12,053 99.0 85,850 47,636 5,763 21,565 299 9,776 
0CD40 11,4 78 94.3 87,473 48,392 5,923 22,219 289 10,005 
Printed by: Adminis1rator Page 1 of1 








2.01 e 1,631 
50 nM BPA-All Colors 
Tube: All Colors 
Population 
• All Events 
• Lymphocytes 
• 8 Cells 
•. O MHC- 11 
·-· . COBO 
·-- · CD86 L D CD40 
100 150 
FSC-A 
50 nM BPA-AJI Colors 
10:1 
PE-A 
50 nM BPA-All Colors 
10:l 10 .. 
PE-Cy7-A 
Experiment Name: 8 L6 Spleen 7-1-1 O 
Specimen Name: 50 nM BPA 
Tube Name: All Colors 




























] I, ,,,,,,, 
102 
50 nM BPA-All Colors 




I I I I liiij I 
10:1 105 
APC-A 
Record Date: Jul 1, 201 0 1:1 2:11 PM 
$OP: Adm inistrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Poeu1at1on #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 18,297 91 .5 77,673 42,309 4,642 15,91 0 404 7,466 2,496 
• 8 Cells 13,140 71 .8 81 ,753 45,818 6 ,402 21,178 274 9,388 3,300 
D MHC- 11 13,046 99.3 81 ,902 45,855 6,432 21,326 272 9,434 3,319 
• coeo 3,230 24.6 89,205 53,839 6 ,824 22,552 1,144 11,961 3,787 
• co06 13,039 99.2 81 ,854 45,761 6 ,432 21,316 259 9,460 3,319 
0 CD40 12,649 96.3 82,779 46,242 6,549 21,753 265 9,604 3,412 
Printed by: Administrator Page 1 of1 









BL6 Spleen 7-1-10 
50 nM E2-All Colors 50 nM E2-All Colors 
1 . ..... . 
. ·: 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 ,,,, 1 00.0 
t • Lymphocytes 1B,1 B1 90.9 90.9 
: ... • B Cells 11,73B 64.6 5B.7 
; D MHC-11 11,615 99.0 5B.1 
- • COBO 3,045 25.9 15.2 
• coB6 11 ,60B 9B.9 5B.O 
0CD40 10,964 93.4 54.B 
50 nM E2-All Colors 
ID~ 1D~ 1D' 1Ds 
PE-A PerCP-Cy5-5-A 
~ 1 .. ""'' 
CDB6 CD40 
I 
I I I 1111111 I 
10~ 10' IDS I02 1D~ IDS 
PE-Cy7-A APC-A 
Experiment Name: BL6 Spleen 7-1-10 
Specimen Name: 50 nM E2 
Tube Name: All Colors 
Record Date: Jul 1, 201 0 1 :04:00 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 1B,1 B1 90.9 76,630 41 ,059 3,B74 13,651 420 6,739 1,B42 1,107 
• B Cells 11,73B 64.6 B2,152 45,2B5 5,901 20,172 296 9,230 2,6B9 1,107 
D MHC-11 11,61 5 99.0 B2,396 45,3B7 5,939 20,379 295 9,303 2,713 1,1 OB 
• coBo 3,045 25.9 B9,092 52,754 6,223 21 ,27B 1,190 11,2B4 2,977 1,103 
• coB6 11,60B 9B.9 B2,307 45,239 5,941 20,361 27B 9,331 2,711 1,107 
0 CD40 10,964 93.4 B3,946 46,001 6,129 21,077 267 9,602 2,B53 1,107 
Printed by: Administrator Page 1of1 
Printed on: Sun Mar 20, 2011 12:27:26 PDT 
NZB Spleen 7-13-10 
Control-Unstained Control-Unstained 
' .. .. 
8 Cells 






Tube: Unstained Control-Unstained 
Population #Events %Parent %Total 
• All Events 20,000 #I#- 100.0 
• Lymphocytes 16,535 82.7 82.7 
• 0 Cells 14,399 87.1 72.0 
... OMHC-11 126 0.9 0.6 
..... COBO 708 4.9 3.5 
• coa6 137 1.0 0.7 60 100 150 200 260 








10:1 10• 10s 
1 'I I I I illll j 
10:1 10· 
I I llliij I 
10s 
PE-Cy7-A APC-A 
Experiment Nam e: NZB Spleen 7-13-1 o 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Jul 13, 2010 1 :08:50 PM 
SOP: Admin istrator 
FSC-A SSC-A 8220 Fl. .. PE-A PerCP-... PE-Cy7-A APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,535 82.7 87,951 46,499 180 99 166 17 90 2,234 
• 8Cells 14,399 87.1 89,634 48,476 203 104 176 19 93 2,235 
D MHC-11 126 0.9 104,305 73,377 1,777 1,674 3,373 328 880 2,490 
• coao 708 4.9 76,591 50,080 826 784 1,808 163 515 2,290 
• coa6 137 1.0 85,716 64,847 1,035 1,039 2,390 569 614 2,258 
0 CD40 147 1.0 98,617 64,340 1,313 1,182 2,460 228 1,029 2,281 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20, 201 1 12:30:33 PDT 
NZB Spleen 7-1 3-10 
Control-I o Control-I G .. . ... 
~ · .. ·: . 
B Cells 






Tube: lgG Control-I G 
Population #Events %Parent %Total 
• All Events 20,000 ###- 100.0 
' • Lymphocytes 17,214 86.1 86.1 
• 8 Cells 14, 191 82.4 71.0 
D MHC-11 143 1.0 0.7 
• co00 757 5.3 3.8 
• co0s 124 0.9 0.6 
0CD40 156 1.1 0.8 
50 100 150 200 250 
FSC-A (x l.OOO) 
Control-I G Control- I G 
MHC-11 
COBO 





10:> 10· 10:> 10· to5 
PE-Cy7-A APC-A 
Experiment Name: NZB Spleen 7-13-10 
Specimen Name: Control 
Tube Name: lgG 
Record Date: Jul 13, 2010 1:10:29 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A Time 
Populatlon #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,214 86.1 89,189 46,628 179 94 163 14 89 1,960 
• 8 Cells 14, 191 82.4 91,352 49,251 214 100 178 16 94 1,954 
D MHC-11 143 1.0 96,464 69,778 1,748 1,636 3,360 280 835 2,055 
• co00 757 5.3 76,656 50,372 820 784 1,857 155 516 1,946 
• c o06 124 0.9 83,923 67,998 1,332 1,202 2,683 620 645 2,124 
0 CD40 156 1.1 97,91 7 61,326 1,348 1,231 2,600 229 998 2,038 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:31 :04 PDT 
NZB Spleen 7-13-10 
Control-All Colors 
B Cells 
50 100 150 200 250 10J 10" 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
Control-Ali Colors 
Population IEvents %Parent %Total 
•All Events 20,000 ## 100.0 
• Lymphocytes 17,521 87.6 87.6 
• BCells 8,446 48.2 42.2 
; ·0 MHC-11 8,089 95.8 40.4 
' • co00 1,678 19.9 8.4 
• co06 8,281 98.0 41 .4 
t 0CD40 7,703 91 .2 38.5 ' 
. 
Restng~- 1 -
ting B Cells 
l • Resting 1,604 19.0 8.0 
• Blastin~ 5,350 63.3 26.8 








10J 10 105 10J 10
5 
PE-Cy7-A APC-A 
Experiment Name: NZB Spleen 7-13-1 O 
Specimen Name: Control 
Tube Name: All Colors 
Record Date: Jul 13, 201 0 1 :11 :42 PM 
SOP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7 ... APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,521 87.6 88,434 46,280 3,493 6,026 467 7,146 1,844 1,852 
• B Cells 8,446 48.2 104,216 59,011 7,083 11,850 600 12,179 3,573 1,834 
D MHC-11 8,089 95.8 105,593 59,765 7,284 12,346 606 12,562 3,704 1,831 
• co00 1,678 19.9 130,629 82,300 7,339 14, 125 2,277 21,104 5,511 1,828 
• co06 8,281 98.0 104,688 59,327 7,162 12,046 594 12,421 3,625 1,834 
0CD40 7,703 91 .2 107,621 60,465 7,509 12, 7 41 611 12,755 3,882 1,831 
• Resting B Cells 1,604 19.0 58,438 35,316 4,133 6,528 337 7,999 1,762 1,859 
• Blasting 8 Cells 5,350 63.3 107,384 55,229 7,612 12,626 445 10,571 3,501 1,820 
Printed by: Adminis1rator Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:36:21 PDT 
NZB Spleen 7-13-10 
5 nM BPA-All Colors 5 nM BPA-All Colors 
B Cells 
50 100 150 200 250 10~ 10• 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
5 nM BPA-All Colors 
Population #Events %Parent 'lb Total 
• All Events 20,000 ### 100.0 
' • Lymphocytes 15,773 78.9 78.9 
• 8 Cells 6,015 38.1 30.1 
~·-·0 MHC-11 5,132 85.3 25.7 
f- · COBO 496 8.2 2.5 
i-.. • CD86 5,117 85.1 25.6 
~· .. ·0 CD40 4,294 71 .4 21 .5 
t • Resting 2,622 43.6 13.1 
L ..... Blastin~ 2,623 43.6 13.1 




CJ 5 nM BPA-All Colors 5 nM BPA-All Colors 
MHC-II 











10~ 10· 10s 
PE-Cy7-A 
Experiment Name: NZB Spleen 7-13-1 O 
Specimen Name: 5 nM BPA 
Tube Name: All Colors 
Record Date: Jul 13, 201 0 1 :26:43 PM 
SOP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7 ... APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 15,773 78.9 72,393 34,487 1,993 2,590 267 3,387 579 4,491 
• 8 Cells 6,015 38.1 77,155 38, 11 4 4,980 6,067 313 5,487 1,297 4,503 
D MHC- 11 5,132 85.3 77,332 38,596 5,214 7,004 311 6,008 1,350 4,493 
• c oao 496 8.2 97,507 57,917 4,1 00 6,657 2,078 6,684 1,891 4,331 
• coa6 5,117 85.1 76,44 7 39,016 5,021 6,680 315 6,445 1,304 4,501 
0 CD40 4,294 71.4 82,315 38,688 5,688 6,962 323 4,629 1,654 4,452 
• Resting 8 Cells 2,622 43.6 58,337 30,492 3,750 4,524 21 1 7,031 929 4,684 
• Blasting 8 Cells 2,623 43.6 94,263 40,158 6,202 7,611 352 3,169 1,660 4,314 
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NZB Spleen 7-13-10 
5 nM E2-All Colors 
. .. ..... ; .... 
50 100 150 200 250 
FSC-A (x 1,000) 
Tube: All Colors 
5 nM E2-All Colors 
Population #Events %Parent %Total 
• All Events 20,000 #### 100.0 
• Lymphocytes 16,264 81.3 81 .3 
• B Cells 8,059 49.6 40.3 
; D MHC-11 7,796 96.7 39.0 
i • co00 2,327 28.9 11.6 
' • co06 7,904 98.1 39.5 
0CD40 7,394 91 .7 37.0 
' • Resting 1,404 
17.4 7.0 
• Blastin~ 5,198 64.5 26.0 




5 nM E2-All Colors 5 nM E2-All Colors 
10~ 10· 105 10~ 10· 105 
PE-A PerCP-Cy5-5-A 
I ]~' "'"'' 
CD40 
I I I I I i I 111111 I 
10~ 10· IDS 102 10~ 10· IDS 
PE-Cy7-A APC-A 
Experiment Name: NZB Spleen 7-13-1 O 
Specimen Name: 5 nM E2 
Tube Name: All Colors 
Record Date: Jul 13, 201 0 1 :16:39 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy? ... APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,264 81 .3 88,665 46,325 4,540 8,887 598 8,241 2,110 2,627 
• B Cells 8,059 49.6 104,807 59,405 8,990 17,179 797 13,713 3,987 2,624 
DMHC-11 7,796 96.7 105,926 60,094 9,205 17,740 803 1 4,019 4,105 2,627 
• co00 2,327 20.9 124,960 78,250 9,540 20,292 2,200 20,064 5,641 2,633 
. CD06 7,904 90.1 105,324 59,023 9,081 17,458 802 13,985 4,043 2,623 
0 CD40 7,394 91 .7 107,906 60,022 9,523 18,450 818 14,162 4,320 2,623 
• Resting B Cells 1,404 17.4 58,049 35,412 4,979 8,797 530 10,020 1,903 2,656 
• Blasting B Cells 5,198 64.5 106,575 55,135 9,505 17,985 623 11,417 3,832 2,622 
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NZB Spleen 7-13-10 
50 nM SPA-All Colors 
.: .... . : .. , - ~:~ 
50 100 150 200 260 
FSC-A (x 1,000) 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 tt:lf:t. 100.0 
• Lymphocytes 17,223 86.1 86.1 
• 8 Cells 7,732 44.9 38.7 
i ·OMHC-11 7,437 96.2 37.2 
• co00 1,419 18.4 7.1 
• co06 7,589 98.2 37.9 
0CD40 6,965 90.1 34.8 
i • Resting 1,649 21 .3 8.2 
· -· · Blastin~ 4,909 63.5 24.5 
PE-A 
50 nM SPA-All Colors 
10:1 10' 105 
PE-Cy7-A 
Experiment Name: NZB Spleen 7-13-1 O 
Specimen Name: 50 nM SPA 
Tube Name: All Colors 
Record Date: Jul 13, 2010 1 :31 :16 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A 
Population #Events %Parent Mean Mean Mean 
• Lymphocytes 17,223 86.1 83,988 42,158 3,057 
• 8 Cells 7,732 44 .9 99,441 54,664 6,632 
D MHC-11 7,437 96.2 100,581 55,258 6, 798 
• co00 1,419 18.4 124,322 77,363 6,825 
• co06 7,589 98.2 99,811 54,942 6,691 
0CD40 6,965 90.1 103,031 56,182 7,065 
• Resting 8 Cells 1,649 21 .3 56,933 35,81 0 4,326 
• Blasting 8 Cells 4,909 63.5 105,503 52,684 7, 140 
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50 nM BPA-All Colors 






PE-A PerCP-... PE-Cy7 ... 
Mean Mean Mean 
5,318 420 6,166 
11 ,288 555 11,113 
11, 713 562 11,407 
13,709 2,194 19,986 
11 ,454 554 11,321 
12,224 577 11,623 
6,664 331 7,610 















NZB Spleen 7-13-10 
50 nM E2-All Colors 
B Cells 
50 100 150 200 250 
10~ 104 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
50 nM E2-All Colors 
Population #Events %Parent %Total 
• All Events 20,000 ### 100.0 
' • Lymphocytes 17,657 88.3 88.3 
• BCells 8,609 48.8 43.0 
i·-.. OMHC-11 8,190 95.1 40.9 
• co00 1,679 19.5 8.4 
·-· · CD86 
8,437 98.0 42.2 
; 0 CD40 7,376 85.7 36.9 
• Resting 2,322 27.0 11 .6 
! 
• Blastin~ 5,041 58.6 25.2 





10~ 104 10~ 104 
PE-A PerCP-Cy5-5-A 
10~ 10 .. 10s 10~ 10 .. 105 
PE-Cy7-A APC-A 
Experiment Name: NZB Spleen 7-13-10 
Specimen Name: 50 nM E2 
Tube Name: All Colors 
Record Date: Jul 13, 201 0 1·20:47 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7 ... APC-A nme 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,657 88.3 85,453 43,319 3,103 5,242 438 7,131 1,445 2,288 
• B Cells 8,609 48.8 98,067 54,569 6,189 10,166 569 11,983 2,731 2,274 
D MHC-11 8,190 95.1 99,421 55,339 6,387 10,654 573 12,396 2,843 2,272 
• co00 1,679 19.5 122,81 3 76,530 6,366 12,034 2,134 19,536 4,281 2,277 
• co06 8,437 98.0 98,468 54,871 6,250 10,333 563 12,226 2,768 2,272 
0 CD40 7,376 85.7 103,441 57,306 6,789 11 ,344 589 12,869 3,122 2,266 
• Resting B Cells 2,322 27.0 57,352 34,421 3,780 5,950 348 8,749 1,506 2,301 
• Blasting B Cells 5,041 58.6 107,045 54,011 6,854 11, 161 503 10,803 2,809 2,262 
Printed by: Administrator Page 1of1 
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NZB Spleen 7-1 5-10 
Control-Unstained 
.... ~ . . . . 




• All Events 
• Lymphocytes 
- - · 8 Cells 
. OMHC-11 
· • co00 






































Experiment Name: NZ8 Spleen 7-15-10 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Jul 15, 201 0 1 :02:25 PM 
$OP: Administrator 
FSC-A SSC-A 8220 Fl. .. 
Population #Events %Parent Mean Mean Mean 
• Lymphocytes 17,579 87.9 78,263 46,493 108 
• 0 Cells 13,674 77.8 80,331 49,702 140 
OMHC-11 95 0.7 79,345 85,923 1,333 
• co00 339 2.5 69,348 70,863 668 
• co06 111 0.8 76,051 71,21 0 791 
0CD40 127 0.9 76,117 74,473 820 
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PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
55 77 8 61 
62 89 9 65 
1,106 2,028 229 473 
529 1,143 111 324 
630 1,179 412 327 









NZB Spleen 7-15-10 
Control-All Colors Control-All Colors 
. ·.· . . 
100 150 200 250 10:1 10" 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 #### 100.0 
• Lymphocytes 18,14 7 90.7 90.7 
- • 8 Cells 9,396 51 .8 47.0 
D MHC-11 9,175 97.6 45.9 
( • co00 2,455 26.1 12.3 
• co06 9,287 98.8 46.4 





Experiment Name: NZB Spleen 7-15-10 
Specimen Name: Control 
Tube Name: All Colors 
Record Date: Jul 15, 2010 1 :05:01 PM 
$OP: Administrator 
FSC-A 
Population #Events %Parent Mean 
• Lymphocytes 18,14 7 90.7 85,032 •s Cells 9,396 51 .8 102,644 
DMHC-11 9,175 97.6 103,569 
• co00 2,455 26.1 118,049 
• co06 9,287 98.8 103,003 
0 CD40 8,923 95.0 104,767 
Printed by: Administrator 


























PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
7,983 313 8,476 2,515 
14,906 360 14,304 4,665 
15,259 363 14,572 4,771 
17,067 1,816 17,746 6,516 
15,063 358 14,472 4,712 









5 nl\4 BPA-All Colors 
· .. : :: :.' :" . .. . . · . . 
Tube: All Colors 
Population 
• All Events 
• Lymphocytes 
t .... 9 Cells 
~-0 MHC-11 
•· • co00 
• co06 
0CD40 





Experiment Name: NZB Spleen 7-15-10 
Specimen Name: 5 nM BPA 
Tube Name: All Colors 










I "ii~ I 
10s 





25.7 11 .4 
98.6 43.9 





Record Date: Jul 15, 201 0 1 :13:55 PM 
$OP: Administrator 
coeo 




FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Population #Events 'lb Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,941 89.7 81,517 49,759 4,310 6,940 319 7,921 2,368 •s Cells 8,897 49.6 98,736 66,510 8,524 13,482 366 13,724 4,564 
OMHC-11 8,630 97.0 99,948 67,353 8,737 13,891 369 14,022 4,696 
• co00 2,286 25.7 112,642 85,888 7,106 14,946 1,847 17,067 6,217 
• co06 8,771 98.6 99,088 66,767 8,609 13,651 362 13,921 4,621 
0CD40 8,372 94.1 101,048 67,921 8,927 14,232 342 14,282 4,808 
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NZB Spleen 7-15-1 0 
5 nM E2-All Colors 5 nM E2-All Colors 
50 100 160 200 250 10:1 105 
FSC-A (x 1.000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 '## 100.0 
• Lymphocytes 17,885 89.4 89.4 .8 Cells 8,852 49.5 44.3 
f OMHC-11 8,587 97.0 42.9 
L. • co00 2,750 31 .1 13.8 
·- • co06 8,747 98.8 43.7 
0CD40 8,320 94.0 41 .6 
5 nM E2-AJI Colors 
c CD60 
5 nM E2-All Colors 
10:1 
PE-Cy7-A 
Experiment Name: NZB Spleen 7-15-10 
Specimen Name: 5 nM E2 
Tube Name: All Colors 
Record Date: Jul 15, 201 0 1 :07:57 PM 
$OP: Administrator 
FSC-A 
Population #Events %Parent Mean 
• Lymphocytes 17,885 89.4 83,766 •s Cells 8,852 49.5 101,056 
D MHC-11 8,587 97.0 102,208 
• co00 2,750 31 .1 113,093 
• c o06 8,747 98.8 101 ,394 
0CD40 8,320 94.0 103,483 
Printed by: Administrator 
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10:1 10 .. 
PerCP-Cy5-5-A 
PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
7,868 358 8,063 2,415 
15,346 434 13,887 4,637 
15,811 438 14,183 4,771 
16,801 1,707 16,472 6,271 
15,511 430 14,055 4,683 









50 nM SPA-All Colors 




~ -· s Cells 
• DMHC-11 
f· • co00 
~ ---· CD86 
•· 0 CD40 
50 nM SPA-All Colors 

















50 nM SPA-NI Colors 
c: CD80 
Experiment Name: NZS Spleen 7-15-1 O 
Specimen Name: 50 nM SPA 
Tube Name: All Colors 
Record Date: Jul 15, 2010 1 :17:23 PM 
$OP: Administrator 
FSC-A 
Population #Events %Parent Mean 
• Lymphocytes 17,297 86.5 79,576 •s Cells 7,615 44.0 96,896 
DMHC-11 7,381 96.9 97,995 
• co00 1,745 22.9 112,233 
• co06 7,511 98.6 97,149 
0CD40 7,112 93.4 99,183 
Printed by: Administrator 


























PE-A PerCP-... PE-Cy7-A 
Mean Mean Mean 
5,809 268 6,986 
12,625 312 13,1 56 
13,017 316 13,447 
14, 161 1,885 16,638 
12, 781 308 13,337 
13,390 295 13,683 


















50 nM E2-All Colors 
. .. . 
Tube: All Colors 
Population 
• All Events 
·· • Lymphocytes 
L. •s Cells 




.. ·.. ·.\ 
50 nM E2-All Colors 
NZB Spleen 7-15-1 0 
50 nM E2-All Colors 




#Events %Parent %Total 
20,000 "" 100.0 17,735 88.7 88.7 
8,382 47.3 41 .9 
8,133 97.0 40.7 
2,324 27.7 11.6 
8,286 98.9 41 .4 
7,794 93.0 39.0 
50 nM E2-All Colors 
c: CD60 
50 nM E2-All Colors 
10:1 10 .. 
PE-Cy7-A 
Experiment Name: NZB Spleen 7-15-10 
Specimen Name: 50 nM E2 
Tube Name: All Colors 
Record Date: Jul 15, 201 0 1 :1 0:58 PM 
$OP: Administrator 
FSC-A 
Population #Events %Parent Mean 
• Lymphocytes 17,735 88.7 80,687 
• 8 Cells 8,382 47.3 98,01 2 
OMHC-11 8,133 97.0 99,021 
• co00 2,324 27.7 110,538 
• cD86 8,286 98.9 98,317 
0CD40 7,794 93.0 100,000 
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10:1 10 .. 
PerCP-Cy5-5-A 
PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
7,435 444 7,944 3,282 
15,132 567 14,126 6,553 
1 5,493 547 14,423 6,743 
17,024 2,442 16,782 12,615 
15,289 567 14,290 6,621 













50 100 160 200 260 10:1 10
5 
FSC·A (X 1,000) 8220 FITC·A 
Tube: Unstained 
Population #Events %Parent %Total 
• All Events 20,000 #II 100.0 
• Lymphocytes 15,B59 79.3 79.3 
• -· 8 Cells 12,6B9 BO.O 63.4 
,. DMHC-11 12B 1.0 0.6 
~ • COBO 592 4.7 3.0 
• coB6 116 0.9 0.6 








10:1 10& 10:1 10
5 
PE-Cy7-A APC-A 
Experiment Name: NZB Spleen 7-17-1 O 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Jul 17, 2010 12:45:0B PM 
$OP: Administrator 
FSC-A SSC-A 8220 Fl. .. PE-A PerCP-... PE-Cy7-A APC·A nme 
Po~ulation #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 15,B59 79.3 BB,529 50,203 150 B2 126 12 7B 1,546 
• 8Cells 12,6B9 BO.O 90,BB2 53,470 1B9 95 14B 15 B6 1,556 
D MHC-11 12B 1.0 76,947 55,649 2,143 1,BOO 3,333 279 1,013 1,541 
• c oBo 592 4.7 69,733 51,900 1,134 946 1,B9B 174 594 1,546 
• c oB6 116 0.9 69,709 55,1 BO 1,430 1,244 2,573 565 755 1,542 
0CD40 131 1.0 79,610 51,927 1,796 1,4B1 2,7B3 233 1,1 BO 1,542 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:42:50 PDT 
NZB Spleen 7-17-10 
Control-All Colors Control-All Colors 
. . ; ~· 
Tube: All Colors 
Population 
•All Events 
l • Lymphocytes 
L .• B Cells 
f·-0 MHC-11 
f ... • co00 
t···• CD86 


















Experiment Name: NZB Spleen 7-17-10 
Specimen Name: Control 
Tube Name: All Colors 



































I I I 11111 I 
IDS 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Po~ulalion #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,428 82 .1 89,777 51,898 4,254 5,883 417 8,556 1,236 
• BCells 8,068 49.1 108,750 69,558 8,454 11 ,445 550 14,966 2,313 
D MHC- 11 7,699 95 .4 110,584 70,797 8,719 11,957 558 15,469 2,403 
• co00 2,481 30.8 125,225 88,964 8,260 12,805 1,722 20,683 3,190 
• co06 7,974 98 .8 109,1 40 69,851 8,5 09 11,556 545. 15, 141 2,333 
0 CD40 6,664 82.6 115,836 74,187 9,330 12,846 585 16,568 2,694 
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NZB Spleen 7-17-10 
5 nM BPA·All Colors 5 nM BPA-All Colors 
.. . 
. ~ ·. : ~ ·. ~ . 
511 100 150 200 250 10~ 10s 
FSC-A (x 1.000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 II# 100.0 
• Lymphocytes 16,726 83.6 83.6 
• B Cells 8,478 50.7 42.4 
. OMHC-11 8,135 96.0 40.7 
'· • co00 2,669 31 .5 13.3 
r- • CD86 8,348 98.5 41 .7 
L CJ CD40 7,405 87.3 37.0 
5 nM BPA-All Colors 5 nM BPA-All Colors 
i 1 .... ,,  ~C-ll I 'E COBO :::J ' """'~' ""'I 0 (.) I 102 10~ 10" 105 10~ 10" 10s 
PE-A PerCP-Cy5-5-A 
5 nM BPA·All Colors 5 nM BPA·All Colors 
CD10 
10~ 10" 10~ 10" 10s 
PE-Cy7-A .A.PC-A 
Experiment Name: NZB Spleen 7-17-10 
Specimen Name: 5 nM BPA 
Tube Name: All Colors 
Record Date: Jul 17, 201012:56:44 PM 
$OP: Administrator 
FSC·A SSC-A FITC·A PE·A PerCP· ... PE-Cy7-A .A.PC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,726 83.6 87,374 52,137 4,578 7,756 434 8,645 1,832 1,089 
• B Cells 8,478 50.7 103,763 68,257 8,832 14,639 545 14,689 3,393 1,083 
D MHC-11 8,135 96.0 105,192 69,332 9,077 15,224 550 15,116 3,517 1,085 
• co00 2,669 31.5 117,794 84,950 8,751 15,905 1,705 20,194 4,775 1,095 
• cD86 8,348 98.5 104,234 68,649 8,906 14,826 540 14,916 3,403 1,082 
0CD40 7,405 87.3 108,637 71 ,484 9,596 16,224 564 15,744 3,819 1,083 
Printed by: Administrator Page 1of1 
Printed on: Sun Mar 20. 2011 12:44:07 PDT 
NZB Spleen 7-1 7-10 
5 nM E2-All Colors 5 nM E2-AJI Colors .. . ·;:· .. 
100 160 200 260 
FSC-A (x 1,000) 
Tube: All Colors 
Population #Events 
• All Events 20,000 
• Lymphocytes 16,734 •s Cells 8,117 
D MHC-11 7,820 
• co00 2,616 
• co06 7,984 
! 
0CD40 7,122 
5 nM E2-AJI Colors 
11 1 11 1111111 I 
10~ 10• 105 
PE-A 
5 nM E2-AJI Colors 
10~ 
PE-Cy7-A 
Experiment Name: NZB Spleen 7-17-10 
Specimen Name: 5 nM E2 
Tube Name: All Colors 

































I I iliiij I 
10
5 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Population #Events %Parent Mean Mean 
• Lymphocytes 16,734 83.7 87,346 51,263 
Mean Mean Mean Mean Mean 
4,264 7,631 462 8,468 1,803 
• B Cells 8,117 48.5 105,565 68,231 8,556 15,033 581 14,822 3,441 
D MHC-11 7,820 96.3 106,922 69,163 8,780 15,575 582 15,221 3,554 
• co00 2,616 32.2 119,614 84,873 8,237 16,252 1,782 20,275 4,623 
• co06 7,984 98.4 106,114 68,643 8,635 15,242 577 15,067 3,453 
0CD40 7,122 87.7 110,103 71,181 9,21 8 16,475 597 15,862 3,853 
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NZB Spleen 7-17-10 
50 nM BPA-All Colors 50 nM BPA-Al l Colors 
... : .:;: 
. .. :. .. . · ..... .. . 
50 100 150 200 250 
FSC-A (x 1,000) 
Tube: All Colors 
Population 










• Lymphocytes •s Cells 
. DMHC-11 
f .. . COBO 
L • • CD86 
0 CD40 
50 nM BPA-All Colors 
10~ 10· 
PE-Cy7-A 
Experiment Name: NZB Spleen 7-17-1 O 
Specimen Name: 50 nM BPA 
Tube Name: All Colors 
Record Date: Jul 17, 2010 1 :00:48 PM 
$OP: Administrator 
FSC-A 
Population #Events %Parent Mean 
• Lymphocytes 15,867 79.3 85,064 
• BCells 7,860 49.5 100,144 
D MHC- 11 7,523 95.7 101,566 
• coao 2,653 33.8 11 2,802 
• coa6 7,695 97.9 100,753 
0 CD40 6,872 87.4 104,976 
Printed by: Administrator 







































50 nM BPA-AJI Colors r CD'IO ,. 
1 I i llilj I 
10• 10s 
PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
7,646 433 8,629 1,797 
14,809 567 14,901 3,410 
15,440 574 15,354 3,517 
16,334 1,669 20,305 4,605 
15,061 559 15,220 3,462 










NZB Spleen 7-17-10 
50 nM E2-All Colors 50 nM E2-All Colors 
• . ;· 1.·,· " 
100 160 200 260 
FSC-A (x 1.0DD) 
Tube: All Colors 
Population 
• All Events 
• Lymphocytes 
l • B Cells 
; .... 0 MHC-11 
~--- · COBO 
: ..• • CD86 
' 0CD40 
50 nM E2-All Colors 
50 nM E2-All Colors 
10:1 10· 
PE-Cy7-A 
Experiment Name: NZB Spleen 7-17-1 0 
Specimen Name: 50 nM E2 































. , I iillilj I 
10• 10s 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,419 82.1 88,528 51, 138 5,163 8,726 735 9,081 4,960 
• B Cells 8,154 49.7 105,072 68,166 10,164 16,856 1,101 15,658 9,461 
D MHC-11 7,820 95.9 106,569 69,122 10,475 17 ,511 1,111 16,091 9,842 
• coeo 3,197 39.2 116,916 82,597 10,132 18,308 2,811 19,590 18,520 
• coe6 8,024 98.4 105,567 68,540 10,261 17,047 1,044 15,914 9,500 
0CD40 7,229 88.7 109,814 70,993 10,991 18,505 1,167 16,348 10,61 7 
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NZB Spleen 7-20-10 
Control-Unstained 




• All Events 
• Lymphocytes 
. .. , 8 Cells 
··· 0 MHC-11 
·-- · COBO 










































Experiment Name: NZ8 Spleen 7-20-10 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Jul 20, 201 0 12:14:20 PM 
$OP: Administrator 
FSC-A SSC-A 8220 Fl... 
Population #Events %Parent Mean Mean Mean 
• Lymphocytes 1 6,531 82.7 91,775 54,009 150 
• 0 Cells 13,655 82.6 95,185 57,589 182 
OMHC-11 135 1.0 91,355 77,930 1,716 
• coao 477 3.5 73,741 62,252 729 
• coa6 134 1.0 84,807 66,422 737 
0CD40 134 1.0 83,206 70,458 1,092 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:48:16 PDT 
Control-Unstained 
B Cels 








I I 1111111 
10:1 10· 
I I II iii j I 
105 
APC-A 
PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
64 91 6 57 
71 100 8 60 
1,384 2,492 141 592 
631 1,426 89 388 
639 1,462 377 479 









NZB Spleen 7-20-10 
Control-All Colors Control-All Colors 
: ...... · : . 
50 100 150 
FSC-A 
Tube: All Colors 
Population 
• All Events 






















1 Ii I ii II I 
105 
Experiment Nam e: NZB Spleen 7-20-10 
Specimen Name: Control 
Tube Name: All Colors 

















1 I I 111 111 I 
10• 105 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 14,930 74.6 88,910 51, 1 98 4,692 6,037 341 8,363 2,069 
• B Cells 7,189 48.2 107,517 68,629 9,132 11,933 428 14,721 4,079 
D MHC- 11 7,054 98.1 108,209 69,097 9,260 12,156 433 14,906 4,150 
• c o00 1,936 26.9 127,196 86,474 8,780 13,296 1,642 21 ,131 5,421 
• co06 7,129 99.2 107,769 68,735 9,182 12,018 421 14,845 4,108 
0 CD40 6,772 94.2 109,934 69,863 9,536 12,547 432 15,164 4,315 
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NZB Spleen 7-20-10 
5 nM BPA-All Colors 
:·. :-:·· .... 
50 100 150 200 250 10:1 105 
FSC-A (X 1,000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 ###- 100.0 
• Lymphocytes 17,327 86.6 86.6 
• B Cells 8,553 49.4 42.8 
... D MHC-11 8,394 98.1 42.0 
· • co00 2,774 32.4 13.9 
··· • co06 8,491 99.3 42.5 
0 CD40 8,162 95.4 40.8 
5 nM BPA-All Colors 5 nM BPA-All Colors 
~1 .. .... , 1 I CD60 c ::J 0 u I T, 1111 I 11iliij I 
102 10:1 10' 105 10:1 10 105 
PE-A PerCP-Cy5-5-A 







I I , Ii ii iii I 
10:1 10· 10
5 102 10:1 10· 10s 
PE-Cy7-A APC-A 
Experiment Name: NZB Spleen 7-20-10 
Specimen Name: 5 nM BPA 
Tube Name: Al l Colors 
Record Date: Jul 20, 201 0 12:31 :41 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A Time 
Po~ulalion #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 17,327 86.6 93,683 54,326 5,111 7,299 381 8,744 2,468 1,619 
• BCells 8,553 49.4 113,390 72,740 10,229 14,326 513 15,486 4,778 1,571 
D MHC- 11 8,394 98.1 114,1 23 73,305 10,378 14,593 519 15,703 4,862 1,570 
• co00 2,774 32.4 132,584 91 ,21 0 10,088 15,803 1,628 21,522 6,517 1,529 
• co06 8,491 99.3 113,593 72,894 10,283 14,389 494 15,600 4,809 1,570 
0 CD40 8,162 95.4 115,281 73,904 10,588 14,886 507 15,952 4,999 1,569 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:50:48 PDT 
NZB Spleen 7-20-10 
5 nM E2-All Colors 5 nM E2-All Colors 
.. . , . 
B Cels 
50 100 160 200 250 10:1 10s 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 ## 100.0 
• Lymphocytes 16,374 81 .9 81 .9 
L • B Cells 8,186 50.0 40.9 
OMHC-11 8,039 98.2 40.2 
• co00 2,725 33.3 13.6 
• co06 8,099 98.9 40.5 
0CD40 7,800 95.3 39.0 






10:1 10:1 10 .. 10s 
PE-A PerCP-Cy5-5-A 
5 nM E2-All Colors 
(010 
10:1 10 .. 10:1 10s 
PE-Cy7-A APC-A 
Experiment Name: NZB Spleen 7-20-10 
Specimen Name: 5 nM E2 
Tube Name: All Colors 
Record Date: Jul 20, 201 0 12:23:27 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,374 81 .9 90,662 54,771 5,282 7,364 375 8,928 2,387 2,408 •s Cells 8,186 50.0 108,151 73,205 10,4 71 14,280 495 15,485 4,571 2,391 
OMHC-11 8,039 98.2 108,854 73,749 10,616 14,536 499 15,676 4,6.(8 2,390 
• co00 2,725 33.3 123,730 88,957 10,400 15,645 1,525 20,768 5,977 2,335 
• co06 8,099 98.9 108,453 73,447 10,541 14,408 490 15,652 4,611 2,388 
0 CD40 7,800 95.3 109,900 74,363 10,844 14,885 501 15,893 4,787 2,388 
Printed by: Administrator Page 1 of 1 
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NZB Spleen 7-20-10 
50 nM SPA-All Colors 50 nM SPA-All Colors 
.. ·:. ·:' ·. 
50 IDD 16D 2DD 26D 1D:i IDS 
FSC-A (x l.DDD) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 tt# 100.0 
• Lymphocytes 14,925 74 .6 74.6 
• s Cells 6,909 46.3 34.5 
. D MHC-11 6,769 9B.O 33.B 
: . • COBO 2,249 32.6 11 .2 
·-· . COBS 6,B31 9B.9 34.2 
0CD40 6,576 95.2 32.9 
50 nM SPA-All Colors 50 nM SPA-Al l Colors 






I I I 111111 1 1iilij I 
ID2 ID:i ID. ID5 ID:i ID. IDS 
PE-A PerCP-Cy5-5-A 
50 nM SPA-All Colors 
(()40 
ID:i ID. ID5 ID:i IDS 
PE-Cy7-A APC-A 
Experiment Name: NZS Spleen 7-20-10 
Specimen Name: 50 nM SPA 
Tube Name: All Colors 
Record Date: Jul 20, 201 0 12:36:54 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A APC-A Time 
Po~ulation #Events %Parent Mean Mean Mean Mean Mean Mean Mean Mean 
• Lymphocytes 14,925 74.6 B9,055 50,1 06 5,250 7,167 366 B,045 2,154 3,59B 
• S Cells 6,909 46.3 106,445 SB,176 11, 196 14,937 492 14,BOS 4,430 3,550 
D MHC-11 6,769 9B.O 107,10B SB,695 11,376 15,241 497 15,029 4,513 3,549 
• c oBo 2,249 32.6 122,022 B2,951 1 O,B53 16,190 1,566 19,726 5,656 3,464 
• c oB6 6,B31 9B.9 106,719 6B,419 11,284 15,0B1 4B2 14,976 4,471 3,551 
0 CD40 6,576 95.2 1 07,900 69,15B 11,59B 15,540 4B3 15,159 4,645 3,549 
Printed by: Administrator Page 1 of 1 
Printed on: Sun Mar 20, 2011 12:51 :07 PDT 
NZB Spleen 7 -20-10 
50 nM E2-All Colors 50 nM E2-All Colors 
50 
Tube: All Colors 
Population 
•All Events 
: • Lymphocytes 
· · · 8 Cells 
[·· 0 MHC-11 
f ...... COBO 
f· ·• CD86 




50 nM E2-All Colors 













Experiment Name: NZ8 Spleen 7-20-1 O 
Specimen Name: 50 nM E2 
Tube Name: All Colors 






















10:1 10 .. 
FITC-A 
10:1 10 .. 
PerCP-Cy5-5-A 
10:1 10 .. 
APC-A 
FSC-A SSC-A FITC-A PE-A PerCP-... PE-Cy7-A 
Population #Events %Parent Mean Mean Mean Mean Mean Mean 
• Lymphocytes 15,336 76.7 92,820 54,506 5,988 7,915 16 9,291 
• 8 Cells 8,062 52.6 11 0,525 71 ,659 , 1,282 14,612 -26 15,500 
D MHC-11 7,936 98.4 111 ,168 72,132 11,425 14,840 -28 15,676 
• coao 534 6.6 11 2,325 80,458 10,473 14,729 1,149 15,785 
• coa6 8,002 99.3 110,716 71,781 11 ,337 14,707 -32 15,616 
0CD40 7,721 95.8 112,162 72,635 11,647 15,166 -37 15,860 
Printed by: Administrator Page 1 of 1 












NZB Spleen 3-3-11 
Control-Unstained 
50 100 150 200 250 1~ 1~ 1~ 
FSC-A (x 1.000) B220 FITC-A 
Tube: Unstained Control-Unstained 
Population #Events %Parent %Total 
• All Events 20,000 ####- 100.0 
• Lymphocytes 16,640 83.2 83.2 
• BCells 167 1.0 0.8 
D MHC-11 90 53.9 0.4 
Oco00 55 32.9 0.3 
t • Resting B Cells 46 27.5 0.2 
• • Blasting B Cells 34 20.4 0.2 
100 150 
FSC-A 









5 10:1 IDS 
PE-A APC-A 
Experiment Name: NZB Spleen 3-3-11 
Specimen Name: Control 
Tube Name: Unstained 
Record Date: Mar 3, 2011 3:37:15 PM 
$OP: Administrator 
FSC-A SSC-A B220 FIT ... PE-A APC-A Time 
Population #Events %Parent Mean Mean Mean Mean Mean Mean 
• Lymphocytes 16,640 83.2 73,562 68,975 129 64 71 1,248 
• B Cells 167 1.0 89,675 133,724 1,000 696 437 1,218 
D MHC-11 90 53.9 77,737 122,587 1,141 1,002 628 1,154 
Oco 00 55 32.9 79,142 121,71 0 1,123 1,010 919 1,277 
• Resting B Cells 46 27.5 48,728 63,429 876 649 468 1,421 
• Blasting B Cells 34 20.4 117,307 139,01 4 909 601 314 1,202 
Printed by: Administrator Page 1 of 1 
Printed on: Fri Mar 25, 201 1 01 :36:50 PDT 
Tube: All Colors 
Population 
• All Events 
• Lymphocytes 
• B Cells 
100 150 
FSC-A 
. D MHC-11 
. D COBO 
· - · Resting B Cells 




Experiment Name: NZB Spleen 3-3-11 
Specimen Name: Control 
Tube Name: All Colors 
NZB Spleen 3-3-11 
200 250 
(x 1.000) 
#Events %Parent %Total 
20,000 ## 100.0 
17,694 88.5 88.5 
8,237 46.6 41 .2 
7,996 97.1 40.0 
657 8.0 3.3 
1,756 21.3 8.8 
5,663 68.8 28.3 
105 
Record Date: Mar 3, 2011 3:41 :11 PM 
$OP: Administrator 
FSC-A SSC-A 
Population #Events %Parent Mean Mean 
• Lymphocytes 17,694 88.5 76,666 71,210 
• B Cells 8,237 46.6 91 ,558 96,537 
O MHC-11 7,996 97.1 92,599 97,472 
Ocoeo 657 8.0 94,807 114,568 
• Resting B Cells 1,756 21.3 46,960 63,253 
• Blasting B Cells 5,663 68.8 102,549 98,035 
Prin1ed by: Administrator Page 1 of 1 




Resting B~ens .• 
. <1.:·· a. -~ . •. " ~ting B CeUs 
50 100 150 200 250 
FSC-A (x 1,000) 
Control-All Colors 
COBO 
ID~ 10· 105 
APC-A 
FITC-A PE-A APC-A Time 
Mean Mean Mean Mean 
4,720 6,779 441 1,224 
9,931 14,051 360 1,216 
10, 169 , 4,437 366 , ,219 
8,678 , 4,068 3,716 1,233 
4,994 6,354 250 1,216 
, , ,437 , 5,834 383 , ,216 
50 
Tube: All Colors 
Population 
• All Events 
• Lymphocytes 





• Resting B Cells 
• Blasting B Cells 
5 nM BPA-All Colors 
100 
PE-A 
Experiment Name: NZB Spleen 3-3-11 
Specimen Name: 5 nM BPA 
Tube Name: All Colors 












%Parent % Total 
####- 100.0 
87.2 87.2 




70.1 31 .2 
Record Date: Mar 3, 2011 3:59:13 PM 
$OP: Administrator 
FSC-A SSC-A 
Population #Events %Parent Mean Mean 
• Lymphocytes 17,448 87.2 79,096 72,118 
• B Cells 8,906 51 .0 93,414 95,243 
D MHC-11 8,659 97.2 94,507 96,079 
Oco00 1,253 14.1 100,138 113,796 
• Resting B Cells 1,775 19.9 46,683 62,247 
• Blasting B Cells 6,245 70.1 103,729 95,878 
Printed by: Administrator Page 1 of 1 
Printed on: Fri Mar 25. 2011 01 :38:14 PDT 
5 nM BPA-AJI Colors 
50 100 150 200 250 
FSC-A (x 1,000) 
100 10s 
APC-A 
FITC-A PE-A APC-A Time 
Mean Mean Mean Mean 
5,255 7,453 622 2,246 
10,149 14,128 369 2,250 
1 0,390 14,524 374 2,251 
10,325 15,709 2,207 2,266 
5,059 6,179 219 2,247 
11 ,522 15,740 361 2,238 
5 nM E2-AJI Colors 
Tube: All Colors 
Population 
• All Events 
• Lymphocytes 





; ..... Resting B Cells 
i • Blasting B Cells 
5 nM E2-All Colors 
100 
PE-A 
Experiment Name: NZB Spleen 3-3-11 
Specimen Name: 5 nM E2 
Tube Name: All Colors 
NZB Spleen 3-3-11 
200 250 
(x 1,000) 
#Events %Parent %Total 
20,000 ##fl. 100.0 
17,210 86.1 86.1 
B,830 51 .3 44.2 
B,553 96.9 42.B 
1 ,230 13.9 6.2 
1,819 20.6 9.1 
6,11 B 69.3 30.6 
10s 
Record Date: Mar 3, 2011 3:50:1 0 PM 
$OP: Administrator 
FSC-A SSC-A 
Population #Events %Parent Mean Mean 
• Lymphocytes 17,210 86.1 79,634 72,558 
• B Cells B,830 51 .3 94,298 94,734 
DMHC- 11 B,553 96.9 95,594 95,645 
O coao 1,230 13.9 99,081 111,324 
• Resting B Cells 1,819 20.6 46,321 64,31 B 
• Blasting B Cells 6,11 B 69.3 104,914 95,112 
Printed by: Administrator Page 1 of 1 
Printed on: Fri Mar 25, 2011 01 :37:34 PDT 
5 nM E2-All Colors 
5 nM E2-All Colors 
Restinq B.~-:. 
-~-· ~ ~ .... ( ... 
50 100 150 200 250 
FSC-A (x 1,000) 
100 10s 
APC-A 
FITC-A PE-A Af'C-A Time 
Mean Mean Mean Mean 
4,356 7,535 1,159 2,956 
B,510 14,249 384 2,953 
B,739 14,703 389 2,958 
B,526 15,240 2,333 2,988 
4,591 6,983 330 2,893 
9,551 15,658 336 2,977 
50 nM SPA-All Colors 
Tube: All Colors 
Population 




-- · 8 Cells .... 0 MHC-11 
r··· D COBO 
\-·· Resting 8 Cells 
i • Blasting 8 Cells 
50 nM SPA-All Colors 
10~ 
PE-A 
Experiment Name: NZ8 Spleen 3-3-11 
Specimen Name: 50 nM SPA 
Tube Name: All Colors 

















20.2 8 .6 
70.B 29.9 
105 
Record Date: Mar 3, 2011 4:03:30 PM 
SOP: Administrator 
FSC-A SSC-A 
Population #Events %Parent Mean Mean 
• Lymphocytes 17,024 85.1 77,269 70,743 •s Cells 8,454 49.7 91,769 94,341 
OMHC-11 8,213 97.1 92,830 95,129 
Ocoeo 1,31 a 15.5 96,100 108,494 
• Resting 8 Cells 1,711 20.2 47,280 64,647 
• Blasting 8 Cells 5,985 70.B 102,083 95,576 
Printed by: Administrator Page 1 of1 
Printed on: Fri Mar 25, 2011 01 :38:59 PDT 
50 nM BPA-AJI Colors 
50 100 150 200 250 




FITC-A PE-A APC-A Time 
Mean Mean Mean Mean 
5,215 7,081 686 1,390 
10,440 13, 782 344 1,390 
10,692 14, 178 348 1,392 
10,321 14,395 1,871 1,397 
5,092 6,121 233 1,366 
11 ,940 15,609 361 1,395 
50 
Tube: All Colors 
Population 




· • BCells 
OMHC-11 
1:1 CD80 
• Restlng B Cells 
• Blasting B Cells 
50 nM E2-All Colors 
10~ 
PE-A 
Experiment Name: NZB Spleen 3-3-11 
Specimen Name: 50 nM E2 
Tube Name: All Colors 




























Record Date: Mar 3, 2011 3:55:03 PM 
$OP: Administrator 
FSC-A SSC-A 
Population #Events %Parent Mean Mean 
• Lymphocytes 17,070 85.4 79,318 70,712 
• B Cells 8,543 50.0 94,505 93,638 
D MHC-11 8,306 97.2 95,539 94,358 
D co00 1,843 21 .6 1 01,832 108,353 
• Resting 8 Cells 1,644 19.2 47,099 63,383 
• Blasting 8 Cells 6,111 71 .5 104,663 94,489 
Printed by: Administrator Page 1 of 1 
Printed on: Fri Mar 25, 2011 01 :38:01 PDT 
50 nM E2-All Colors 
50 nM E2-All Colors 
,• ..... . 
Resting B,~els· . ' .·:> 
' Blasting B CeUs 
50 100 150 200 250 
FSC-A (x 1,000) 
10~ 10'" 105 
APC-A 
FITC-A PE-A APC-A Time 
Mean Mean Mean Mean 
5,626 8,463 989 1,969 
11 ,147 16,382 445 , ,967 
, , ,405 , 6,842 450 1,971 
11 ,370 18,115 1,839 2,135 
5,404 7,182 307 1,958 
12,689 18,282 396 1,960 
LPS Negative 3-30-11 
BL6-Unstalned 
Lymphocytes 
50 100 150 200 250 
FSC-A (x 1,000) 
Tube: Unstained 
Population IEvents %Parent % Total 
•All Events 20,000 ## 100.0 
• Lymphocytes 19,029 95.1 95.1 
• B Cells 19,029 100.0 95.1 
' .Q MHC- 134 0.7 0.7 
· • co00 504 2.6 2.5 
f • co06 87 0.5 0.4 
t 0 CD40 43 0.2 0.2 
[··· • Restil 6,511 34.2 32.6 







Experiment Name: LPS Negative 3-30-11 
Specimen Name: BL6 
Tube Name: Unstained 
Record Date: Mar 30, 2011 6:56:12 PM 
$OP: Administrator 
FSC-A SSC-A FITC-A 
Population IEvents %Parent Mean Mean Mean 
• Lymphocytes 19,029 95.1 55,482 38,689 60 
• B Cells 19,029 100.0 55,482 38,689 60 
OMHC- 11 134 0.7 52,523 80,264 1,027 
• co00 504 2.6 55,260 66,498 410 
• co06 87 0.5 48,811 80,372 977 
0 CD40 43 0.2 59,380 100,688 1,412 
• Resting B Cells 6,511 34.2 36,514 40,304 34 
• Blasting B Cells 10,702 56.2 68,096 30,692 66 
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PE-A PerCP-... PE-Cy7 ... APC-A Time 
Mean Mean Mean Mean Mean 
32 77 11 39 2,402 
32 77 11 39 2,402 
1,193 3,542 708 604 2,351 
440 1,424 230 257 2,457 
1,203 3,902 1,025 670 2,290 
1 ,654 5,068 1,023 1,063 2,399 
24 75 10 43 2,425 
24 37 5 25 2,402 
LPS Negative 3-30-11 
BL6-I G 
Lymphocytes 
50 100 150 200 250 
FSC-A (x 1.000) 
Tube: lgG 8L6-I G 
Population #Events %Parent %Total 
• All Events 20,000 
• Lymphocytes 18,932 
• B Cells 193 
' D MHC- 107 
· • coao 156 
1 • COBS 55 
, Q CD40 38 
; .. ··• Restil 38 
1 • s1asti 23 
Printed by: Administrator 









11 .9 0.1 
RestingB Cells 
a::=:2ng8 Cells 









60 100 160 200 260 10:1 10· 
FSC-A (x 1,000) FITC-A 
Tube: All Colors 
Population #Events %Parent %Total 
• All Events 20,000 ## 100.0 
• Lymphocytes 19,072 95.4 95.4 
• 8 Cells 8,925 46.8 44.6 
: 0MHC- 8,723 97.7 43.6 
• co00 1,048 11 .7 5.2 
• co06 4,688 52.5 23.4 
;- 0 CD40 6,013 67.4 30.1 
; ... • Restil 1,066 11 .9 5.3 
L_ .• Blasli 7,459 83.6 37.3 
10:1 10· 
PE-Cy7-A 
Experiment Name: LPS Negative 3-30-11 
Specimen Name: BL6 
Tube Name: All Colors 
Record Date: Mar 30, 2011 7:00:37 PM 
$OP: Administrator 
FSC-A 
Population # Events %Parent Mean 
• Lymphocytes 19,072 95.4 56,298 
• BCells 8,925 46.8 65,103 
D MHC-11 8,723 97.7 65,200 
• co00 1,048 11 . 7 67,044 
• co06 4,688 52.5 66,248 
0 CD40 6,013 67.4 67,500 
• Resting 8 Cells 1,066 11 .9 39,037 
• Blasting B Cells 7,459 83.6 67,799 
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FITC-A PE-A PerCP-... PE-Cy7 ... 
Mean Mean Mean Mean 
2,653 4,281 70 785 
5,553 8,578 74 1,193 
5,638 8,771 74 1,189 
5,953 10,591 917 1,982 
6,091 10,785 96 2,159 
6,266 9,742 68 1,204 
4,273 6,701 114 2,095 
5,668 8,516 13 837 


















• All Events 
• Lymphocytes 
: 
• 8 Cells 
i· 0 MHC-
i···• COBO 
i • cos6 
! 0CD40 
100 150 200 250 
FSC-A (x 1,000) 
























Experiment Name: LPS Negative 3-30-11 
Specimen Name: NZ8MIF1 
Tube Name: Unstained 
Record Date: Mar 30, 2011 6:41 :27 PM 
SOP: Administrator 
FSC-A SSC-A 8220 Fl ... 
Population #Events %Parent Mean Mean Mean 
• Lymphocytes 17,388 86.9 52,564 39,541 64 
• 8 Cells 17,388 100.0 52,564 39,541 64 
OMHC-11 148 0.9 62,784 69,167 1,107 
• coso 703 4.0 54,014 54,449 466 
• cos6 136 0.8 58,578 67,080 1,017 
0 CD40 142 0.8 59,974 65,925 1,017 
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50 100 150 200 250 









PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
44 126 27 53 
44 126 27 53 
1,362 5,147 1,425 1,104 
528 2,012 509 454 
1,271 5,240 1,668 1,150 















• All Events 20,000 
• Lymphocytes 17,545 
· ·• 8 Cells 153 
··· 0MHC- 111 
· • co00 148 
•·· . CD86 
96 
' 0 CD40 98 





















Experiment Name: LPS Negative 3-30-11 
Specimen Name: NZBNVF1 
Tube Name: lgG 
Record Date: Mar 30, 2011 6:42:54 PM 
SOP: Administrator 
FSC-A SSC-A 
Population #Events %Parent Mean Mean 
• Lymphocytes 17,545 87.7 53,553 38,445 
• BCells 153 0.9 68,497 72,042 
D MHC-11 111 72.5 70,161 72,000 
• co00 148 96.7 68,862 70,735 
• co05 96 62.7 68,546 69,326 
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NZBNIJF 1-1 G 
50 100 150 200 250 






PE-A PerCP-... PE-Cy7-A APC-A 
Mean Mean Mean Mean 
41 123 28 50 
1,299 4,908 1,399 1,087 
1,554 5,935 1,711 1,296 
1,331 5,070 1,446 1,120 
1,556 6,288 1,980 1,367 









NZBM'F1 -All Colors 
Lymphocytes 
50 100 150 200 
FSC-A 
Tube: NI Colors 
Population #Events %Parent 
• All Events 20,000 ,,,, 
• Lymphocytes 17,697 88.5 
• B Cells 5,617 31 .7 
0MHC- 5,181 92.2 
; 
• coao ' 640 11 .4 
i • co06 2,1 BO 38.8 
' CD40 4,636 82.5 
i-·· Restil 414 7.4 
L-· Blast! 4,973 98.5 
Printed by: Administrator 
Printed on: Fri Apr 1, 201 1 08:55:58 PDT 













NZBNVF1 -All Colors 











Acquired cell death and flow cytometric data. 
Cell Recovery 
Cell Recovery: Total Cells 
SL6 
SL6 
6/22/2 6/24/2 6/29/2 7/1/20 Average 
010 010 010 10 s Standard Deviations 
219000 790000 199000 101000 1495000 6976866 
Day 1 Total 000 00 000 000 00 5.36 
It Aliquoted 365000 131666 331666 168333 2491666 1162811 
to Flasks 00 66.7 66.7 33 6.67 0.89 
Day 2 SL6 Recovery per 
Treatments treatment 
225000 560000 310000 505000 9022321 
Control 00 0 0 0 9062500 .856 0.36 
340000 560000 390000 365000 996138. 
Comp Control 0 0 0 0 4137500 3773 0.17 
375000 365000 430000 405000 295451. 
5 nM E2 0 0 0 0 3937500 6317 0.16 
235000 285000 315000 350000 487125. 
50 nM E2 0 0 0 0 2962500 9249 0.12 
265000 360000 365000 365000 492231. 
5 nM SPA 0 0 0 0 3387500 3142 0.14 
180000 315000 265000 290000 586657. 
50 nM SPA 0 0 0 0 2625000 1969 0.11 
364500 244500 207500 228000 2611250 7055892 
Day 2 Totals 00 00 00 00 0 .927 
Ratio 0.1664 0.3094 0.1042 0.2257 0.17466 0.08743 




7/13/20 7/15/20 7/17/20 7/20/2 Average 
10 10 10 010 s Standard Deviations 
122000 720000 106000 950000 9875000 209980 
Day 1 Total 000 00 000 00 0 15.78 
It Aliquoted 203333 120000 176666 158333 1645833 349966 
to Flasks 33.33 00 66.67 33.3 3.33 9.297 
Day 2 NZS Recovery per 
Treatments treatment 
400000 350000 400000 485000 560319. 
Control 0 0 0 0 4087500 8491 0.25 
Comp 290000 280000 300000 375000 432772. 
Control 0 0 0 0 3112500 0724 0.19 
5 nM E2 425000 330000 375000 420000 3875000 444409. 0.24 
Zuber167 
0 0 0 0 7209 
280000 270000 350000 350000 434932. 
50 nM E2 0 0 0 0 3125000 945 0.19 
480000 220000 335000 280000 111233 
5 nM BPA 0 0 0 0 3287500 6.13 0.20 
350000 195000 325000 375000 801431. 
50 nM BPA 0 0 0 0 3112500 0118 0.19 
222500 164500 208500 228500 2060000 289078 
Day 2 Totals 00 00 00 00 0 9.973 
Ratio 0.18237 0.22847 0.19669 0.2405 0 .20860 0.02706 
Dayl/Day2 7049 2222 8113 2632 7595 0121 
Cell Viabili ty 
Ratio Live/ Dead 
Cells 
BL6 
6/22/20 6/24/20 6/29/20 7/1/201 BL6 Standard 
10 10 10 0 Averages Deviations 
Day 1 5 .61 10.29 2.90 7.42 6.55 3.10 
Control 1.90 1.80 1.48 2.06 1.81 0.25 
Comp 
Control 2.24 1.80 1.69 2.32 2.01 0.31 
5 nM E2 3.41 1.92 2.19 2.68 2.55 0.66 
50 nM E2 5.71 4.18 2.94 2.68 3.88 1.39 
5 nM BPA 3.42 3.00 1.35 3.29 2.77 0.96 
50 nM 
BPA 8.00 2.50 1.41 3.14 3.76 2.91 
Ratio NZB/ W 
Live/Dead Fl 
7/13/20 7/15/20 7/17/20 7/20/20 NZB Standard 
10 10 10 10 Averages Deviations 
Day 1 3.21 9.29 7.15 6.31 6.49 2.52 
Control 2.48 4.83 2.33 2.73 3.09 1.17 
Comp 
Control 2.87 4.09 3.29 3.17 3.35 0.52 
5 nM E2 2.27 2.30 1.88 2.50 2.24 0.26 
50 nM E2 1.95 5.75 2.89 1.92 3.13 1.81 
5 nM BPA 2.00 2.38 3.47 3.31 2.79 0 .71 
50nM 
BPA 1.41 4.57 3.06 3 .41 3.11 1.30 
Yellow Highlight symbolizes removal from data analysis due to obvious technical 
error, i.e. fai lure to add antibody. 
Zuber168 
Parental Percentage Data 
% S Cell within Lymphocytes 
Strain SL6 NZS 
6/22/2 6/24/2 7/1/20 7/13/ 7/15/ 7/17/ 7/20/ 
Date 010 010 6/29/2010 10 2010 2010 2010 2010 
Control 70 64.5 67.4 70.1 48.2 51.8 49.1 48.2 
SnM 




E2 64.8 64.8 66 64.6 48.8 47.3 49.7 52.6 +J to 
QI 5nM ..... 
I-
SPA 71.5 57.7 65.5 57.1 38.1 49.6 50.7 49.4 
SOnM 
SPA 58 62.3 66.2 71.8 44.9 44 49.S 46.3 
BL6 
Ave rag Std. Std. 
e Error NZB Average Error 
Con tr 1.323S 0.8Sl 
o l 68 OS 49.32S 836 
S nM 2.1297 0.318 
E2 64.77S 01 49.4 8S2 
SO nM 0.3201 l.llS 
E2 6S.OS S6 49.6 796 
SnM 3.432S 2.963 
BPA 62.9S 6S 46.9S 809 
SOnM 2.9332 l.20S 
BPA 64.S7S s 46.17S 111 
% S Cells Expressing MHC-11 
Strain SL6 NZS 
6/22/2 6/24/2 7/1/20 7/13/ 7/15/ 7/17/ 7/20/ 
Date 010 010 6/29/2010 10 2010 2010 2010 2010 
Control 99.3 98.7 98.1 99.3 95.8 97.6 95.4 98.1 
5nM 
+J E2 98.2 98.6 98.3 99.2 96.7 97 96.3 98.2 
c 
50 nM QI 
E 
E2 98.3 98.4 98.2 99 95.1 97 95 .9 98.4 +J to 
QI 5nM .... 
I-
SPA 98.7 98.8 98.2 97.8 85.3 97 96 98.1 
50nM 
SPA 98.3 98.5 98.6 99.3 96.2 96.9 95.7 98 
BL6 
Ave rag Std . Std. 
e Error NZB Average Error 
Con tr 98.8S 0.2872 96.73 0.662 
Zuber169 
ol 28 539 
SnM 0.409 
E2 98.58 0.225 . 97.05 268 
50 nM 0.1796 0.715 
E2 98.48 99 96.6 309 
SnM 0.2322 2.964 
BPA 98.38 89 94.1 512 
SOnM 0.2174 0.498 
BPA 98.68 66 96.7 331 
% B Cells Expressing 
CD80 
St rain BL6 NZB 
6/22/20 6/24/20 6/29/2 7/1/20 7 /13/2 7/15/2 7/17/2 7/20/2 
Date 10 10 010 10 010 010 010 010 
Control 35.8 32.6 26.3 26.2 19.9 26.1 30.8 26.9 
5 nM E2 34.3 37.5 28 25.3 28.9 31.1 32.2 33.3 .... 
SOnM c 
Q) 
E .... E2 39.3 44.7 26.3 25.9 19.5 27.7 39.2 6.6 
ro SnM Q) 
~ BPA 43 35.7 24.5 24.3 8.2 25.7 31.S 32.4 
SOnM 
BPA 35.3 35.1 25.4 24.6 18.4 22.9 33 .8 32.3 
BL6 Std. Std. 
Average Error NZB Average Error 
Contro 2.38620 2.2555 
I 30.225 2 25.925 03 
5nM 2.80368 0.9393 
E2 31.275 1 31.375 04 
50 nM 6.8647 
E2 34.05 4.72114 23.25 04 
5nM 4.56588 5.6164 
BPA 31.875 3 24.45 19 
50 nM 2.94929 3.7082 
BPA 30.1 4 26.85 12 
% B Cells Expressing 
CD86 
Strain BL6 NZB 
6/22/20 6/24/20 6/29/2 7/1/20 7/13/2 7/15/2 7/17/2 7 /20/2 
Dat e 10 10 010 10 010 010 010 010 
Control 99 98.7 97.2 3.3 98 98.8 98.8 99.2 
5 nM E2 98.3 98.8 97.1 99 98.1 98.8 98.4 98.9 .... 
50 nM c 
Q) 
E .... E2 98 98.7 96.8 98.9 98 98.9 98.4 99.3 
ro SnM Q) ... 
f- BPA 98.6 98.7 96.6 97.6 85.1 98.6 98.S 99.3 
SOnM 
BPA 97.9 98.8 97.7 99.2 98.2 98.6 97.9 98 
Zuber170 
BL6 Std. Std. 
Average Error NZB Average Error 
Contra O.SS677 0.2S16 
I 98.3 6 98.7 61 
SnM 0.42622 0.1848 
E2 98.3 4 98.S5 42 
SO nM 0.47434 0.2843 
E2 98.1 2 98.6S 12 
SnM 0.49223 3.4296 
BPA 97.875 1 95.37S 2 
SO nM 0.3S823 0 .1547 
BPA 98.4 6 98.175 85 
% B Cells Expressing 
CD40 
Strain BL6 NZB 
6/22/20 6/24/20 6/29/2 7/1/20 7/13/2 7/15/2 7/17/2 7/ 20/2 
Date 10 10 010 10 010 010 010 010 
Control 88.2 90.9 84.1 95.1 91.2 95 82 .6 94.2 
5 nM E2 86.6 90.8 87.8 94.3 91.7 94 87.7 95.3 .... 
SOnM c 
Q) 
E E2 87.8 88.8 86.1 .... 93.4 85.7 93 88.7 95 .8 
ro SnM Q) ..... 
I- BPA 91.1 89.7 87 97.6 71.4 94 .1 87.3 95 .4 
50 nM 
BPA 85.2 88.3 92.3 96.3 90.1 93.4 87.4 95.2 
BL6 Std. Std. 
Average Error NZB Average Error 
Contra 2.31206 2.8371 
I 89.S75 1 90.7S OS 
SnM 1.71919 1.6670 
E2 89.87S 3 92.175 21 
SO nM 1.S6118 2.2409 
E2 89.025 3 90.8 08 
SnM S.5106 
BPA 91.35 2.2S037 87.0S 71 
SOnM 2.41190 1.7336 
BPA 90.S2S 6 91.S2S 74 
Ratio of B cells expressing CD80/ B cells expressing 
CD86 
BL6 SE NZB SE % Difference 
Control 0.307477 0.26266S 17.06072 
S nM E2 0.3181S9 0.318366 -0.06S21 
50nM 
E2 0.34709S 0.291941 18.89202 
SnM 
BPA 0 .32S67 0.2S63S6 27.03813 
50nM 





Background MFI for each color for Unstained Control 
lymphocytes 
Strain BL6 NZB 
6/22/20 6/24/20 6/29/20 7/1/20 7/13/20 7/15/20 7/17/20 7/20/20 
Date 10 10 10 10 10 10 10 10 
PE 90 69 68 83 99 55 82 64 
PerCP-
CyS-5 136 110 97 148 166 77 126 91 
PE-Cy7 11 11 12 17 17 8 12 6 
APC 80 73 69 75 90 61 78 57 
MFI of MHC-11 Within B Cells Controlled to 
Background 
Strain BL6 NZB 
6/22/20 6/24/20 6/29/20 7 /1/20 7/13/20 7/ 15/ 20 7/17/ 20 7/20/20 
Date 10 10 10 10 10 10 10 10 
Control 374.22 345.41 277.12 276.75 119.70 271.02 139.57 186.45 
5 nM E2 409.96 461.14 305.22 257.63 173.43 279.02 183.33 223.13 .... 
50 nM c 
Q) 
E .... E2 441.48 417.81 297.49 243 .04 102.69 275.13 205.56 228.31 
n:> SnM Q) .... 
f- BPA 517.18 423.90 286.24 195.05 61.28 245.13 178.52 223.84 
SOnM 
BPA 405.70 435 .78 371.00 255.16 114.02 229.55 180.60 233.39 
BL6 
BL6 Std. NZB Std. Percent 
Average Error Average Error d ifference 
Control 318.37 24.64 179.19 33.66 77.68 
5 nM E2 358.49 46.72 214.73 23 .97 66.95 
50nM 
E2 349.95 47.58 202.92 36.41 72.46 
5 nM 
BPA 355.59 71.51 177.19 41.06 100.68 
50 nM 
BPA 366.91 39.53 189.39 27.85 93.73 
MFI of CD80 Within B Cells Controlled to 
Background 
Strain BL6 NZB 
6/22/20 6/24/20 6/29/20 7/1/20 7/13/2 7/ 15/ 2 7/ 17/2 7/20/2 
Date 10 10 10 10 010 010 010 010 
.... 
c Control 6.21 3.70 4.09 2.64 3.61 4.68 4.37 4.70 Q) 
E 
5 nM E2 4.60 4.69 3.60 2.13 4.80 5.64 4.61 5.44 .... n:> 
Q) 
;:: SOnM 4.24 6.30 3.22 2.00 3.43 7.36 8 .74 -0.29 
Zuber 173 
E2 -5nM 
BPA 5.74 4.95 3.84 2.49 1.89 4.75 4.33 5.64 
50nM 
BPA 4.46 4.86 4.29 1.85 3.34 4.05 4.50 5.41 
BL6 
BL6 Std. NZB Std. Percent 
Average Error Average Error difference 
Control 4.16 0.7S 4.34 0.2S -4.13 
5 nM E2 3.76 0.60 S.12 0.2S -26.69 
SO nM 
E2 3.94 0.91 6.51 l.S9 -39.Sl 
SnM 
BPA 4.2S 0.71 4.15 0.80 2.41 
SO nM 
BPA 3.87 0.68 4.33 0.43 -10.61 
MFI of CD86 Within B Cells Controlled to 
Background 
Strain BL6 NZB 
6/22/20 6/24/20 6/29/20 7/1/20 7/13/2 7/15/2 7/17/2 7/20/2 
Date 10 10 10 10 010 010 010 010 
1788.0 1247.1 2453.5 
Control 1034.09 985.82 773.08 1.06 716.41 0 7 0 
1735.8 1235.1 2580.8 
.... 5 nM E2 901 .73 1049.91 775.92 569.24 806.65 8 7 3 c 
Cll 
50nM 1765.7 1304.8 2583.3 E .... 
E2 865.00 981.00 760.17 542.94 705.06 5 3 3 ro Cll 
~ 5nM 1715.5 1224.0 2581.0 
BPA 1047.09 941.91 746.33 552.06 322.76 0 8 0 
50nM 1644.5 1241.7 2467.6 
BPA 843.27 988.45 898.08 552.24 653.71 0 5 7 
BL6 
BL6 Std. NZB Std. Percent 
Average Error Average Error difference 
Contro l 931.00 80.18 1551.27 371.88 -39.98 
5 nM E2 824.20 101.77 1S89.63 381.07 -48.15 
50 nM 
E2 787.28 93.10 1S89.74 396.03 -50.48 
SnM 
BPA 821.85 109.41 1460.84 471.78 -43.74 
SO nM 
BPA 820.51 94.30 1501.91 380.81 -4S.37 
MFI of CD40 Within B Cells Controlled to 
Background 
Zuber 174 
Strain BL6 NZB 
6/22/20 6/24/20 6/29/20 7/1/20 7/13/2 7/15/2 7/17/2 7/20/2 
Date 10 10 10 10 010 010 010 010 
Control 37.86 44.10 34.49 45.77 39.70 76.48 29.65 71.56 
5 nM E2 49.30 44.44 43.48 35.71 44.30 76.02 44.12 80.19 .., 
50nM c 
Q) 
E .., E2 40.84 76.47 38.96 35.85 30.34 107.43 121.29 79.21 
ro 5 nM Q) ..... 
I- BPA 51.55 41.99 39.94 34.00 14.41 74.82 43.50 83.82 
50nM 
BPA 37.75 41.92 55.88 44.00 30.29 92.05 43 .72 77.72 
BL6 
BL6 Std . NZB Std. Percent 
Average Error Average Error difference 
Control 40.56 2.64 S4.3S ll.S8 -2S.38 
S nM E2 43 .23 2.81 61.16 9.82 -29 .31 
SO nM 
E2 48.03 9.53 84.57 20.08 -43 .21 
SnM 
BPA 41.87 3.64 S4.14 lS .81 -22.66 
SO nM 
BPA 44.89 3.89 60.94 14.39 -26.3S 
